US20160222455A1

US20160222455A1 - Methods for diagnosing ischemia

Info

Publication number: US20160222455A1
Application number: US15/092,599
Authority: US
Inventors: Huichun Xu; Frank Sharp
Original assignee: University of California
Current assignee: University of California
Priority date: 2007-05-01
Filing date: 2016-04-06
Publication date: 2016-08-04
Also published as: CN101688245B; WO2008137465A1; CA2685382C; EP2311981A1; EP2152907A1; US20200157624A1; CA2685382A1; US11421276B2; US20100197518A1; EP2311981B1; CN101688245A; HK1156368A1

Abstract

This invention provides methods and compositions for diagnosing ischemia, ischemia reference expression profiles, and methods for identifying compounds for treating or preventing ischemia.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 12/598,107, filed on Mar. 25, 2010, which is the U.S. national stage entry under 35 U.S.C. §371 of Intl. Appl. No. PCT/US2008/062064, filed on Apr. 30, 2008, which claims the benefit of U.S. Provisional Application No. 60/915,366, filed on May 1, 2007, which are hereby incorporated herein by reference in their entireties for all purposes.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

This invention was made with Government support under Grant No. NS043252, NS028167, NS042774, NS044283 and NS056302, awarded by the National Institutes of Health and National Institute of Neurological Disorders and Stroke (NINDS). The government has certain rights in this invention.

BACKGROUND OF THE INVENTION

Ischemic events such as stroke are the third leading cause of death in America. Different subtypes of stroke have their own specific management strategy and a precise diagnosis is critical for the timely treatment of various stroke patients. Currently the gold standard for the diagnosis of acute ischemic stroke versus hemorrhagic stroke relies on imaging technology. However, so far there is no such gold standard for determining the etiology of ischemic stroke. Currently the etiology of ischemic stroke largely depends on the clinician's judgment from indirect clinical information. The main etiologies of acute ischemic stroke include atherothrombotic stroke and cardioembolic stroke. Atheroembolic stroke dictates surgery or aspirin and platelet inhibitor(s); and cardioembolic strokes require treatment with anticoagulant medications such as, e.g., coumadin.
To determine the cause of stroke, patients have magnetic resonance imaging or carotid dopplers to determine if they have atherosclerosis in the carotid and cardiac echocardiograms to determine if they have clot in the heart. The cardiac echocardiogram is very specific, but very insensitive. Even with the best of information, determining the actual cause of stroke is impassible: that is, there is no current direct test for cause. Moreover, somewhere between 30% and 50% of all subjects with transient ischemic attacks and stroke have an unknown cause of stroke.
Thus, there is a need in the art for methods for accurately diagnosing ischemic events (including e.g., stroke and transient ischemic attacks). The present invention meets these and other needs.

BRIEF SUMMARY OF THE INVENTION

The present invention provides methods for diagnosing ischemia (e.g., embolic and thrombotic stroke and transient ischemic attacks) by detecting expression levels of genes differentially expressed in ischemia.
One embodiment of the invention provides methods for diagnosing an ischemia or a predisposition for developing an ischemia. The methods comprise: determining a level of expression of a plurality of ischemia-associated genes in a biological sample from a mammalian subject, wherein a difference (i.e. increase or decrease) of said level compared to a normal control level of the genes indicates that said subject suffers from or is at risk of developing ischemia, wherein said plurality of ischemia-associated genes is selected from the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7. For example, in some embodiments, the level of expression of a plurality, i.e., two or more genes, selected from Table 1 is determined, i.e., two or more of LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1 (also called, NAIP///LOC728519), TSHZ3, DF (also called, CFD), FBN2, IER3, NUMB, LAK (also called, ALPK1), CD8B1, RRAS2, C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185 and C7orf41. In some embodiments, the expression level of 5 or more, 10 or more, 15 or more, 20 or more, or 23 of the genes listed in Table 1 is determined.
In some embodiments, the difference (i.e., increase or decrease) is at least about 1.3 fold, 1.4 fold, or 1.5 fold higher or lower, respectively, than a normal control level.
In some embodiments, the expression level of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 genes selected from LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, LAK, CD8B1 and RRAS2, identified in Tables 1, 9 and 10, is determined. In some embodiments, at least about a 1.3 fold increase in expression of the following genes: LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, and LAK when compared to the normal control level, and at least about a 1.3 fold decrease in expression of the following genes: CD8B1 and RRAS2 when compared to the normal control level indicates that the subject has experienced or is at risk for a cardioembolic stroke.
In some embodiments, the expression level of 2, 3, 4, 5, 6, 7, 8, 9 or 10 genes selected from C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41 and LAK, identified in Tables 1, 8 and 10, is determined. In some embodiments, at least about a 1.3 fold decrease in expression of the following genes: C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41 and LAK when compared to the normal control level indicates that the subject has experienced or is at risk for an atherothrombotic stroke or atheroembolic stroke. In some embodiments, the ischemia is selected from embolic stroke, thrombotic stroke, and transient ischemic attack. In some embodiments, the sample is blood. In some embodiments, the level of expression is determined by detecting hybridization of an ischemia-associated gene probe to a gene transcript of said biological sample. In some embodiments, the hybridization step is carried out on a nucleic acid array.
Another embodiment of the invention provides an ischemia reference expression profile, comprising a pattern of gene expression of a plurality of the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7. In some embodiments, the ischemia reference expression profile, comprises a pattern of gene expression of a plurality of the genes set forth in Table 1. In some embodiments, at least about a 1.3 fold increase in expression of the following genes: LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, and LAK when compared to the normal control level, and at least about a 1.3 fold decrease in expression of the following genes: CD8B1 and RRAS2 when compared to the normal control level is a reference expression profile for cardioembolic stroke. In some embodiments, at least about a 1.3 fold decrease in expression of the following genes: C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41, and LAK when compared to the normal control level is a reference expression profile for atherothrombotic stroke or atheroembolic stroke.
Yet another embodiment of the invention provides methods of screening for a compound for treating or preventing ischemia. The methods comprise: a) contacting a candidate compound with a cell expressing one or more genes set forth in Table 1, 2, 3, 4, 5, 6, or 7; and b) selecting a compound that modulates the expression level of one or more genes set forth in Table 1, 2, 3, 4, 5, 6, or 7. In some embodiments a compound that decreases the expression of at least one gene selected from the group consisting of: LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, and LAK when compared to the normal control level, or increases the expression of at least one gene selected from the group consisting of: CD8B1 and RRAS2 relative to a control level is identified as a compound useful for treating or preventing ischemia, including, e.g., cardioembolic stroke. In some embodiments, a compound that increases the expression of at least one gene selected from the group consisting of: C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41, and LAK is identified as a compound useful for treating or preventing ischemia, including, e.g., atherothrombotic stroke or atheroembolic stroke.
A further embodiment of the invention provides an array comprising a plurality of polynucleotides which specifically bind (i.e., specifically hybridize) to a plurality of nucleic acid sequences set forth in Table 1, 2, 3, 4, 5, 6 or 7. In some embodiments, the invention provides an array comprising a plurality of polynucleotides which specifically bind (i.e., specifically hybridize) to a plurality of nucleic acid sequences set forth in Table 1.
Another embodiment of the invention provides a reaction mixture comprising a plurality of polynucleotides which specifically hybridize (e.g., primers) to a plurality of nucleic acid sequences set forth in Table 1, 2, 3, 4, 5, 6 or 7. In some embodiments, the invention provides a reaction mixture comprising a plurality of polynucleotides which specifically hybridize (e.g., primers) to a plurality of nucleic acid sequences set forth in Table 1. In some embodiments, the reaction mixture is a PCR mixture, for example, a multiplex PCR mixture.
These and other embodiments of the invention are further described by the detailed description that follows.

BRIEF DESCRIPTION OF THE TABLES

Table 1 sets forth a list of 23 genes differentially expressed in ischemia (e.g., cardioembolic stroke, artherothrombotic stroke, and transient ischemic attacks).
Table 2 sets forth a list of 77 genes differentially expressed in ischemia (e.g., cardioembolic stroke, artherothrombotic stroke, and transient ischemic attacks).
Table 3 sets forth a list of 95 genes differentially expressed in ischemia (e.g., cardioembolic stroke, artherothrombotic stroke, and transient ischemic attacks).
Table 4 sets forth a list of 133 genes differentially expressed in ischemia (e.g., cardioembolic stroke, artherothrombotic stroke, and transient ischemic attacks).
Table 5 sets forth a list of 259 genes differentially expressed in ischemia (e.g., cardioembolic stroke, artherothrombotic stroke, and transient ischemic attacks).
Table 6 sets forth a list of 466 genes differentially expressed in ischemia (e.g., cardioembolic stroke, artherothrombotic stroke, and transient ischemic attacks).
Table 7 sets forth a list of 706 genes differentially expressed in ischemia (e.g., cardioembolic stroke, artherothrombotic stroke, and transient ischemic attacks).
Table 8 sets forth relative expression levels of selected genes described in Example 1 as differentially expressed in atherothrombotic stroke relative to normal control subjects.
Table 9 sets forth relative expression levels of selected genes described in Example 1 as differentially expressed in cardioembolic stroke subjects relative to normal control subjects.
Table 10 sets forth the relative expression levels of genes listed in Table 1 in cardioembolic stroke subjects relative to normal control subjects; atheroembolic stroke subjects relative to normal control, and cardioembolic stroke subjects relative to atheroembolic stroke subjects.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an expression heatmap of genes differentially regulated between cardioembolic and atherosclerotic stroke patients with at least a 1.5 fold change.

FIG. 2 illustrates etiology prediction of stroke samples with unknown etiology according to the expression pattern of 23 genes using PAM.

FIG. 3 illustrates a function comparison of cardioembolic stroke-specific genes versus atherosclerotic stroke-specific genes. Obvious duplication of function classes is omitted for clarity purposes.

FIG. 4a illustrates expression activities of atherosclerotic stroke-specific genes across subtypes of healthy blood cells.

FIG. 4b illustrates expression activities of cardioembolic stroke-specific genes across subtypes of healthy blood cells.

FIG. 5 illustrates etiology prediction of stroke samples from unknown etiologies by cluster analysis.

FIG. 6 illustrates a 10-fold cross validation result for known cardioembolic stroke samples with 23 genes in PAM.

FIG. 7 illustrates a 10-fold cross validation result for known atherosclerotic stroke samples with 23 genes in PAM.

DETAILED DESCRIPTION OF THE INVENTION

I. Introduction

The present invention provides methods for the diagnosis of ischemia (e.g., stroke and transient ischemic attacks (“TIA”)).
The invention is based on identification of differential gene expression patterns in subjects with an ischemia (e.g., stroke and TIA). Detection of the expression patterns of a plurality of the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7 leads to a definitive diagnosis of the type of ischemia that a subject has developed or is at risk for developing. Therefore, this invention provides the first direct method for determining the causes of ischemia (stroke and TIA).
The gene expression patterns described herein can conveniently be used to diagnose, monitor and prognose ischemia (e.g., stroke and TIA). For example, the gene expression patterns can be detected to definitively classify the type of ischemic event that a subject has developed or has a predisposition for developing. In some embodiments, the gene expression patterns can also be used as ischemic reference profiles. In other embodiments, the gene expression patterns can be used to identify compounds for treating or preventing ischemia.

II. Definitions

Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry and nucleic acid chemistry and hybridization described below are those well known and commonly employed in the art. Standard techniques are used for nucleic acid and peptide synthesis. Generally, enzymatic reactions and purification steps are performed according to the manufacturer's specifications. The techniques and procedures are generally performed according to conventional methods in the art and various general references (see generally, Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL, 3rd ed. (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. and Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1990-2008, Wiley Interscience), which are provided throughout this document. The nomenclature used herein and the laboratory procedures in analytical chemistry, and organic synthetic described below are those well known and commonly employed in the art. Standard techniques, or modifications thereof, are used for chemical syntheses and chemical analyses.
“Ischemia” or “ischemic event” as used herein refers to diseases and disorders characterized by inadequate blood supply (i.e., circulation) to a local area due to blockage of the blood vessels to the area. Ischemia includes for example, strokes and transient ischemic attacks. Strokes include, e.g., ischemic stroke (including, but not limited to, cardioembolic strokes, atheroembolic or atherothrombotic strokes, i.e., strokes caused by atherosclerosis in the carotid, aorta, heart, and brain, small vessel strokes (i.e., lacunar strokes), strokes caused by diseases of the vessel wall, i.e., vasculitis, strokes caused by infection, strokes caused by hematological disorders, strokes caused by migraines, and strokes caused by medications such as hormone therapy), hemorrhagic ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage.
“Ischemia reference expression profile” refers to the pattern of expression of a set of genes (e.g., a plurality of the genes set forth in Tables 1, 2, 3, 4, 5, 6 or 7) differentially expressed (i.e., overexpressed or underexpressed) in ischemia relative to a normal control. A gene from Tables 1, 2, 3, 4, 5, 6 or 7 that is expressed at a level that is at least about 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9 or 10 fold higher than the level in a normal control is a gene overexpressed in ischemia and a gene from Tables 1, 2, 3, 4, 5, 6 or 7 that is expressed at a level that is at least about 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9 or 10 fold lower than the level in a normal control is a gene underexpressed in ischemia. Alternately, genes that are expressed at a level that is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% higher than the level in a normal control is a gene overexpressed in ischemia and a gene that is expressed at a level that is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% lower than the level in a normal control is a gene underexpressed in ischemia.
A “plurality” refers to two or more, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or more (e.g., genes). In some embodiments, a plurality refers to 50, 96, 100, 150, 192, 200, 250, 384 or 500 genes. In some embodiments, “plurality” refers to all genes listed in one or more tables, e.g., all genes listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6 and/or Table 7.
“Sample” or “biological sample” includes sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histologic purposes. Such samples include blood, sputum, tissue, lysed cells, brain biopsy, cultured cells, e.g., primary cultures, explants, and transformed cells, stool, urine, etc. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate, e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.
“Array” as used herein refers to a solid support comprising attached nucleic acid or peptide probes. Arrays typically comprise a plurality of different nucleic acid or peptide probes that are coupled to a surface of a substrate in different, known locations. These arrays, also described as “microarrays” or colloquially “chips” have been generally described in the art, for example, U.S. Pat. Nos. 5,143,854, 5,445,934, 5,744,305, 5,677,195, 6,040,193, 5,424,186 and Fodor et al., Science, 251:767-777 (1991). These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase synthesis methods. Techniques for the synthesis of these arrays using mechanical synthesis methods are described in, e.g., U.S. Pat. No. 5,384,261. Arrays may comprise a planar surface or may be nucleic acids or peptides on beads, gels, polymeric surfaces, fibers such as fiber optics, glass or any other appropriate substrate as described in, e.g., U.S. Pat. Nos. 5,770,358, 5,789,162, 5,708,153, 6,040,193 and 5,800,992. Arrays may be packaged in such a manner as to allow for diagnostics or other manipulation of an all inclusive device, as described in, e.g., U.S. Pat. Nos. 5,856,174 and 5,922,591.
The term “gene” means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).
The terms “nucleic acid” and “polynucleotide” are used interchangeably herein to refer to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).
Unless otherwise indicated, a particular nucleic acid sequence also encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.
The phrase “stringent hybridization conditions” refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acid, but to no other sequences. Stringent hybridization conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Probes, “Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent hybridization conditions are selected to be about 5-10° C. lower than the thermal melting point for the specific sequence at a defined ionic strength Ph. The T_mis the temperature (under defined ionic strength, Ph, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m, 50% of the probes are occupied at equilibrium). Stringent hybridization conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at Ph 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C. for long probes (e.g., greater than 50 nucleotides). Stringent hybridization conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, optionally 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5×SSC, and 1% SDS, incubating at 42° C., or, 5×SSC, 1% SDS, incubating at 65° C., with wash in 0.2×SSC, and 0.1% SDS at 65° C.
Nucleic acids that do not hybridize to each other under stringent hybridization conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary “moderately stringent hybridization conditions” include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 1×SSC at 45° C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.
The terms “isolated,” “purified,” or “biologically pure” refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. The term “purified” denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure.
The term “heterologous” when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).
An “expression vector” is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.
The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.
The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, α-carboxyglutamate, and O-phosphoserine. “Amino acid analogs” refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. “Amino acid mimetics” refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
“Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.
As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.
The following eight groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Glycine (G);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine I, Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);
- 7) Serine (S), Threonine (T); and
- 8) Cysteine (C), Methionine (M)
- (see, e.g., Creighton, Proteins (1984)).

The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity over a specified region of an ischemia-associated gene (e.g., a gene set forth in Table 1, 2, 3, 4, 5, 6, or 7), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be “substantially identical.” This definition also refers to the compliment of a test sequence. Preferably, the identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.
For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. For sequence comparison of nucleic acids and proteins to ischemia-associated nucleic acids and proteins, the BLAST and BLAST 2.0 algorithms and the default parameters discussed below are used.
A “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).
A preferred example of algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=−4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparison of both strands.
The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.
An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.
The phrase “selectively (or specifically) hybridizes to” refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).
By “host cell” is meant a cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be, for example, prokaryotic cells such as E. coli or eukaryotic cells such as yeast cells or mammalian cells such as CHO cells.
“Inhibitors,” “activators,” and “modulators” of expression or of activity are used to refer to inhibitory, activating, or modulating molecules, respectively, identified using in vitro and in vivo assays for expression or activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term “modulator” includes inhibitors and activators. Inhibitors are agents that, e.g., inhibit expression of a polypeptide or polynucleotide of the invention or bind to, partially or totally block stimulation or enzymatic activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity of a polypeptide or polynucleotide of the invention, e.g., antagonists. Activators are agents that, e.g., induce or activate the expression of a polypeptide or polynucleotide of the invention or bind to, stimulate, increase, open, activate, facilitate, enhance activation or enzymatic activity, sensitize or up regulate the activity of a polypeptide or polynucleotide of the invention, e.g., agonists. Modulators include naturally occurring and synthetic ligands, antagonists, agonists, small chemical molecules and the like. Assays to identify inhibitors and activators include, e.g., applying putative modulator compounds to cells, in the presence or absence of a polypeptide or polynucleotide of the invention and then determining the functional effects on a polypeptide or polynucleotide of the invention activity. Samples or assays comprising a polypeptide or polynucleotide of the invention that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of effect. Control samples (untreated with modulators) are assigned a relative activity value of 100%. Inhibition is achieved when the activity value of a polypeptide or polynucleotide of the invention relative to the control is about 80%, optionally 50% or 25-1%. Activation is achieved when the activity value of a polypeptide or polynucleotide of the invention relative to the control is 110%, optionally 150%, optionally 200-500%, or 1000-3000% higher.
The term “test compound” or “drug candidate” or “modulator” or grammatical equivalents as used herein describes any molecule, either naturally occurring or synthetic, e.g., protein, oligopeptide (e.g., from about 5 to about 25 amino acids in length, preferably from about 10 to 20 or 12 to 18 amino acids in length, preferably 12, 15, or 18 amino acids in length), small organic molecule, polysaccharide, lipid, fatty acid, polynucleotide, RNAi, oligonucleotide, etc. The test compound can be in the form of a library of test compounds, such as a combinatorial or randomized library that provides a sufficient range of diversity. Test compounds are optionally linked to a fusion partner, e.g., targeting compounds, rescue compounds, dimerization compounds, stabilizing compounds, addressable compounds, and other functional moieties. Conventionally, new chemical entities with useful properties are generated by identifying a test compound (called a “lead compound”) with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.
A “small organic molecule” refers to an organic molecule, either naturally occurring or synthetic, that has a molecular weight of more than about 50 Daltons and less than about 2500 Daltons, preferably less than about 2000 Daltons, preferably between about 100 to about 1000 Daltons, more preferably between about 200 to about 500 Daltons.

III. Diagnosis of Ischemia

The invention provides methods for diagnosing ischemia (e.g., stroke or transient ischemic attacks) or a predisposition for developing ischemia by detecting the expression of a plurality of ischemia-associated genes in a sample (e.g., a blood sample) from a subject. In some embodiments of the invention, expression of a plurality of the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7 is detected. In one preferred embodiment, expression of a plurality of the genes set forth in Table 1 is detected. In one embodiment, at least about a 1.3 fold increase in expression of the following genes: LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, and LAK when compared to the normal control level, and at least about a 1.3 fold decrease in expression of the following genes: CD8B1 and RRAS2 when compared to the normal control level indicates that the subject has experienced or is at risk for a cardioembolic stroke. In another embodiment, at least about a 1.3 fold decrease in expression of the following genes: C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41, and LAK when compared to the normal control level indicates that the subject has experienced or is at risk for an atherothrombotic stroke or atheroembolic stroke.
Gene expression may be measured using any method known in the art. One of skill in the art will appreciate that the means of measuring gene expression is not a critical aspect of the invention. A variety of methods of specific DNA and RNA measurement using nucleic acid hybridization techniques are known to those of skill in the art (see, Sambrook, supra and Ausubel, supra) and may be used to detect the expression of the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7. Some methods involve an electrophoretic separation (e.g., Southern blot for detecting DNA, and Northern blot for detecting RNA), but measurement of DNA and RNA can also be carried out in the absence of electrophoretic separation (e.g., by dot blot). Southern blot of genomic DNA (e.g., from a human) can be used for screening for restriction fragment length polymorphism (RFLP) to detect the presence of a genetic disorder affecting a polypeptide of the invention.
The selection of a nucleic acid hybridization format is not critical. A variety of nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assays and competition or displacement assays. Hybridization techniques are generally described in Hames and Higgins Nucleic Acid Hybridization, A Practical Approach, IRL Press (1985); Gall and Pardue, Proc. Natl. Acad. Sci. U.S.A., 63:378-383 (1969); and John et al. Nature, 223:582-587 (1969).
Detection of a hybridization complex may require the binding of a signal-generating complex to a duplex of target and probe polynucleotides or nucleic acids. Typically, such binding occurs through ligand and anti-ligand interactions as between a ligand-conjugated probe and an anti-ligand conjugated with a signal. The binding of the signal generation complex is also readily amenable to accelerations by exposure to ultrasonic energy.
The label may also allow indirect detection of the hybridization complex. For example, where the label is a hapten or antigen, the sample can be detected by using antibodies. In these systems, a signal is generated by attaching fluorescent or enzyme molecules to the antibodies or in some cases, by attachment to a radioactive label (see, e.g., Tijssen, “Practice and Theory of Enzyme Immunoassays,” Laboratory Techniques in Biochemistry and Molecular Biology, Burdon and van Knippenberg Eds., Elsevier (1985), pp. 9-20).
The probes are typically labeled either directly, as with isotopes, chromophores, lumiphores, chromogens, or indirectly, such as with biotin, to which a streptavidin complex may later bind. Thus, the detectable labels used in the assays of the present invention can be primary labels (where the label comprises an element that is detected directly or that produces a directly detectable element) or secondary labels (where the detected label binds to a primary label, e.g., as is common in immunological labeling). Typically, labeled signal nucleic acids are used to detect hybridization. Complementary nucleic acids or signal nucleic acids may be labeled by any one of several methods typically used to detect the presence of hybridized polynucleotides. The most common method of detection is the use of autoradiography with ³H, ¹²⁵I, ³⁵S, ¹⁴C. or ³²P-labeled probes or the like.
Other labels include, e.g., ligands that bind to labeled antibodies, fluorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labeled ligand. An introduction to labels, labeling procedures and detection of labels is found in Polak and Van Noorden Introduction to Immunocytochemistry, 2nd ed., Springer Verlag, NY (1997); and in Haugland Handbook of Fluorescent Probes and Research Chemicals, a combined handbook and catalogue Published by Molecular Probes, Inc. (1996).
In general, a detector which monitors a particular probe or probe combination is used to detect the detection reagent label. Typical detectors include spectrophotometers, phototubes and photodiodes, microscopes, scintillation counters, cameras, film and the like, as well as combinations thereof. Examples of suitable detectors are widely available from a variety of commercial sources known to persons of skill in the art. Commonly, an optical image of a substrate comprising bound labeling moieties is digitized for subsequent computer analysis.
Most typically, the amount of RNA is measured by quantifying the amount of label fixed to the solid support by binding of the detection reagent. Typically, the presence of a modulator during incubation will increase or decrease the amount of label fixed to the solid support relative to a control incubation which does not comprise the modulator, or as compared to a baseline established for a particular reaction type. Means of detecting and quantifying labels are well known to those of skill in the art.
In preferred embodiments, the target nucleic acid or the probe is immobilized on a solid support. Solid supports suitable for use in the assays of the invention are known to those of skill in the art. As used herein, a solid support is a matrix of material in a substantially fixed arrangement.
For example, in one embodiment of the invention, microarrays are used to detect the pattern of gene expression. Microarrays provide one method for the simultaneous measurement of the expression levels of large numbers of genes. Each array consists of a reproducible pattern of a plurality of nucleic acids (e.g., a plurality of nucleic acids that hybridize to a plurality of the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7) attached to a solid support. In one embodiment, the array contains a plurality of nucleic acids that hybridize to a plurality of the genes listed in Table 1. Labeled RNA or DNA is hybridized to complementary probes on the array and then detected by laser scanning. Hybridization intensities for each probe on the array are determined and converted to a quantitative read-out of relative gene expression levels in ischemia (e.g., stroke or transient ischemic attacks).
In some embodiments, a sample is obtained from a subject, total mRNA is isolated from the sample and is converted to labeled cRNA and then hybridized to an array. Relative transcript levels are calculated by reference to appropriate controls present on the array and in the sample. See Mahadevappa and Warrington, Nat. Biotechnol. 17, 1134-1136 (1999).
A variety of automated solid-phase assay techniques are also appropriate. For instance, very large scale immobilized polymer arrays (VLSIPS™), available from Affymetrix, Inc. (Santa Clara, Calif.) can be used to detect changes in expression levels of a plurality of genes involved in the same regulatory pathways simultaneously. See, Tijssen, supra, Fodor et al. (1991) Science, 251: 767-777; Sheldon et al. (1993) Clinical Chemistry 39(4): 718-719, and Kozal et al. (1996) Nature Medicine 2(7): 753-759.
Detection can be accomplished, for example, by using a labeled detection moiety that binds specifically to duplex nucleic acids (e.g., an antibody that is specific for RNA-DNA duplexes). One preferred example uses an antibody that recognizes DNA-RNA heteroduplexes in which the antibody is linked to an enzyme (typically by recombinant or covalent chemical bonding). The antibody is detected when the enzyme reacts with its substrate, producing a detectable product. Coutlee et al. (1989) Analytical Biochemistry 181:153-162; Bogulavski (1986) et al. J. Immunol. Methods 89:123-130; Prooijen-Knegt (1982) Exp. Cell Res. 141:397-407; Rudkin (1976) Nature 265:472-473, Stollar (1970) Proc. Nat'l Acad. Sci. USA 65:993-1000; Ballard (1982) Mol. Immunol. 19:793-799; Pisetsky and Caster (1982) Mol. Immunol. 19:645-650; Viscidi et al. (1988) J. Clin. Microbial. 41:199-209; and Kiney et al. (1989) J. Clin. Microbiol. 27:6-12 describe antibodies to RNA duplexes, including homo and heteroduplexes. Kits comprising antibodies specific for DNA:RNA hybrids are available, e.g., from Digene Diagnostics, Inc. (Beltsville, Md.).
In addition to available antibodies, one of skill in the art can easily make antibodies specific for nucleic acid duplexes using existing techniques, or modify those antibodies that are commercially or publicly available. In addition to the art referenced above, general methods for producing polyclonal and monoclonal antibodies are known to those of skill in the art (see, e.g., Paul (3rd ed.) Fundamental Immunology Raven Press, Ltd., NY (1993); Coligan, et al., Current Protocols in Immunology, Wiley Interscience (1991-2008); Harlow and Lane, Antibodies: A Laboratory Manual Cold Spring Harbor Press, NY (1988); Harlow and Lane, Using Antibodies, Cold Spring Harbor Press, NY (1999); Stites et al. (eds.) Basic and Clinical Immunology (4th ed.) Lange Medical Publications, Los Altos, Calif., and references cited therein; Goding Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York, N.Y., (1986); and Kohler and Milstein Nature 256: 495-497 (1975)). Other suitable techniques for antibody preparation include selection of libraries of recombinant antibodies in phage or similar vectors (see, Huse et al. Science 246:1275-1281 (1989); and Ward et al. Nature 341:544-546 (1989)). Specific monoclonal and polyclonal antibodies and antisera will usually bind with a K_Dof at least about 0.1 μM, preferably at least about 0.01 μM or better, and most typically and preferably, 0.001 μM or better.
The nucleic acids used in this invention can be either positive or negative probes. Positive probes bind to their targets and the presence of duplex formation is evidence of the presence of the target. Negative probes fail to bind to the suspect target and the absence of duplex formation is evidence of the presence of the target. For example, the use of a wild type specific nucleic acid probe or PCR primers may serve as a negative probe in an assay sample where only the nucleotide sequence of interest is present.
The sensitivity of the hybridization assays may be enhanced through use of a nucleic acid amplification system that multiplies the target nucleic acid being detected. Examples of such systems include the polymerase chain reaction (PCR) system, in particular RT-PCR or real time PCR, and the ligase chain reaction (LCR) system. Other methods recently described in the art are the nucleic acid sequence based amplification (NASBA, Cangene, Mississauga, Ontario) and Q Beta Replicase systems. These systems can be used to directly identify mutants where the PCR or LCR primers are designed to be extended or ligated only when a selected sequence is present. Alternatively, the selected sequences can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation.
An alternative means for determining the level of expression of the nucleic acids of the present invention is in situ hybridization. In situ hybridization assays are well known and are generally described in Angerer et al., Methods Enzymol. 152:649-660 (1987). In an in situ hybridization assay, cells, preferentially human cells from the cerebellum or the hippocampus, are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of specific probes that are labeled. The probes are preferably labeled with radioisotopes or fluorescent reporters.
In one embodiment of the invention, microarrays are used to detect the pattern of gene expression. Microarrays provide one method for the simultaneous measurement of the expression levels of large numbers of genes. Each array consists of a reproducible pattern of a plurality of nucleic acids (e.g., a plurality of nucleic acids that hybridize to a plurality of the genes set forth in Table 1, 2, 3, 4, 5, 6 or 7) attached to a solid support. In one embodiment, the array contains a plurality of nucleic acids that hybridize to a plurality of the genes listed in Table 1. Labeled RNA or DNA is hybridized to complementary probes on the array and then detected by laser scanning. Hybridization intensities for each probe on the array are determined and converted to a quantitative read-out of relative gene expression levels in ischemia (e.g., stroke or transient ischemic attacks)
In some embodiments, a sample is obtained from a subject, total mRNA is isolated from the sample and is converted to labeled cRNA and then hybridized to an array. Relative transcript levels are calculated by reference to appropriate controls present on the array and in the sample. See Mahadevappa and Warrington, Nat. Biotechnol. 17, 1134-1136 (1999).
In other embodiments, quantitative RT-PCR is used to detect the expression of a plurality of the genes set forth in Tables 1, 2, 3, 4, 5, 6 or 7. In one embodiment, quantitative RT-PCR is used to detect a plurality of the genes listed in Table 1. A general overview of the applicable technology can be found, for example, in A-Z of Quantitative PCR, Bustin, ed., 2004, International University Line; Quantitative PCR Protocols, Kochanowski and Reischl, eds., 1999, Humana Press; Clinical Applications of PCR, Lo, ed., 2006, Humana Press; PCR Protocols: A Guide to Methods and Applications (Innis et al. eds. (1990)) and PCR Technology: Principles and Applications for DNA Amplification (Erlich, ed. (1992)). In addition, amplification technology is described in U.S. Pat. Nos. 4,683,195 and 4,683,202. Methods for multiplex PCR, known in the art, are applicable to the present invention.
Accordingly, in one embodiment of the invention provides a reaction mixture comprising a plurality of polynucleotides which specifically hybridize (e.g., primers) to a plurality of nucleic acid sequences of the genes set forth in Table 1, 2, 3, 4, 5, 6 or 7. In some embodiments, the invention provides a reaction mixture comprising a plurality of polynucleotides which specifically hybridize (e.g., primers) to a plurality of nucleic acid sequences of the genes set forth in Table 1. In some embodiments, the reaction mixture is a PCR mixture, for example, a multiplex PCR mixture.
This invention relies on routine techniques in the field of recombinant genetics. Generally, the nomenclature and the laboratory procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. Basic texts disclosing the general methods of use in this invention include Sambrook et al., Molecular Cloning, A Laboratory Manual (3rd ed. 2001); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994-2008, Wiley Interscience)).
For nucleic acids, sizes are given in either kilobases (kb) or base pairs (bp). These are estimates derived from agarose or acrylamide gel electrophoresis, from sequenced nucleic acids, or from published DNA sequences. For proteins, sizes are given in kilodaltons (kDa) or amino acid residue numbers. Proteins sizes are estimated from gel electrophoresis, from sequenced proteins, from derived amino acid sequences, or from published protein sequences.
Oligonucleotides that are not commercially available can be chemically synthesized according to the solid phase phosphoramidite triester method first described by Beaucage & Caruthers, Tetrahedron Letts. 22:1859-1862 (1981), using an automated synthesizer, as described in Van Devanter et. al., Nucleic Acids Res. 12:6159-6168 (1984). Purification of oligonucleotides is by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson & Reanier, J. Chrom. 255:137-149 (1983).

IV. Ischemia Reference Profiles

The invention also provides ischemia reference profiles. The reference profiles comprise information correlating the expression levels of a plurality of ischemia-associated genes (i.e., a plurality of the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7) to particular types of ischemia. In one embodiment, the ischemia reference profile correlates the expression levels of a plurality of the genes listed in Table 1 to particular types of ischemia. The profiles can conveniently be used to diagnose, monitor and prognose ischemia.
One embodiment of the invention provides an ischemia reference profile for subjects who have experienced or are at risk for experiencing cardioembolic stroke. Accordingly, the ischemia reference profile correlates the expression levels of a plurality of the genes selected from LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, LAK, CD8B1 and RRAS2. For example, an expression profile exhibiting at least about a 1.3 fold increase in expression of the following genes: LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, and LAK when compared to the normal control level, and at least about a 1.3 fold decrease in expression of the following genes: CD8B1 and RRAS2 when compared to the normal control level is a reference profile for a subject who has experienced or is at risk for a cardioembolic stroke.
One embodiment of the invention provides an ischemia reference profile for subjects who have experienced or are at risk for experiencing atherothrombotic stroke. Accordingly, the ischemia reference profile correlates the expression levels of a plurality of the genes selected from C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41, and LAK. An expression profile exhibiting at least about a 1.3 fold decrease in expression of the following genes: C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41, and LAK when compared to the normal control level is a reference profile for a subject who has experienced or is at risk for an atherothrombotic stroke.
The reference profiles can be entered into a database, e.g., a relational database comprising data fitted into predefined categories. Each table, or relation, contains one or more data categories in columns. Each row contains a unique instance of data for the categories defined by the columns. For example, a typical database for the invention would include a table that describes a sample with columns for age, gender, reproductive status, expression profile and so forth. Another table would describe a disease: symptoms, level, sample identification, expression profile and so forth. In one embodiment, the invention matches the experimental sample to a database of reference samples. The database is assembled with a plurality of different samples to be used as reference samples. An individual reference sample in one embodiment will be obtained from a patient during a visit to a medical professional. Information about the physiological, disease and/or pharmacological status of the sample will also be obtained through any method available. This may include, but is not limited to, expression profile analysis, clinical analysis, medical history and/or patient interview. For example, the patient could be interviewed to determine age, sex, ethnic origin, symptoms or past diagnosis of disease, and the identity of any therapies the patient is currently undergoing. A plurality of these reference samples will be taken. A single individual may contribute a single reference sample or more than one sample over time. One skilled in the art will recognize that confidence levels in predictions based on comparison to a database increase as the number of reference samples in the database increases.
The database is organized into groups of reference samples. Each reference sample contains information about physiological, pharmacological and/or disease status. In one aspect the database is a relational database with data organized in three data tables, one where the samples are grouped primarily by physiological status, one where the samples are grouped primarily by disease status and one where the samples are grouped primarily by pharmacological status. Within each table the samples can be further grouped according to the two remaining categories. For example the physiological status table could be further categorized according to disease and pharmacological status.
As will be appreciated by one of skill in the art, the present invention may be embodied as a method, data processing system or program products. Accordingly, the present invention may take the form of data analysis systems, methods, analysis software, etc. Software written according to the present invention is to be stored in some form of computer readable medium, such as memory, hard-drive, DVD ROM or CD ROM, or transmitted over a network, and executed by a processor. The present invention also provides a computer system for analyzing physiological states, levels of disease states and/or therapeutic efficacy. The computer system comprises a processor, and memory coupled to said processor which encodes one or more programs. The programs encoded in memory cause the processor to perform the steps of the above methods wherein the expression profiles and information about physiological, pharmacological and disease states are received by the computer system as input. Computer systems may be used to execute the software of an embodiment of the invention (see, e.g., U.S. Pat. No. 5,733,729).

V. Methods of Identifying Compounds for Treating or Preventing Ischemia

The invention also provides methods of identifying compounds for treating or preventing ischemia. Compounds for treating or preventing ischemia can be readily identified according to methods well known to those of skill in the art.
A number of different screening protocols can be utilized to identify agents that modulate the level of activity or expression of ischemia-associated genes (i.e., agents that decrease the activity or expression of genes overexpressed in ischemia and increase the activity or expression of genes underexpressed in ischemia).
Preliminary screens can be conducted by screening for agents that modulate expression of ischemia-associated genes. The screening methods of the invention can be performed as in vitro or cell-based assays. Cell based assays can be performed in any cells which express one or more ischemia-associated genes. One of skill in the art will appreciate that ischemia-associated genes can be expressed in cells that do not contain endogenous ischemia-associated genes. Cell-based assays may involve whole cells or cell fractions to screen for agent binding or modulation of ischemia-associated genes Suitable cell-based assays are described in, e.g., DePaola et al., Annals of Biomedical Engineering 29: 1-9 (2001).
In vivo assays can also be used to identify agents that can be used to treat or prevent ischemia. The basic format of such methods involves administering a lead compound identified during an initial screen to an animal that serves as a model for ischemia and then determining if in fact the ischemia is ameliorated. The animal models utilized in validation studies generally are mammals of any kind. Specific examples of suitable animals include, but are not limited to, primates (e.g., chimpanzees, monkeys, and the like) and rodents (e.g., mice, rats, guinea pigs, rabbits, and the like).
The agents tested as potential modulators of ischemia-associated gene expression can be any small chemical compound, or a biological entity, such as a polypeptide, sugar, nucleic acid or lipid. Essentially any chemical compound can be used as a potential modulator in the assays of the invention, although most often compounds that can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays).
In one embodiment, high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such “combinatorial chemical libraries” or “ligand libraries” are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics.
A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.
Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka, Int. J. Pept. Prot. Res. 37:487-493 (1991) and Houghton et al., Nature 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (e.g., PCT Publication No. WO 91/19735), encoded peptides (e.g., PCT Publication WO 93/20242), random bio-oligomers (e.g., PCT Publication No. WO 92/00091), benzodiazepines (e.g., U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)), nucleic acid libraries (see Ausubel, Berger and Sambrook, all supra), peptide nucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology, 14(3):309-314 (1996) and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science, 274:1520-1522 (1996) and U.S. Pat. No. 5,593,853), small organic molecule libraries (see, e.g., benzodiazepines, Baum C&EN, January 18, page 33 (1993); isoprenoids, U.S. Pat. No. 5,569,588; thiazolidinones and metathiazanones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S. Pat. No. 5,288,514, and the like).
Devices for the preparation of combinatorial libraries are commercially available (see, e.g., ECIS™, Applied BioPhysics Inc., Troy, N.Y., MPS, 390 MPS, Advanced Chem Tech, Louisville Ky., Symphony, Rainin, Woburn, Mass., 433A Applied Biosystems, Foster City, Calif., 9050 Plus, Millipore, Bedford, Mass.). In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Tripos, Inc., St. Louis, Mo., 3D Pharmaceuticals, Exton, Pa., Martek Biosciences, Columbia, Md., etc.).

VI. Kits

The invention also provides kits for diagnosing ischemia or a predisposition for developing ischemia. For example, the invention provides kits that include one or more reaction vessels that have aliquots of some or all of the reaction components of the invention in them. Aliquots can be in liquid or dried form. Reaction vessels can include sample processing cartridges or other vessels that allow for the containment, processing and/or amplification of samples in the same vessel. The kits may comprise a plurality of nucleic acid probes that hybridize to a plurality the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7. In one embodiment, the kits comprise a plurality of nucleic acid probes that hybridize to a plurality of the genes set forth in Table 1. The probes may be immobilized on an array as described herein. In addition, the kit can comprise appropriate buffers, salts and other reagents to facilitate amplification and/or detection reactions (e.g., primers) for determining the expression levels of a plurality of the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7. In one embodiment, the kit comprises appropriate buffers, salts and other reagents to facilitate amplification and/or detection reactions (e.g., primers) for determining the expression levels of a plurality of the genes set forth in Table 1. The kits can also include written instructions for the use of the kit.

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

Materials and Methods

Human Subjects:

Acute ischemic stroke patients (n=45 samples from 15 patients) were enrolled in the CLEAR trial. The Institutional Review Boards at the participating institutions approved the study protocols and consent forms. Stroke patients were diagnosed clinically and computed tomography brain scans performed to exclude hemorrhage. Following informed consent, patients were randomized to receive either standard-dose r-tPA (Activase) or a combination of eptifibatide and low-dose r-tPA (Activase) in a 1:3 ratio in a double-blinded manner within 3 hr of the onset of stroke. Blood (15 ml) was drawn from each patient into PAXgene tubes before the treatment (“<3 hr samples”), approximately 2 hours after the thrombolysis treatment (“5 hr samples”) and 24 hours after the stroke onset (“24 hr samples”), respectively. A total of 45 blood samples were collected from the subjects with stroke. For additional information see ClinicalTrials.gov under identifier NCT00250991.
The etiology of the strokes was assessed using the TOAST criteria (Adams et al. Stroke (1993) 24:35-41) and classified as: Atherosclerotic stroke, Cardioembolic stroke and Stroke with undetermined etiology. Patients with small artery lacunar stroke were generally excluded from the CLEAR trial because of the study design, and none of the patients reported here had lacunar stroke.
Control peripheral blood samples were drawn from 8 healthy volunteers (n=16 samples). Each volunteer contributed two independent blood samples one day apart. Healthy controls had no history of cardiovascular or cerebral vascular disease, recent infection or hematological disease.

Sample Processing

Whole blood (15 ml) was collected into 6 PAXgene vacutainers (PreAnalytiX, Hilden, Germany) via antecubital fossa venipuncture from each subject. PAXgene tubes were frozen at −80° C. after 2 hr at room temperature. Total RNA was isolated (PAXgene blood RNA kit, PreAnalytiX, Germany) according to the manufacturer's protocol. The RNA is from PMNs (Neutrophils, basophils and eosinophils), mononuclear cells (PBMC-lymphocytes, macrophage/monocytes), platelets and red blood cell precursors.

Microarray Hybridization and RT-PCR

RNA samples were labeled, hybridized and scanned according to standard Affymetrix Protocols (Affymetrix Expression Analysis Technical Manual). 10 μg total RNA was labeled using the One-Cycle Target Labeling protocol. Affymetrix Human U133 Plus 2 arrays that contain more that 54,000 probe sets were used for each RNA sample. The RNA samples are also subject to RT-PCR.

Microarray Data Analysis

Probe-level data was saved in Affymetrix.cel files and summarized with Robust Multi-array Average (RMA) software (on the worldwide web at bioconductor.org/). Statistical analyses including a one-way analysis of variance (ANOVA) for cardioembolic stroke, atherosclerotic stroke, Stroke of undetermined etiology and controls) were performed using Genespring software (Silicon Genetics, Redwood City, Calif.). The Benjamini-Hochberg false discovery rate (FDR) was used to control for multiple comparisons with a 5% FDR (<0.05) being considered significant. Different fold change filters were applied to minimize type-two error. Direct comparison between cardioembolic stroke and atherosclerotic stroke was also performed (Student's t-test) to compare with the ANOVA analysis. Demographic data were analyzed with the Student T test or Fisher's exact test. The methods have been described in detail in our previous studies. See, e.g., Tang et al., Brain Res Mol Brain Res (2004) 132:155-167; Tang et al., Ann Neurol (2004) 56:808-814; and Tang et al., J Cereb Blood Flow Metab (2006) 26(8):1089-102.

Example 1

Identification of Genes Differentially Expressed in Cardioembolic Strokes and Atherothrombotic Strokes

Demographic Data for Cardioembolic and Atherosclerotic Stroke Patients

There were no significant age, gender or race differences and no differences in history of hypercholesterolemia or hypertension between the groups. Many of the cardioembolic stroke patients had a history of heart disease while none of the atherosclerotic stroke patients did (p=0.06).

Differential Expression Profiles of Cardioembolic Stroke and Atherosclerotic Stroke

The one-way ANOVA (FDR<0.05, Student-Newman-Keuls post hoc test, equal variance) yielded 660 genes that were differentially regulated for cardioembolic vs. atherosclerotic stroke. The Student t-test (p<0.001) yielded 135 genes that were differentially regulated for cardioembolic stroke vs atherosclerotic stroke. Of these 135 genes identified using the t-test, 95 of these were also identified using the one-way ANOVA. Using a 1.5 fold change filter, a total of 77 genes were significantly regulated between cardioembolic stroke and atherosclerotic stroke (significant using ANOVA or T-test; fold change>1.5). A Pearson cluster analysis using these 77 genes showed clear segregation of samples from controls and samples from subjects with cardioembolic stroke compared with subjects with atherosclerotic stroke at each of the times following stroke (FIG. 1). This also held true whether cluster analysis was performed using the 660 genes from the ANOVA analysis or the 135 genes from the t-test.
We next examined possible confounding factors on the identified etiology-related genes. Of the 54 genes identified as race-related (white/black, t-test. FDR<0.05, fold change>1.5), none are among the 77 etiology-related genes. Of the 424 genes identified as being regulated by aspirin in patients on aspirin prior to the stroke, only 5 were among the 77 etiology-related genes (6.5%) (Tang et al., Med Hypotheses (2006) 67:462-466).

Etiology Prediction of Undetermined Patients

Prediction Analysis of Microarrays (PAM) was used to determine the minimum number of genes that differentiate cardioembolic from atherosclerotic stroke. PAM employs shrunken nearest centroids to find the most reliable genes that differentiate two or more classes. (Tang et al., 2006, supra; Tibshirani et al., 2002, Proc Natl Acad Sci USA 99:6567-6572) PAM identified a minimum of 23 genes that best differentiated cardioembolic from atherosclerotic stroke. A 10 fold cross validation with a leave-one-out approach showed that these 23 genes correctly classified 32 of 33 samples from subjects with known causes of stroke (Table 1).
With regard to healthy controls, the 23 genes can be classified into 3 subgroups, using a 1.3 fold change in expression as a significant change. LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, and LAK exhibit at least a 1.3 fold increase in expression in subjects with cardioembolic stroke versus control subjects and RRAS2 and CD8B1 exhibit at least a 1.3 fold decrease in expression in subjects with cardioembolic stroke versus control subjects. C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41, and LAK exhibit at least 1.3 fold decrease in expression in subjects with atherothrombotic stroke versus control subjects.
Thus, by examining the expression level of 23 genes, we can achieve 95.2% sensitivity and 100% specificity for the diagnosis of cardioembolic stroke, 100% sensitivity and 95.2% specificity for atherothrombotic stroke, respectively. Thus, only a short list of genes needs to be screened for a single patient and this can be done simultaneously on a single real time PCR panel. The power of this list of genes was shown by predicting the cause of stroke in six additional patients with an unknown cause of stroke. All six of these six patients were diagnosed as having cardioembolic stroke, which would mean that they should be treated with Coumadin rather than other types of therapy to prevent future strokes.
By examining the blood gene expression of as few as 23 genes, we are able to differentiate cardioembolic stroke from atherothrombotic stroke in an objective manner as early as three hours after onset of stroke. As noted, the gene expression profiles disclosed herein can be used to determine the cause of the stroke or TIA in those patients who have an unknown etiology.
PAM and the minimum set of 23 genes were used to predict the etiology of the subjects whose cause of stroke could not be determined based upon clinical TOAST criteria. PAM classified all 12 of the unknown samples as being cardioembolic stroke with probabilities over 90% (92.9-99.9%, FIG. 2).

Function Analysis of Atherosclerotic and Cardioembolism Regulated Genes

The differentially regulated genes between cardioembolic stroke and atherosclerotic stroke were then classified by cluster analysis. Two subgroups of genes were identified: one is mainly regulated in cardioembolic stroke relative to healthy control (281 genes at 1.2 fold filter or 148 genes at 1.3 fold filter), the other is mainly regulated in atherosclerotic stroke relative to healthy control (84 genes at 1.2 fold filter or 63 genes at 1.3 fold filter). The functions of the two etiology-specific gene lists were then explored in the Nextbio System (Cupertino, Calif., USA), a web-based data search and analysis engine. The genes were ranked according to fold change and then queried against GO, KEGG pathways and REACTOME databases in Nextbio with p value 0.05 cut off. This analysis found that the genes regulated by cardioembolic stroke were mainly involved in response to pathogens, including immune cell activation, defense response, proliferation and apoptosis. In contrast, the genes mainly regulated by atherosclerotic stroke were related to hemostasis, cytokines and chemokines (FIG. 3). For many of the functional pathways represented, there is little overlap between the pathways related to atherosclerotic versus cardioembolic stroke.
Comparison of all the high throughput studies deposited in the Nextbio system (currently 6000 studies) to our study showed that atherosclerotic-specific expression profiles shared the most genes with Crohn's disease (28 genes in common)(GEO Series GSE3365), (Burczynski et al., J Mol Diagn (2006) 8:51-61) ulcerative colitis (14 genes in common) (GEO Series GSE3365), (Burczynski et al., 2006, supra) and rheumatoid arthritis (26 genes in common)(GEO Series GSE4588). On the other hand, cardioembolism-specific expression profiles were most similar to those from patients with sepsis and septic shock (105 genes and 109 genes in common at day 1, respectively)(GEO Series GSE4607). (Wong et al., Physiol Genomics (2007) 30(2):146-55).

Cell Type Sources of the Stroke Etiology Regulated Genes

The genes regulated in cardioembolic versus atherosclerotic stroke might or might not be expressed in restricted cell types in blood. Using our reference gene list derived from healthy controls, (Du et al., Genomics (2006) 87(6):693-703) most of the genes regulated in atherosclerotic stroke appear to be regulated in platelets and monocytes (FIG. 4a ) whereas most of the genes regulated in cardioembolic stroke appear to be expressed in neutrophils (FIG. 4b ).

Example 2

Diagnosis of Stroke

A blood sample will be obtained. RNA is isolated from the blood sample and the RNA labeled and applied to a microarray or similar platform to examine all expressed genes in blood (including, e.g., the genes set forth in Tables 1, 2, 3, 4, 5, or 6). From the microarray the expression of every gene in blood can then be calculated. Suitable software such as Prediction Analysis of Microarrays (PAM) is then used to calculate the probability that the changes of gene expression in the patient are due to a stroke. A probability of 85% of more that the changes represent a stroke is used to confirm the diagnosis of stroke.
The next step is to then determine the cause of the stroke. This is important because strokes from atherosclerosis may require surgery or vascular stenting; and strokes from cardioembolism require anti-coagulation with suitable mediacations including, e.g., Coumadin, Warfarin, and the like; and strokes from lacunar disease/hypertension require treatment with aspirin and other anti-platelet agents combined with drugs for the hypertension. From the same microarray used to make the diagnosis of a stroke, the expression of the genes listed in Table 1 is assessed in the patient's blood sample. The expression of these genes is compared to a control or reference sample, or to a combination of genes on the array that serve as control genes. As shown in Table 1, the genes that increase in stroke due to atherosclerosis are decreased in stroke due to cardioembolism; and the genes that increase in stroke due to cardioembolism decrease in stroke due to atherosclerosis; and some genes only change either in stroke due to cardioembolism or only change in stroke due to atherosclerosis. The profile of expression of all 23 genes is again entered into PAM, and PAM calculates the probability that the stroke in a given patient is either cardioembolic, atherosclerotic or due to some other cause. If the probability is 85% or greater for a given cause of stroke, then the cause of stroke will be reported. If the probability is 50% for any cause of stroke then the gene expression profile will not have been able to determine the cause of stroke.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, patent applications and accession numbers cited herein are hereby incorporated by reference in their entirety for all purposes.

TABLE 1

				Fold Difference
	Human	Gene		(Cardioembolic vs.
GenBank ID	UniGene ID	Symbol	Gene description	Atherothrombotic)

BC003064	481980	DAB2	disabled homolog 2, mitogen-responsive	1.449
			phosphoprotein (Drosophila)
NM_001343	481980	DAB2	disabled homolog 2, mitogen-responsive	1.531
			phosphoprotein (Drosophila)
NM_003897	591785	IER3	immediate early response 3	1.421
NM_017526	23581	LEPROT	leptin receptor overlapping transcript	1.464
NM_001999	519294	FBN2	fibrillin 2 (congenital contractural	1.64
			arachnodactyly)
NM_007150	16622	ZNF185	zinc finger protein 185 (LIM domain)	1.544
NM_000945	280604	PPP3R1	protein phosphatase 3 (formerly	1.503
			2B), regulatory subunit B,
			19 kDa, alpha isoform (calcineurin B, type I)
NM_004536	191356	BIRC1	NLR family, apoptosis inhibitory	1.417
		(NAIP ///	protein /// similar to Baculoviral IAP
		LOC728519)	repeat-containing protein 1 (Neuronal
			apoptosis inhibitory protein)
NM_001928	155597	CFD	complement factor D (adipsin)	1.542
NM_000419	411312	ITGA2B	integrin, alpha 2b (platelet glycoprotein	2.146
			IIb of IIb/IIIa complex, antigen CD41)
NM_004931	405667	CD8B	CD8b molecule	−1.785714286
AI753792	502004	RRAS2	related RAS viral (r-ras) oncogene homolog 2	−1.736111111
AA149644	150718	JAM3	junctional adhesion molecule 3	1.424
R64130	2164	PPBP	pro-platelet basic protein (chemokine	1.75
			(C-X-C motif) ligand 7)
AW296309	405667	CD8B	CD8b molecule	−1.526717557
NM_020152	222802	C21orf7	chromosome 21 open reading frame 7	1.527
BG251467	122514	SLC25A37	solute carrier family 25, member 37	1.444
AL136805	278436	TSHZ3	teashirt family zinc finger 3	1.439
AI520949	110675	PVRL2	poliovirus receptor-related 2	1.64
			(herpesvirus entry mediator B)
W73230	200100	C7orf41	chromosome 7 open reading frame 41	1.489
AI215106	591381	INSR	Insulin receptor	1.501
AW270105	144309	PCGF3	Polycomb group ring finger 3	1.495
BE867789	110675	PVRL2	poliovirus receptor-related 2	1.561
			(herpesvirus entry mediator B)
BE867789	110675	PVRL2	poliovirus receptor-related 2	2.028
			(herpesvirus entry mediator B)
AW167424	585653	NUMB	Numb homolog (Drosophila)	1.896
AI971212	434494	SYNJ2	synaptojanin	2	1.443
AA521086	99691	ALPK1	alpha-kinase 1	1.952

TABLE 2

GenBank ID	Unigene	Common Name	Gene description

AA167449	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AV646597	Hs.529901		MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
NM_000607	Hs.567311	ORM1	orosomucoid	1
BE644917	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AA628440	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AI733564	Hs.478588		Transcribed sequence with weak similarity to protein pir:
			A40138 (H. sapiens) A40138 glycogen phosphorylase
NM_000419	Hs.411312	ITGA2B	integrin, alpha 2b (platelet glycoprotein IIb
			of IIb/IIIa complex, antigen CD41B)
BE867789	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
AA521086	Hs.99691	LAK	lymphocyte alpha-kinase
AB023212	Hs.158722	PCNX	pecanex homolog (Drosophila)
AL109714	Hs.459049	LOC283687	hypothetical protein LOC283687
L10343		PI3	elafin has been sequenced at the protein level;
			pre-elafin has not; its existence is
			assumed from its molecular weight
			(PAGE analysis); putative; Homo sapiens
			elafin precursor, gene, complete cds.
AW167424	Hs.585653	NUMB	numb homolog (Drosophila)
M35999	Hs.218040	ITGB3	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
NM_002638	Hs.112341	PI3	protease inhibitor 3, skin-derived (SKALP)
AI929792	Hs.21374		Transcribed sequences
NM_000607	Hs.567311	ORM2	orosomucoid	1
R64130	Hs.2164	PPBP	pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
NM_003118	Hs.111779	SPARC	secreted protein, acidic, cysteine-rich (osteonectin)
NM_002736	Hs.433068	PRKAR2B	protein kinase, cAMP-dependent, regulatory, type II, beta
AA703239	Hs.159430		Transcribed sequence with weak similarity
			to protein prf: 1303335A (H. sapiens)
			1303335A decay accelerating factor long [Homo sapiens]
NM_004666	Hs.12114	VNN1	vanin	1
NM_016348	Hs.519694	C5orf4	chromosome 5 open reading frame 4
BI868572		DKFZp686115217	603392679F1 NIH_MGC_90 Homo sapiens cDNA
			clone IMAGE: 5402706 5′, mRNA sequence.
AW205418	Hs.495097	KIAA2025	KIAA2025 protein
NM_001999	Hs.519294	FBN2	fibrillin 2 (congenital contractural arachnodactyly)
AI520949	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
M25915	Hs.436657	CLU	clusterin (complement lysis inhibitor,
			SP-40, 40, sulfated glycoprotein 2,
			testosterone-repressed prostate message 2, apolipoprotein J)
BF055462	Hs.164226	THBS1	thrombospondin	1
AI679555	Hs.527653		Transcribed sequence with weak similarity
			to protein ref: NP_060312.1 (H. sapiens)
			hypothetical protein FLJ20489 [Homo sapiens]
AW051321	Hs.464137		CDNA FLJ30303 fis, clone BRACE2003269
NM_000129	Hs.335513	F13A1	coagulation factor XIII, A1 polypeptide
BE896490	Hs.595327	SNAP29	synaptosomal-associated protein, 29 kDa
NM_000697	Hs.422967	ALOX12	arachidonate 12-lipoxygenase
AA181060	Hs.349283		Clone IMAGE: 5288883, mRNA
NM_002619	Hs.81564	PF4	platelet factor 4 (chemokine (C-X-C motif) ligand 4)
AU157823		PYGL	AU157823 PLACE1 Homo sapiens cDNA clone
			PLACE1009595 3′, mRNA sequence.
BE867789	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
AA526844	Hs.556600	MYLK	MSTP083 mRNA, complete cds
BF435438	Hs.80720		Full length insert cDNA YH93B03
NM_005231	Hs.632133	EMS1	ems1 sequence (mammary tumor and squamous cell
			carcinoma-associated (p80/85 src substrate)
NM_007150	Hs.16622	ZNF185	zinc finger protein 185 (LIM domain)
NM_001928	Hs.155597	DF	D component of complement (adipsin)
NM_003831	Hs.445511	RIOK3	RIO kinase 3 (yeast)
NM_022763	Hs.159430	FAD104	FAD104
NM_001343	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
NM_020152	Hs.222802	C21orf7	chromosome 21 open reading frame 7
BC029493	Hs.369265	IRAK3	interleukin-1 receptor-associated kinase 3
BF976693	Hs.376675		CDNA FLJ34100 fis, clone FCBBF3007597
NM_000945	Hs.280604	PPP3R1	protein phosphatase 3 (formerly 2B), regulatory
			subunit B, 19 kDa, alpha isoform (calcineurin B, type I)
AI215106	Hs.591381	INSR	insulin receptor
X82240	Hs.2484	TCL1A	T-cell leukemia/lymphoma 1A
AW296309	Hs.405667	CD8B1	CD8 antigen, beta polypeptide 1 (p37)
M85256	Hs.554197	IGKC	Isolate donor Z clone Z55K immunoglobulin kappa
			light chain variable region mRNA, partial cds
AF439512	Hs.387787	KLRK1	killer cell lectin-like receptor subfamily K, member 1
NM_005442	Hs.591663	EOMES	eomesodermin homolog (Xenopus laevis)
AI424825	Hs.435052	ATP8A1	ATPase, aminophospholipid transporter
			(APLT), Class I, type 8A, member 1
NM_006159	Hs.505326	NELL2	NEL-like 2 (chicken)
BI547087			603190322F1 NIH_MGC_95 Homo sapiens cDNA
			clone IMAGE: 5261717 5′, mRNA sequence.
BC001872	Hs.510635	IGHM	synonym: MU; Homo sapiens immunoglobulin
			heavy constant mu, mRNA
			(cDNA clone MGC: 1228 IMAGE: 3544448), complete cds.
AW006735	Hs.85258	CD8A	CD8 antigen, alpha polypeptide (p32)
NM_007360	Hs.387787	KLRK1	killer cell lectin-like receptor subfamily K, member 1
NM_002261	Hs.74082	KLRC3	synonyms: NKG2E, NKG2-E; isoform
			NKG2-E is encoded by transcript variant
			NKG2-E; go_component: integral to membrane
			[goid 0016021] [evidence IEA];
			go_function: transmembrane receptor activity
			[goid 0004888] [evidence TAS]
			[pmid 9683661]; go_function: lectin
			[goid 0005530] [evidence IEA];
			go_function: sugar binding [goid 0005529]
			[evidence IEA]; go_process: cellular
			defense response [goid 0006968] [evidence TAS]
			[pmid 9683661]; go_process:
			heterophilic cell adhesion [goid 0007157]
			[evidence IEA]; Homo sapiens killer
			cell lectin-like receptor subfamily C, member 3
			(KLRC3), transcript variant NKG2-E, mRNA.
M13231	Hs.534032	TRGV9	T cell receptor gamma locus
AI753792	Hs.502004	RRAS2	related RAS viral (r-ras) oncogene homolog 2
M16768	Hs.534032	TRGV9	T-cell receptor (V-J-C) precursor; Human
			T-cell receptor gamma chain VJCI-
			CII-CIII region mRNA, complete cds.
NM_003175	Hs.458346	XCL1	chemokine (C motif) ligand 2
U96394	Hs.449601	IGL@	Clone P2-147 anti-oxidized LDL immunoglobulin
			light chain Fab mRNA, partial cds
M27331	Hs.534032	TRGV9	T cell receptor gamma locus
U23772	Hs.546295	XCL1	chemokine (C motif) ligand 1
NM_004931	Hs.405667	CD8B1	CD8 antigen, beta polypeptide 1 (p37)
NM_006275	Hs.6891	SFRS6	splicing factor, arginine/serine-rich 6
BC020552	Hs.379186	PDCD6	programmed cell death 6
NM_001548	Hs.20315	IFIT1	interferon-induced protein with tetratricopeptide repeats 1
BC005248	Hs.461178	EIF1AY	eukaryotic translation initiation factor 1A, Y-linked
NM_004660	Hs.99120	DDX3Y	DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked
NM_001008	Hs.282376	RPS4Y1	ribosomal protein S4, Y-linked

TABLE 3

GenBank ID	Unigene	Common Name	Gene description

AI733564	Hs.478588		Transcribed sequence with weak similarity
			to protein pir: A40138 (H. sapiens)
			A40138 glycogen phosphorylase
NM_000419	Hs.411312	ITGA2B	integrin, alpha 2b (platelet glycoprotein
			IIb of IIb/IIIa complex, antigen CD41B)
BE867789	Hs.110675	PVRL2	poliovirus receptor-related 2
			(herpesvirus entry mediator B)
AA521086	Hs.99691	LAK	lymphocyte alpha-kinase
AW167424	Hs.585653	NUMB	numb homolog (Drosophila)
R64130	Hs.2164	PPBP	pro-platelet basic protein (chemokine
			(C-X-C motif) ligand 7)
BI868572		DKFZp686I15217	603392679F1 NIH_MGC_90 Homo sapiens
			cDNA clone IMAGE: 5402706 5′,
			mRNA sequence.
NM_001999	Hs.519294	FBN2	fibrillin 2 (congenital contractural arachnodactyly)
AI520949	Hs.110675	PVRL2	poliovirus receptor-related 2
			(herpesvirus entry mediator B)
AW051321	Hs.464137		CDNA FLJ30303 fis, clone BRACE2003269
BE896490	Hs.595327	SNAP29	synaptosomal-associated protein, 29 kDa
AA181060	Hs.349283		Clone IMAGE: 5288883, mRNA
BE867789	Hs.110675	PVRL2	poliovirus receptor-related 2
			(herpesvirus entry mediator B)
NM_007150	Hs.16622	ZNF185	zinc5t finger protein 185 (LIM domain)
NM_001928	Hs.155597	DF	D component of complement (adipsin)
NM_001343	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
NM_020152	Hs.222802	C21orf7	chromosome 21 open reading frame 7
BF976693	Hs.376675		CDNA FLJ34100 fis, clone FCBBF3007597
NM_000945	Hs.280604	PPP3R1	protein phosphatase 3 (formerly 2B), regulatory
			subunit B, 19 kDa, alpha isoform (calcineurin B, type I)
AI215106	Hs.591381	INSR	insulin receptor
AW270105	Hs.643902	RNF3	ring finger protein 3
W73230	Hs.200100	Ells1	zd56c09.s1 Soares_fetal_heart_NbHH19W
			Homo sapiens cDNA clone IMAGE:
			344656 3′ similar to contains element
			MER10 repetitive element;, mRNA sequence.
NM_017526	Hs.23581	OBRGRP	leptin receptor
AW205122	Hs.496572	FLJ22679	hypothetical protein FLJ22679
BC003064	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
N63920	Hs.596025		CDNA clone IMAGE: 5294823, partial cds
BG251467	Hs.122514	MSCP	mitochondrial solute carrier protein
AI971212	Hs.434494	SYNJ2	synaptojanin	2
AL136805	Hs.278436	ZNF537	zinc finger protein 537
AA149644	Hs.150718	JAM3	junctional adhesion molecule 3
AW665656	Hs.633892	GLUL	glutamate-ammonia ligase (glutamine synthase)
NM_003897	Hs.591785	IER3	immediate early response 3
NM_004536	Hs.191356	BIRC1	baculoviral IAP repeat-containing 1
AI719730	Hs.24258	GUCY1A3	guanylate cyclase	1, soluble, alpha 3
AW796364	Hs.371594	MKNK1	Transcribed sequence with weak
			similarity to protein ref: NP_060265.1
			(H. sapiens) hypothetical protein
			FLJ20378 [Homo sapiens]
BC043380	Hs.468274		CDNA clone IMAGE: 5223469, partial cds
AA482548	Hs.497873	WDR26	zt34b03.s1 Soares ovary tumor NbHOT
			Homo sapiens cDNA clone
			IMAGE: 724205 3′, mRNA sequence.
AI476341	Hs.93825		CDNA FLJ39784 fis, clone SPLEN2002314
NM_009590	Hs.143102	AOC2	amine oxidase, copper containing 2 (retina-specific)
AA218974		LOC158563	zr02g12.s1 Stratagene NT2 neuronal
			precursor 937230 Homo sapiens cDNA
			clone IMAGE: 650374 3′, mRNA sequence.
AA010315	Hs.60371		Transcribed sequences
BE439987	Hs.462214	GAS7	growth arrest-specific 7
AI356228	Hs.515351	KIAA1533	KIAA1533
AK023845		USP34	ubiquitin specific protease 34
AI650285	Hs.287299		Transcribed sequence with weak
			similarity to protein ref: NP_060312.1
			(H. sapiens) hypothetical protein
			FLJ20489 [Homo sapiens]
BE221883	Hs.11184	UBE2R2	ubiquitin-conjugating enzyme E2R 2
BG337478	Hs.128037		CDNA FLJ38117 fis, clone D3OST2003797
AV723666		EFCBP2	AV723666 HTB Homo sapiens cDNA
			clone HTBABA11 5′, mRNA sequence.
BG334495	Hs.631749	LOC284021	hypothetical protein LOC284021
AI962978	Hs.469244	WASF2	WAS protein family, member 2
AW297879	Hs.436271		Transcribed sequences
NM_000313	Hs.64016	PROS1	protein S (alpha)
BF446281	Hs.433307	BCKDHA	branched chain keto acid dehydrogenase E1, alpha
			polypeptide (maple syrup urine disease)
AI476341	Hs.93825		CDNA FLJ39784 fis, clone SPLEN2002314
NM_002413	Hs.81874	MGST2	microsomal glutathione S-transferase 2
AI698731	Hs.202238		Transcribed sequences
BM849515	Hs.636486	LRRK1	leucine-rich repeat kinase 1
AK096134	Hs.378150		Chromosome 4 unknown transcript 1 variant 2 mRNA,
			partial sequence, alternatively spliced
AV700946	Hs.432337		Transcribed sequence with weak similarity
			to protein pir: 149130 (M.musculus)
			149130 reverse transcriptase-mouse
BE083088	Hs.591602	SSFA2	RC2-BT0642-030400-021-c05 BT0642
			Homo sapiens cDNA, mRNA sequence.
AF315688	Hs.591083	IFNK	interferon, kappa
BC013319	Hs.506381	FGD6	FYVE, RhoGEF and PH domain containing 6
NM_018407	Hs.492314	LAPTM4B	lysosomal associated protein transmembrane 4 beta
BC026969	Hs.492716	MGC21654	Homo sapiens unknown MGC21654 product, mRNA
			(cDNA clone IMAGE: 5116073), partial cds.
BC015590	Hs.382046		CDNA clone IMAGE: 4643842, partial cds
NM_014015	Hs.592051	DEXI	dexamethasone-induced transcript
AW572279	Hs.515840	DNMT3A	DNA (cytosine-5-)-methyltransferase 3 alpha
AL359941	Hs.593311		programmed cell death 6
BC019022	Hs.531856	dJ383J4.3	hypothetical gene supported by BC007071
AI692169	Hs.379186	PDCD6	wd37e07.x1 Soares_NFL_T_GBC_S1
			Homo sapiens cDNA clone
			IMAGE: 2330340 3′, mRNA sequence.
AC006033			Homo sapiens, Similar to steroidogenic
			acute regulatory protein related, clone
			MGC: 3251 IMAGE: 3505985, mRNA,
			complete cds.; H_NH0121A08.9 This
			gene was based on gi(13111773 13543614 14042926);
			Homo sapiens BAC clone
			RP11-121A8 from 7, complete sequence.
AL521959	Hs.487479	PSCD3	pleckstrin homology, Sec7 and coiled-coil domains 3
W67995	Hs.54943	FXC1	fracture callus	1 homolog (rat)
AW083371	Hs.173878	NIPSNAP1	nipsnap homolog 1 (C. elegans)
AF044954	Hs.513266	NDUFB10	NADH dehydrogenase (ubiquinone)
			1 beta subcomplex, 10, 22 kDa
AI347139	Hs.8162	MGC39372	hypothetical protein MGC39372
AK074465	Hs.462833	FLJ31952	hypothetical protein FLJ31952
AI609285	Hs.503891	USP28	tw83h09.x1 NCI_CGAP_HN5 Homo sapiens
			cDNA clone IMAGE: 2266337 3′
			similar to contains Alu repetitive
			element; contains element MER29 repetitive
			element;, mRNA sequence.
NM_000107	Hs.643521	DDB2	damage-specific DNA binding protein 2, 48 kDa
NM_005317	Hs.465511	GZMM	granzyme M (lymphocyte met-ase 1)
BC040914	Hs.322462		Clone IMAGE: 5745627, mRNA
AK001164	Hs.599785		CDNA FLJ10302 fis, clone NT2RM2000042
NM_005608	Hs.155975	PTPRCAP	protein tyrosine phosphatase, receptor
			type, C-associated protein
NM_013330	Hs.642710	NA4E7	non-metastatic cells 7, protein expressed
			in (nucleoside-diphosphate kinase)
AB020630	Hs.45719	PPP1R16B	protein phosphatase	1, regulatory (inhibitor) subunit 16B
AB020630	Hs.45719	PPP1R16B	protein phosphatase	1, regulatory (inhibitor) subunit 16B
AF298547	Hs.369279	NALP2	NACHT, leucine rich repeat and PYD containing 2
AW157571	Hs.479066	MARLIN1	multiple coiled-coil GABABR1-binding protein
AA767131	Hs.121432	KIAA0073	KIAA0073 protein
NM_004356	Hs.54457	CD81	CD81 antigen (target of antiproliferative antibody 1)
AI702465	Hs.23606		Transcribed sequences
U90339	Hs.584739	ADK	adenosine kinase
AW296309	Hs.405667	CD8B1	CD8 antigen, beta polypeptide 1 (p37)
AI753792	Hs.502004	RRAS2	related RAS viral (r-ras) oncogene homolog 2
NM_004931	Hs.405667	CD8B1	CD8 antigen, beta polypeptide 1 (p37)

TABLE 4

GenBank	Unigene
ID	ID	Common Name	Gene Description

AA167449	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AV646597	Hs.529901		MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
NM_000607	Hs.567311	ORM1	orosomucoid	1
BE644917	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AA628440	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AI733564	Hs.478588		Transcribed sequence with weak similarity
			to protein pir: A40138 (H. sapiens)
			A40138 glycogen phosphorylase
NM_000419	Hs.411312	ITGA2B	integrin, alpha 2b (platelet glycoprotein IIb
			of IIb/IIIa complex, antigen CD41B)
BE867789	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
AA521086	Hs.99691	LAK	lymphocyte alpha-kinase
AB023212	Hs.158722	PCNX	pecanex homolog (Drosophila)
AL109714	Hs.459049	LOC283687	hypothetical protein LOC283687
L10343		PI3	elafin has been sequenced at the protein level; pre-elafin
			has not; its existence is assumed from its molecular
			weight (PAGE analysis); putative; Homo sapiens
			elafin precursor, gene, complete cds.
AW167424	Hs.585653	NUMB	numb homolog (Drosophila)
M35999	Hs.218040	ITGB3	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
NM_002638	Hs.112341	PI3	protease inhibitor 3, skin-derived (SKALP)
AI929792	Hs.21374		Transcribed sequences
NM_000607	Hs.567311	ORM2	orosomucoid	1
R64130	Hs.2164	PPBP	pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
NM_003118	Hs.111779	SPARC	secreted protein, acidic, cysteine-rich (osteonectin)
NM_002736	Hs.433068	PRKAR2B	protein kinase, cAMP-dependent, regulatory, type II, beta
AA703239	Hs.159430		Transcribed sequence with weak similarity
			to protein prf: 1303335A (H. sapiens)
			1303335A decay accelerating factor long [Homo sapiens]
NM_004666	Hs.12114	VNN1	vanin	1
NM_016348	Hs.519694	C5orf4	chromosome 5 open reading frame 4
BI868572		DKFZp686I15217	603392679F1 NIH_MGC_90 Homo sapiens cDNA
			clone IMAGE: 5402706 5′, mRNA sequence.
AW205418	Hs.495097	KIAA2025	KIAA2025 protein
NM_001999	Hs.519294	FBN2	fibrillin 2 (congenital contractural arachnodactyly)
AI520949	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
M25915	Hs.436657	CLU	clusterin (complement lysis inhibitor, SP-40,
			40, sulfated glycoprotein 2, testosterone-repressed
			prostate message 2, apolipoprotein J)
BF055462	Hs.164226	THBS1	thrombospondin	1
AI679555	Hs.527653		Transcribed sequence with weak similarity
			to protein ref: NP_060312.1
			(H. sapiens) hypothetical protein FLJ20489 [Homo sapiens]
AW051321	Hs.464137		CDNA FLJ30303 fis, clone BRACE2003269
NM_000129	Hs.335513	F13A1	coagulation factor XIII, A1 polypeptide
BE896490	Hs.595327	SNAP29	synaptosomal-associated protein, 29 kDa
NM_000697	Hs.422967	ALOX12	arachidonate 12-lipoxygenase
AA181060	Hs.349283		Clone IMAGE: 5288883, mRNA
NM_002619	Hs.81564	PF4	platelet factor 4 (chemokine (C-X-C motif) ligand 4)
AU157823		PYGL	AU157823 PLACE1 Homo sapiens cDNA clone
			PLACE1009595 3′, mRNA sequence.
BE867789	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
AA526844	Hs.556600	MYLK	MSTP083 mRNA, complete cds
BF435438	Hs.80720		Full length insert cDNA YH93B03
NM_005231	Hs.632133	EMS1	ems1 sequence (mammary tumor and squamous cell
			carcinoma-associated (p80/85 src substrate)
NM_007150	Hs.16622	ZNF185	zinc finger protein 185 (LIM domain)
NM_001928	Hs.155597	DF	D component of complement (adipsin)
NM_003831	Hs.445511	RIOK3	RIO kinase 3 (yeast)
NM_022763	Hs.159430	FAD104	FAD104
NM_001343	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
NM_020152	Hs.222802	C21orf7	chromosome 21 open reading frame 7
BC029493	Hs.369265	IRAK3	interleukin-1 receptor-associated kinase 3
BF976693	Hs.376675		CDNA FLJ34100 fis, clone FCBBF3007597
NM_000945	Hs.280604	PPP3R1	protein phosphatase 3 (formerly 2B), regulatory
			subunit B, 19 kDa, alpha isoform (calcineurin B, type I)
AI215106	Hs.591381	INSR	insulin receptor
AI817801	Hs.191356	BIRC1	Transcribed sequence with strong similarity
			to protein sp: Q13075 (H. sapiens)
			BIR1_HUMAN Baculoviral IAP repeat-containing protein 1
AW270105	Hs.643902	RNF3	ring finger protein 3
BG913589	Hs.59214	LOC144871	DnaJ (Hsp40) homolog, subfamily C, member 3
W73230	Hs.200100	Ells1	zd56c09.s1 Soares_fetal_heart_NbHH19W
			Homo sapiens cDNA clone IMAGE: 344656 3′ similar
			to contains element MER10 repetitive element;,
			mRNA sequence.
BF691447	Hs.644051	B4GALT5	UDP-Gal: betaGlcNAc beta 1,4-galactosyltransferase,
			polypeptide 5
NM_005502	Hs.429294	ABCA1	ATP-binding cassette, sub-family A (ABC1), member 1
NM_000361	Hs.2030	THBD	thrombomodulin
AK024569	Hs.195403	DOCKS	dedicator of cytokinesis 5
AB051833	Hs.123239	ACRBP	acrosin binding protein
NM_004126	Hs.83381	GNG11	guanine nucleotide binding protein (G protein), gamma 11
Y07846	Hs.322852	GAS2L1	growth arrest-specific 2 like 1
BE327727	Hs.443301		Transcribed sequences
M36532	Hs.155097	CA2	carbonic anhydrase II
NM_017526	Hs.23581	OBRGRP	leptin receptor
AW205122	Hs.496572	FLJ22679	hypothetical protein FLJ22679
AI141116	Hs.123239	ACRBP	acrosin binding protein
AW293296	Hs.163893		Transcribed sequences
N63244	Hs.592143	TUBB1	tubulin, beta 1
BG120535		VNN1	602346858F1 NIH_MGC_90 Homo sapiens cDNA
			clone IMAGE: 4441695 5′, mRNA sequence.
AU152763	Hs.586165		CDNA FLJ10742 lis, clone NT2RP3001629
BC003064	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
N63920	Hs.596025		CDNA clone IMAGE: 5294823, partial cds
BG251467	Hs.122514	MSCP	mitochondrial solute carrier protein
AF237762	Hs.306199	GPR84	G protein-coupled receptor 84
AW206560	Hs.609146		Transcribed sequences
AI971212	Hs.434494	SYNJ2	synaptojanin	2
AL136805	Hs.278436	ZNF537	zinc finger protein 537
BC026299	Hs.518727		Clone IMAGE: 4275461, mRNA
BE675324	Hs.200770		Transcribed sequences
NM_021647	Hs.178121	KIAA0626
NM_018482	Hs.106015	DDEF1	synonyms: PAP, PAG2, ASAP1, ZG14P,
			KIAA1249; Homo sapiens development and
			differentiation enhancing factor 1 (DDEF1), mRNA.
AA149644	Hs.150718	JAM3	junctional adhesion molecule 3
AF325460	Hs.351812	CLECSF7	C-type (calcium dependent, carbohydrate-recognition domain)
			lectin, superfamily member 7
AW665656	Hs.633892	GLUL	glutamate-ammonia ligase (glutamine synthase)
AA417099	Hs.465709		Transcribed sequences
NM_003897	Hs.591785	IER3	immediate early response 3
AF275260	Hs.592117	CXCL16	chemokine (C-X-C motif) ligand 16
AF001540		MALAT-1	PRO1073 protein
AI640434	Hs.601545	FLJ10357	hypothetical protein FLJ10357
AW043859	Hs.235795		Clone IMAGE: 5263020, mRNA
H68759	Hs.122514		Transcribed sequences
NM_004536	Hs.191356	BIRC1	baculoviral IAP repeat-containing 1
AF086010	Hs.335205		Full length insert cDNA clone YW04H08
NM_003189	Hs.73828	TAL1	T-cell acute lymphocytic leukemia 1
AW138767	Hs.274256	ELOVL7	hypothetical protein FLJ23563
NM_003693	Hs.534497	SCARF1	scavenger receptor class F, member 1
BG177759	Hs.497873	WDR26	WD repeat domain 26
U49396	Hs.408615	P2RX5	purinergic receptor P2X, ligand-gated ion channel, 5
AA781795	Hs.546467	EPSTI1	epithelial stromal interaction 1 (breast)
BF433219			Transcribed sequences
BC003574	Hs.2484	TCL1A	T-cell leukemia/lymphoma 1A
AB051458	Hs.419171	KIAA1671	KIAA1671 protein
NM_004114	Hs.6540	FGF13	fibroblast growth factor 13
BF446578	Hs.125293	RASGEF1A	RasGEF domain family, member 1A
AA931562	Hs.444049		Transcribed sequence with weak similarity
			to protein ref: NP_060312.1
			(H. sapiens) hypothetical protein FLJ20489 [Homo sapiens]
BF514552	Hs.292449	FCRH3	Fc receptor-like protein 3
X82240	Hs.2484	TCL1A	T-cell leukemia/lymphoma 1A
AW296309	Hs.405667	CD8B1	CD8 antigen, beta polypeptide 1 (p37)
M85256	Hs.554197	IGKC	Isolate donor Z clone Z55K immunoglobulin kappa
			light chain variable region mRNA, partial cds
AF439512	Hs.387787	KLRK1	killer cell lectin-like receptor subfamily K, member 1
NM_005442	Hs.591663	EOMES	eomesodermin homolog (Xenopus laevis)
AI424825	Hs.435052	ATP8A1	ATPase, aminophospholipid transporter (APLT),
			Class I, type 8A, member 1
NM_006159	Hs.505326	NELL2	NEL-like 2 (chicken)
BI547087			603190322F1 NIH_MGC_95 Homo sapiens cDNA
			clone IMAGE: 5261717 5′, mRNA sequence.
BC001872	Hs.510635	IGHM	synonym: MU; Homo sapiens immunoglobulin
			heavy constant mu, mRNA
			(cDNA clone MGC: 1228 IMAGE: 3544448), complete cds.
AW006735	Hs.85258	CD8A	CD8 antigen, alpha polypeptide (p32)
NM_007360	Hs.387787	KLRK1	killer cell lectin-like receptor subfamily K, member 1
NM_002261	Hs.74082	KLRC3	synonyms: NKG2E, NKG2-E; isoform NKG2-E is
			encoded by transcript variant NKG2-E; go_component:
			integral to membrane [goid 0016021] [evidence IEA];
			go_function: transmembrane receptor activity
			[goid 0004888] [evidence TAS] [pmid 9683661];
			go_function: lectin [goid 0005530] [evidence IEA];
			go_function: sugar binding [goid 0005529] [evidence IEA];
			go_process: cellular defense response [goid 0006968]
			[evidence TAS] [pmid 9683661]; go_process:
			heterophilic cell adhesion [goid 0007157] [evidence
			IEA]; Homo sapiens killer cell lectin-like receptor
			subfamily C, member 3 (KLRC3), transcript variant
			NKG2-E, mRNA.
M13231	Hs.534032	TRGV9	T cell receptor gamma locus
AI753792	Hs.502004	RRAS2	related RAS viral (r-ras) oncogene homolog 2
M16768	Hs.534032	TRGV9	T-cell receptor (V-J-C) precursor; Human
			T-cell receptor gamma chain VJCI-
			CII-CIII region mRNA, complete cds.
NM_003175	Hs.458346	XCL1	chemokine (C motif) ligand 2
U96394	Hs.449601	IGL@	Clone P2-147 anti-oxidized LDL immunoglobulin light
			chain Fab mRNA, partial cds
M27331	Hs.534032	TRGV9	T cell receptor gamma locus
U23772	Hs.546295	XCL1	chemokine (C motif) ligand 1
NM_004931	Hs.405667	CD8B1	CD8 antigen, beta polypeptide 1 (p37)
NM_006275	Hs.6891	SFRS6	splicing factor, arginine/serine-rich 6
BC020552	Hs.379186	PDCD6	programmed cell death 6
NM_001548	Hs.20315	IFIT1	interferon-induced protein with tetratricopeptide repeats 1
BC005248	Hs.461178	EIF1AY	eukaryotic translation initiation factor 1A, Y-linked
NM_004660	Hs.99120	DDX3Y	DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked
NM_001008	Hs.282376	RPS4Y1	ribosomal protein S4, Y-linked

TABLE 5

GenBank	Unigene
ID	ID	Common Name	Gene Description

AA167449	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AV646597	Hs.529901		MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
NM_000607	Hs.567311	ORM1	orosomucoid	1
BE644917	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AA628440	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AI733564	Hs.478588		Transcribed sequence with weak similarity to protein
			pir: A40138 (H. sapiens) A40138 glycogen phosphorylase
NM_000419	Hs.411312	ITGA2B	integrin, alpha 2b (platelet glycoprotein IIb of
			IIb/IIIa complex, antigen CD41B)
BE867789	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
AA521086	Hs.99691	LAK	lymphocyte alpha-kinase
AB023212	Hs.158722	PCNX	pecanex homolog (Drosophila)
AL109714	Hs.459049	LOC283687	hypothetical protein LOC283687
L10343		PI3	elafin has been sequenced at the protein level;
			pre-elafin has not; its existence is assumed from its molecular
			weight (PAGE analysis); putative; Homo sapiens elafin
			precursor, gene, complete cds.
AW167424	Hs.585653	NUMB	numb homolog (Drosophila)
M35999	Hs.218040	ITGB3	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
NM_002638	Hs.112341	PI3	protease inhibitor 3, skin-derived (SKALP)
AI929792	Hs.21374		Transcribed sequences
NM_000607	Hs.567311	ORM2	orosomucoid	1
R64130	Hs.2164	PPBP	pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
NM_003118	Hs.111779	SPARC	secreted protein, acidic, cysteine-rich (osteonectin)
NM_002736	Hs.433068	PRKAR2B	protein kinase, cAMP-dependent, regulatory, type II, beta
AA703239	Hs.159430		Transcribed sequence with weak similarity
			to protein prf: 1303335A (H. sapiens)
			1303335A decay accelerating factor long [Homo sapiens]
NM_004666	Hs.12114	VNN1	vanin	1
NM_016348	Hs.519694	C5orf4	chromosome 5 open reading frame 4
BI868572		DKFZp686I15217	603392679F1 NIH_MGC_90 Homo sapiens cDNA
			clone IMAGE: 5402706 5′, mRNA sequence.
AW205418	Hs.495097	KIAA2025	KIAA2025 protein
NM_001999	Hs.519294	FBN2	fibrillin 2 (congenital contractural arachnodactyly)
AI520949	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
M25915	Hs.436657	CLU	clusterin (complement lysis inhibitor, SP-40, 40,
			sulfated glycoprotein 2, testosterone-
			repressed prostate message 2, apolipoprotein J)
BF055462	Hs.164226	THBS1	thrombospondin	1
AI679555	Hs.527653		Transcribed sequence with weak similarity
			to protein ref: NP_060312.1 (H. sapiens)
			hypothetical protein FLJ20489 [Homo sapiens]
AW051321	Hs.464137		CDNA FLJ30303 fis, clone BRACE2003269
NM_000129	Hs.335513	F13A1	coagulation factor XIII, A1 polypeptide
BE896490	Hs.595327	SNAP29	synaptosomal-associated protein, 29 kDa
NM_000697	Hs.422967	ALOX12	arachidonate 12-lipoxygenase
AA181060	Hs.349283		Clone IMAGE: 5288883, mRNA
NM_002619	Hs.81564	PF4	platelet factor 4 (chemokine (C-X-C motif) ligand 4)
AU157823		PYGL	AU157823 PLACE1 Homo sapiens cDNA clone
			PLACE1009595 3′, mRNA sequence.
BE867789	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
AA526844	Hs.556600	MYLK	MSTP083 mRNA, complete cds
BF435438	Hs.80720		Full length insert cDNA YH93B03
NM_005231	Hs.632133	EMS1	ems1 sequence (mammary tumor and squamous cell
			carcinoma-associated (p80/85 src substrate)
NM_007150	Hs.16622	ZNF185	zinc finger protein 185 (LIM domain)
NM_001928	Hs.155597	DF	D component of complement (adipsin)
NM_003831	Hs.445511	RIOK3	RIO kinase 3 (yeast)
NM_022763	Hs.159430	FAD104	FAD104
NM_001343	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
NM_020152	Hs.222802	C21orf7	chromosome 21 open reading frame 7
BC029493	Hs.369265	IRAK3	interleukin-1 receptor-associated kinase 3
BF976693	Hs.376675		CDNA FLJ34100 fis, clone FCBBF3007597
NM_000945	Hs.280604	PPP3R1	protein phosphatase 3 (formerly 2B), regulatory subunit B,
			19 kDa, alpha isoform (calcineurin B, type I)
AI215106	Hs.591381	INSR	insulin receptor
AI817801	Hs.191356	BIRC1	Transcribed sequence with strong similarity to protein
			sp: Q13075 (H. sapiens) BIR1_HUMAN
			Baculoviral IAP repeat-containing protein 1
AW270105	Hs.643902	RNF3	ring finger protein 3
BG913589	Hs.59214	LOC144871	DnaJ (Hsp40) homolog, subfamily C, member 3
W73230	Hs.200100	Ells1	zd56c09.s1 Soares_fetal_heart_NbHH19W
			Homo sapiens cDNA clone IMAGE: 344656 3′ similar to
			contains element MER10 repetitive element;, mRNA
			sequence.
BF691447	Hs.644051	B4GALT5	UDP-Gal: betaGlcNAc beta 1,4-galactosyltransferase,
			polypeptide 5
NM_005502	Hs.429294	ABCA1	ATP-binding cassette, sub-family A (ABC1), member 1
NM_000361	Hs.2030	THBD	thrombomodulin
AK024569	Hs.195403	DOCK5	dedicator of cytokinesis 5
AB051833	Hs.123239	ACRBP	acrosin binding protein
NM_004126	Hs.83381	GNG11	guanine nucleotide binding protein (G protein), gamma 11
Y07846	Hs.322852	GAS2L1	growth arrest-specific 2 like 1
BE327727	Hs.443301		Transcribed sequences
M36532	Hs.155097	CA2	carbonic anhydrase II
NM_017526	Hs.23581	OBRGRP	leptin receptor
AW205122	Hs.496572	FLJ22679	hypothetical protein FLJ22679
AI141116	Hs.123239	ACRBP	acrosin binding protein
AW293296	Hs.163893		Transcribed sequences
N63244	Hs.592143	TUBB1	tubulin, beta 1
BG120535		VNN1	602346858F1 NIH_MGC_90 Homo sapiens cDNA clone
			IMAGE: 4441695 5′, mRNA sequence.
AU152763	Hs.586165		CDNA FLJ10742 fis, clone NT2RP3001629
BC003064	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
N63920	Hs.596025		CDNA clone IMAGE: 5294823, partial cds
BG251467	Hs.122514	MSCP	mitochondrial solute carrier protein
AF237762	Hs.306199	GPR84	G protein-coupled receptor 84
AW206560	Hs.609146		Transcribed sequences
AI971212	Hs.434494	SYNJ2	synaptojanin	2
AL136805	Hs.278436	ZNF537	zinc finger protein 537
BC026299	Hs.518727		Clone IMAGE: 4275461, mRNA
BE675324	Hs.200770		Transcribed sequences
NM_021647	Hs.178121	KIAA0626
NM_018482	Hs.106015	DDEF1	synonyms: PAP, PAG2, ASAP1,
			ZG14P, KIAA1249; Homo sapiens development
			and differentiation enhancing factor 1 (DDEF1), mRNA.
AA149644	Hs.150718	JAM3	junctional adhesion molecule 3
AF325460	Hs.351812	CLECSF7	C-type (calcium dependent, carbohydrate-recognition
			domain) lectin, superfamily member 7
AW665656	Hs.633892	GLUL	glutamate-ammonia ligase (glutamine synthase)
AA417099	Hs.465709		Transcribed sequences
NM_003897	Hs.591785	IER3	immediate early response 3
AF275260	Hs.592117	CXCL16	chemokine (C-X-C motif) ligand 16
AF001540		MALAT-1	PRO1073 protein
AI640434	Hs.601545	FLJ10357	hypothetical protein FLJ10357
AW043859	Hs.235795		Clone IMAGE: 5263020, mRNA
H68759	Hs.122514		Transcribed sequences
NM_004536	Hs.191356	BIRC1	baculoviral IAP repeat-containing 1
AF086010	Hs.335205		Full length insert cDNA clone YW04H08
NM_003189	Hs.73828	TAL1	T-cell acute lymphocytic leukemia 1
AW138767	Hs.274256	ELOVL7	hypothetical protein FLJ23563
NM_003693	Hs.534497	SCARF1	scavenger receptor class F, member 1
BG177759	Hs.497873	WDR26	WD repeat domain 26
AW264036	Hs.478588	BCL6	B-cell CLL/lymphoma 6 (zinc finger protein 51)
AL119957	Hs.59214	DNAJC3	DnaJ (Hsp40) homolog, subfamily C, member 3
NM_018388	Hs.105134	MBNL3	muscleblind-like 3 (Drosophila)
AI640434	Hs.601545	FLJ10357	hypothetical protein FLJ10357
AI332764	Hs.516646		Transcribed sequences
AI719730	Hs.24258	GUCY1A3	guanylate cyclase 1, soluble, alpha 3
NM_130441	Hs.351812	CLECSF7	C-type (calcium dependent, carbohydrate-recognition
			domain) lectin, superfamily member 7
AW796364	Hs.371594	MKNK1	Transcribed sequence with weak similarity
			to protein ref: NP_060265.1 (H. sapiens)
			hypothetical protein FLJ20378 [Homo sapiens]
BC043380	Hs.468274		CDNA clone IMAGE: 5223469, partial cds
NM_017698		FLJ22679
AW069181	Hs.603149	ZAK	cr43e01.x1 Human bone marrow stromal cells Homo sapiens
			cDNA clone HBMSC_cr43e01 3′, mRNA sequence.
AF350881	Hs.272225	TRPM6	transient receptor potential cation channel,
			subfamily M, member 6
AA082707	Hs.592262	MLL5	myeloid/lymphoid or mixed-lineage leukemia 5
			(trithorax homolog, Drosophila)
AL035700		SH3BGRL2	continued from bA177G23.1 in Em: AL451064 match:
			proteins: Tr: O75368 Sw: P55822 Tr: Q9BPY5 Tr: Q9BRB8
			Sw: Q9WUZ7; Human DNA sequence from
			clone RP1-75K24 on chromosome 6q13-15 Contains
			the the 3′ end of the SH3BGRL2 gene for SH3 domain
			binding glutamic acid-rich protein-like 2, complete
			sequence.
N66571	Hs.501898	MRVI1	murine retrovirus integration site 1 homolog
AA482548	Hs.497873	WDR26	zt34b03.s1 Soares ovary tumor NbHOT Homo sapiens
			cDNA clone IMAGE: 724205 3′, mRNA sequence.
AI052659	Hs.334019		Transcribed sequences
AF074331		PAPSS2	Homo sapiens PAPS synthetase-2 (PAPSS2)
			mRNA, complete cds.
AI682905	Hs.280342	PRKAR1A	protein kinase, cAMP-dependent, regulatory, type I, alpha
			(tissue specific extinguisher 1)
AI022066	Hs.480763		Transcribed sequences
AI953847	Hs.148741	IBRDC2	IBR domain containing 2
NM_000361	Hs.2030	THBD	thrombomodulin
AY151286	Hs.196384	PTGS2	prostaglandin-endoperoxide synthase 2 (prostaglandin
			G/H synthase and cyclooxygenase)
AL713724	Hs.487994		MRNA; cDNA DKFZp667O0416 (from clone DKFZp667O0416)
AI831952	Hs.567518	NDE1	nudE nuclear distribution gene E homolog 1 (A. nidulans)
N45231	Hs.513053	DNAJA4	DnaJ (Hsp40) homolog, subfamily A, member 4
AA044825	Hs.520757	TBXAS1	thromboxane A synthase 1 (platelet, cytochrome
			P450, family 5, subfamily A)
AI476341	Hs.93825		CDNA FLJ39784 fis, clone SPLEN2002314
BF195718	Hs.221889	CSDA	cold shock domain protein A
AL833423	Hs.379548		MRNA; cDNA DKFZp313H2139 (from clone DKFZp313H2139)
NM_009590	Hs.143102	AOC2	amine oxidase, copper containing 2 (retina-specific)
AA770170	Hs.499489	MIR	c-mir, cellular modulator of immune recognition
BE965029	Hs.501928	MICAL2	601658812R1 NIH_MGC_69 Homo sapiens cDNA clone
			IMAGE: 3886131 3′, mRNA sequence.
BC018042	Hs.279815	CSAD	cysteine sulfinic acid decarboxylase
AA218974		LOC158563	zr02g12.s1 Stmtagene NT2 neuronal precursor 937230
			Homo sapiens cDNA clone IMAGE: 650374 3′, mRNA sequence.
AF188298	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
NM_005906	Hs.446125	MAK	male germ cell-associated kinase
BC002716	Hs.496572	FLJ22679	hypothetical protein FLJ22679
AK023512	Hs.463439	SPAG9	sperm associated antigen 9
AA010315	Hs.60371		Transcribed sequences
AF051151	Hs.135853	TLR5	toll-like receptor 5
BU929456		OSTF1	AGENCOURT_10424238 NIH_MGC_79 Homo sapiens
			cDNA clone IMAGE: 6663343 5′, mRNA sequence.
NM_002607	Hs.535898	PDGFA	platelet-derived growth factor alpha polypeptide
AK024748	Hs.297343	CAMKK2	calcium/calmodulin-dependent protein kinase kinase 2, beta
U76248	Hs.477959	SIAH2	seven in absentia homolog 2 (Drosophila)
AI819198	Hs.208229	GPR54	G protein-coupled receptor 54
AI452469	Hs.605187		Transcribed sequence with weak similarity to protein
			ref: NP_009032.1 (H. sapiens) sarcosine dehydrogenase;
			dimethylglycine dehydrogenase-like 1 [Homo sapiens]
AA037483	Hs.458395	HIST1H2BC	zk34a02.s1 Soares pregnant_uterus_NbHPU Homo sapiens
			cDNA clone IMAGE: 484682 3′, mRNA sequence.
U56237	Hs.631534	FCAR	Fc fragment of IgA, receptor for
N66045	Hs.29189		Transcribed sequences
AW299958	Hs.524491	PAPSS2	3′-phosphoadenosine 5′-phosphosulfate synthase 2
AK021983	Hs.106015		CDNA FLJ11921 fis, clone HEMBB1000318
NM_002398	Hs.526754	MEIS1	Meis1, myeloid ecotropic viral integration
			site
1 homolog (mouse)
AV725666	Hs.220950	FOXO3A	CDNA clone IMAGE: 4814010, partial cds
AK026714	Hs.7886	PELI1	pellino homolog 1 (Drosophila)
NM_005373	Hs.82906	MPL	CDC20 cell division cycle 20 homolog (S. cerevisiae)
AK024382			unnamed protein product; Homo sapiens
			cDNA FLJ14320 fis, clone PLACE3000455.
AA702409	Hs.592017		Transcribed sequences
AI074467	Hs.593643		Transcribed sequences
AI368358	Hs.496969	NPL	N-acetylneuraminate pyruvate lyase
			(dihydrodipicolinate synthase)
H28667	Hs.444451	ZAK	sterile alpha motif and leucine zipper containing kinase AZK
AL544951	Hs.280604	PPP3R1	AL544951 Homo sapiens PLACENTA
			COT 25-NORMALIZED Homo sapiens
			cDNA clone CS0DI012YC11 5-PRIME, mRNA sequence.
AL050388	Hs.487046	SOD2	superoxide dismutase	2, mitochondrial
AI829674	Hs.584845		Transcribed sequences
NM_018324	Hs.24309	THEDC1	hypothetical protein FLJ11106
AA362254	Hs.529633		Transcribed sequences
AW130600	Hs.99472		MRNA; cDNA DKFZp564O0862 (from clone DKFZp564O0862)
N25732	Hs.591328	FOXO3A	yx83c03.s1 Soares melanocyte 2NbHM Homo sapiens cDNA
			clone IMAGE: 268324 3′, mRNA sequence.
NM_017815	Hs.442782	C14orf94	chromosome 14 open reading frame 94
AK055448		ZNF587	Homo sapiens cDNA FLJ30886 fis, clone FEBRA2005014,
			weakly similar to ZINC FINGER PROTEIN 84.
S69189	Hs.464137	ACOX1	acyl-Coenzyme A oxidase 1, palmitoyl
AU146027	Hs.592326		AU146027 HEMBA1 Homo sapiens cDNA clone
			HEMBA1006595 3′, mRNA sequence.
BE439987	Hs.462214	GAS7	growth arrest-specific 7
AI363213	Hs.381058	KIAA0146	KIAA0146 protein
BF508786	Hs.613959		MRNA; cDNA DKFZp686J24234
			(from clone DKFZp686J24234)
BF680284	Hs.34558		CDNA: FLJ21199 fis, clone COL00235
H93077	Hs.519694	C5orf4	chromosome 5 open reading frame 4
AI798924	Hs.191850		Transcribed sequences
W19983	Hs.370725	OSBPL1A	oxysterol binding protein-like 1A
AA057437	Hs.458747		Transcribed sequences
NM_024565	Hs.14070	FLJ14166	hypothetical protein FLJ14166
AI356228	Hs.515351	KIAA1533	KIAA1533
AI937121	Hs.29282		Transcribed sequences
AI806045	Hs.61438		Transcribed sequences
N24643	Hs.446017	WSB1	WD repeat and SOCS box-containing 1
AU122258			AU122258 MAMMA1 Homo sapiens cDNA clone
			MAMMA1002009 5′, mRNA sequence.
AI278204	Hs.99472		MRNA; cDNA DKFZp564O0862 (from clone DKFZp564O0862)
AW450374	Hs.593734		Clone IMAGE: 4824518, mRNA
BE888885	Hs.220950	FOXO3A	CDNA clone IMAGE: 4814010, partial cds
AK023845		USP34	ubiquitin specific protease 34
BF511336	Hs.591641		Transcribed sequences
R12665	Hs.11594		CDNA FLJ27273 fis, clone TMS00761
BC006428	Hs.189119	CXXC5	CXXC finger 5
AI354636	Hs.586401		qu95c03.x1 NCI_CGAP_Gas4 Homo sapiens cDNA clone
			IMAGE: 1979812 3′, mRNA sequence.
AK025248	Hs.546419	FLJ13220	hypothetical protein FLJ13220
BE675549	Hs.79170	TTC9	tetratricopeptide repeat domain 9
NM_000579	Hs.450802	CCR5	chemokine (C-C motif) receptor 5
AB020630	Hs.45719	PPP1R16B	protein phosphatase 1, regulatory (inhibitor) subunit 16B
NM_002985	Hs.514821	CCL5	chemokine (C-C motif) ligand 5
NM_014392	Hs.518595	D4S234E	DNA segment on chromosome 4 (unique) 234 expressed sequence
AI821566	Hs.642748	TTC16	torsin family 2, member A
AA771779	Hs.461074	ZFP90	zinc finger protein 90 homolog (mouse)
AI084226	Hs.58831	TOSO	regulator of Fas-induced apoptosis
AF057557	Hs.58831	TOSO	regulator of Fas-induced apoptosis
NM_005356	Hs.470627	LCK	lymphocyte-specific protein tyrosine kinase
BC041468	Hs.434746	LOC339988	Hypothetical protein LOC339988 (LOC339988), mRNA
BC002556		RAB3IP
NM_002002	Hs.465778	FCER2	Fc fragment of IgE, low affinity II, receptor for (CD23A)
NM_018556	Hs.590883	SIRPB2	signal-regulatory protein beta 2
AB020630	Hs.45719	PPP1R16B	protein phosphatase 1, regulatory (inhibitor) subunit 16B
AF298547	Hs.369279	NALP2	NACHT, leucine rich repeat and PYD containing 2
AW157571	Hs.479066	MARLIN1	multiple coiled-coil GABABR1-binding protein
AA767131	Hs.121432	KIAA0073	KIAA0073 protein
M21121	Hs.514821	CCL5	chemokine (C-C motif) ligand 5
NM_004356	Hs.54457	CD81	CD81 antigen (target of antiproliferative antibody 1)
BF432238	Hs.585799	ZNF286	CDNA FLJ31089 fis, clone IMR321000092
NM_004310	Hs.160673	RHOH	ras homolog gene family, member H
BC000533	Hs.567374	EIF3S8	eukaryotic translation initiation factor 3, subunit 8, 110 kDa
U07236	Hs.470627	LCK	lymphocyte-specific protein tyrosine kinase
AI702465	Hs.23606		Transcribed sequences
AU155091	Hs.633678		Clone IMAGE: 4814008, mRNA
U90339	Hs.584739	ADK	adenosine kinase
AW575245	Hs.266331	FREB	Fc receptor homolog expressed in B cells
NM_030915	Hs.567598	LBH	likely ortholog of mouse limb-bud and heart gene
AI524095	Hs.403857	LY9	lymphocyte antigen 9
AW204712	Hs.385493	C10orf128	hypothetical protein LOC170371
U49396	Hs.408615	P2RX5	purinergic receptor P2X, ligand-gated ion channel, 5
AA781795	Hs.546467	EPSTI1	epithelial stromal interaction 1 (breast)
BF433219			Transcribed sequences
BC003574	Hs.2484	TCL1A	T-cell leukemia/lymphoma 1A
AB051458	Hs.419171	KIAA1671	KIAA1671 protein
NM_004114	Hs.6540	FGF13	fibroblast growth factor 13
BF446578	Hs.125293	RASGEF1A	RasGEF domain family, member 1A
AA931562	Hs.444049		Transcribed sequence with weak similarity to protein ref:
			NP_060312.1 (H. sapiens) hypothetical
			protein FLJ20489 [Homo sapiens]
BF514552	Hs.292449	FCRH3	Fc receptor-like protein 3
X82240	Hs.2484	TCL1A	T-cell leukemia/lymphoma 1A
AW296309	Hs.405667	CD8B1	CD8 antigen, beta polypeptide 1 (p37)
M85256	Hs.554197	IGKC	Isolate donor Z clone Z55K immunoglobulin kappa light
			chain variable region mRNA, partial cds
AF439512	Hs.387787	KLRK1	killer cell lectin-like receptor subfamily K, member 1
NM_005442	Hs.591663	EOMES	eomesodermin homolog (Xenopus laevis)
AI424825	Hs.435052	ATP8A1	ATPase, aminophospholipid transporter
			(APLT), Class I, type 8A, member 1
NM_006159	Hs.505326	NELL2	NEL-like 2 (chicken)
BI547087			603190322F1 NIH_MGC_95 Homo sapiens cDNA
			clone IMAGE: 5261717 5′, mRNA sequence.
BC001872	Hs.510635	IGHM	synonym: MU; Homo sapiens immunoglobulin
			heavy constant mu, mRNA (cDNA
			clone MGC: 1228 IMAGE: 3544448), complete cds.
AW006735	Hs.85258	CD8A	CD8 antigen, alpha polypeptide (p32)
NM_007360	Hs.387787	KLRK1	killer cell lectin-like receptor subfamily K, member 1
NM_002261	Hs.74082	KLRC3	synonyms: NKG2E, NKG2-E; isoform NKG2-E is
			encoded by transcript variant NKG2-E; go_component:
			integral to membrane [goid 0016021] [evidence IEA];
			go_function: transmembrane receptor activity [goid 0004888]
			[evidence TAS] [pmid 9683661]; go_function: lectin
			[goid 0005530] [evidence IEA]; go_function: sugar
			binding [goid 0005529] [evidence IEA]; go_process:
			cellular defense response [goid 0006968] [evidence TAS]
			[pmid 9683661]; go_process: heterophilic cell adhesion
			[goid 0007157] [evidence IEA]; Homo sapiens killer
			cell lectin-like receptor subfamily C, member 3
			(KLRC3), transcript variant NKG2-E, mRNA.
M13231	Hs.534032	TRGV9	T cell receptor gamma locus
AI753792	Hs.502004	RRAS2	related RAS viral (r-ras) oncogene homolog 2
M16768	Hs.534032	TRGV9	T-cell receptor (V-J-C) precursor; Human T-cell receptor
			gamma chain VJCI-CII-CIII region mRNA, complete cds.
NM_003175	Hs.458346	XCL1	chemokine (C motif) ligand 2
U96394	Hs.449601	IGL4	Clone P2-147 anti-oxidized LDL immunoglobulin
			light chain Fab mRNA, partial cds
M27331	Hs.534032	TRGV9	T cell receptor gamma locus
U23772	Hs.546295	XCL1	chemokine (C motif) ligand 1
NM_004931	Hs.405667	CD8B1	CD8 antigen, beta polypeptide 1 (p37)
NM_006275	Hs.6891	SFRS6	splicing factor, arginine/serine-rich 6
BC020552	Hs.379186	PDCD6	programmed cell death 6
NM_001548	Hs.20315	IFIT1	interferon-induced protein with tetratricopeptide repeats 1
BC005248	Hs.461178	EIF1AY	eukaryotic translation initiation factor 1A, Y-linked
NM_004660	Hs.99120	DDX3Y	DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked
NM_001008	Hs.282376	RPS4Y1	ribosomal protein S4, Y-linked

TABLE 6

GenBank	Unigene
ID	ID	Common Name	Gene Description

AA167449	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AV646597	Hs.529901		MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
NM_000607	Hs.567311	ORM1	orosomucoid	1
BE644917	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AA628440	Hs.529901	XIST	MRNA; cDNA DKFZp686K10163
			(from clone DKFZp686K10163)
AI733564	Hs.478588		Transcribed sequence with weak similarity to protein
			pir: A40138 (H. sapiens) A40138 glycogen phosphorylase
NM_000419	Hs.411312	ITGA2B	integrin, alpha 2b (platelet glycoprotein IIb
			of IIb/IIIa complex, antigen CD41B)
BE867789	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
AA521086	Hs.99691	LAK	lymphocyte alpha-kinase
AB023212	Hs.158722	PCNX	pecanex homolog (Drosophila)
AL109714	Hs.459049	LOC283687	hypothetical protein LOC283687
L10343		PI3	elafin has been sequenced at the protein level; pre-elafin
			has not; its existence is assumed from its molecular weight
			(PAGE analysis); putative; Homo sapiens elafin
			precursor, gene, complete cds.
AW167424	Hs.585653	NUMB	numb homolog (Drosophila)
M35999	Hs.218040	ITGB3	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
NM_002638	Hs.112341	PI3	protease inhibitor 3, skin-derived (SKALP)
AI929792	Hs.21374		Transcribed sequences
NM_000607	Hs.567311	ORM2	orosomucoid	1
R64130	Hs.2164	PPBP	pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
NM_003118	Hs.111779	SPARC	secreted protein, acidic, cysteine-rich (osteonectin)
NM_002736	Hs.433068	PRKAR2B	protein kinase, cAMP-dependent, regulatory, type II, beta
AA703239	Hs.159430		Transcribed sequence with weak similarity
			to protein prf: 1303335A (H. sapiens)
			1303335A decay accelerating factor long [Homo sapiens]
NM_004666	Hs.12114	VNN1	vanin	1
NM_016348	Hs.519694	C5orf4	chromosome 5 open reading frame 4
BI868572		DKFZp686I15217	603392679F1 NIH_MGC_90 Homo sapiens cDNA clone
			IMAGE: 5402706 5′, mRNA sequence.
AW205418	Hs.495097	KIAA2025	KIAA2025 protein
NM_001999	Hs.519294	FBN2	fibrillin 2 (congenital contractural arachnodactyly)
AI520949	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
M25915	Hs.436657	CLU	clusterin (complement lysis inhibitor, SP-40, 40,
			sulfated glycoprotein 2, testosterone-
			repressed prostate message 2, apolipoprotein J)
BF055462	Hs.164226	THBS1	thrombospondin	1
AI679555	Hs.527653		Transcribed sequence with weak similarity to
			protein ref: NP_060312.1 (H. sapiens)
			hypothetical protein FLJ20489 [Homo sapiens]
AW051321	Hs.464137		CDNA FLJ30303 fis, clone BRACE2003269
NM_000129	Hs.335513	F13A1	coagulation factor XIII, A1 polypeptide
BE896490	Hs.595327	SNAP29	synaptosomal-associated protein, 29 kDa
NM_000697	Hs.422967	ALOX12	arachidonate 12-lipoxygenase
AA181060	Hs.349283		Clone IMAGE: 5288883, mRNA
NM_002619	Hs.81564	PF4	platelet factor 4 (chemokine (C-X-C motif) ligand 4)
AU157823		PYGL	AU157823 PLACE1 Homo sapiens cDNA clone
			PLACE1009595 3′, mRNA sequence.
BE867789	Hs.110675	PVRL2	poliovirus receptor-related 2 (herpesvirus entry mediator B)
AA526844	Hs.556600	MYLK	MSTP083 mRNA, complete cds
BF435438	Hs.80720		Full length insert cDNA YH93B03
NM_005231	Hs.632133	EMS1	ems1 sequence (mammary tumor and squamous cell
			carcinoma-associated (p80/85 src substrate)
NM_007150	Hs.16622	ZNF185	zinc finger protein 185 (LIM domain)
NM_001928	Hs.155597	DF	D component of complement (adipsin)
NM_003831	Hs.445511	RIOK3	RIO kinase 3 (yeast)
NM_022763	Hs.159430	FAD104	FAD104
NM_001343	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
NM_020152	Hs.222802	C21orf7	chromosome 21 open reading frame 7
BC029493	Hs.369265	IRAK3	interleukin-1 receptor-associated kinase 3
BF976693	Hs.376675		CDNA FLJ34100 fis, clone FCBBF3007597
NM_000945	Hs.280604	PPP3R1	protein phosphatase 3 (formerly 2B), regulatory
			subunit B, 19 kDa, alpha isoform (calcineurin B, type I)
AI215106	Hs.591381	INSR	insulin receptor
AI817801	Hs.191356	BIRC1	Transcribed sequence with strong similarity
			to protein sp: Q13075 (H. sapiens)
			BIR1_HUMAN Baculoviral IAP repeat-containing protein 1
AW270105	Hs.643902	RNF3	ring finger protein 3
BG913589	Hs.59214	LOC144871	DnaJ (Hsp40) homolog, subfamily C, member 3
W73230	Hs.200100	Ells1	zd56c09.s1 Soares_fetal_heart_NbHH19W Homo sapiens
			cDNA clone IMAGE: 344656 3′ similar to contains element
			MER10 repetitive element;, mRNA sequence.
BF691447	Hs.644051	B4GALT5	UDP-Gal: betaGlcNAc beta 1,4-galactosyltransferase,
			polypeptide 5
NM_005502	Hs.429294	ABCA1	ATP-binding cassette, sub-family A (ABC1), member 1
NM_000361	Hs.2030	THBD	thrombomodulin
AK024569	Hs.195403	DOCK5	dedicator of cytokinesis 5
AB051833	Hs.123239	ACRBP	acrosin binding protein
NM_004126	Hs.83381	GNG11	guanine nucleotide binding protein (G protein), gamma 11
Y07846	Hs.322852	GAS2L1	growth arrest-specific 2 like 1
BE327727	Hs.443301		Transcribed sequences
M36532	Hs.155097	CA2	carbonic anhydrase II
NM_017526	Hs.23581	OBRGRP	leptin receptor
AW205122	Hs.496572	FLJ22679	hypothetical protein FLJ22679
AI141116	Hs.123239	ACRBP	acrosin binding protein
AW293296	Hs.163893		Transcribed sequences
N63244	Hs.592143	TUBB1	tubulin, beta 1
BG120535		VNN1	602346858F1 NIH_MGC_90 Homo sapiens cDNA clone
			IMAGE: 4441695 5′, mRNA sequence.
AU152763	Hs.586165		CDNA FLJ10742 fis, clone NT2RP3001629
BC003064	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
N63920	Hs.596025		CDNA clone IMAGE: 5294823, partial cds
BG251467	Hs.122514	MSCP	mitochondrial solute carrier protein
AF237762	Hs.306199	GPR84	G protein-coupled receptor 84
AW206560	Hs.609146		Transcribed sequences
AI971212	Hs.434494	SYNJ2	synaptojanin	2
AL136805	Hs.278436	ZNF537	zinc finger protein 537
BC026299	Hs.518727		Clone IMAGE: 4275461, mRNA
BE675324	Hs.200770		Transcribed sequences
NM_021647	Hs.178121	KIAA0626
NM_018482	Hs.106015	DDEF1	synonyms: PAP, PAG2, ASAP1, ZG14P,
			KIAA1249; Homo sapiens development
			and differentiation enhancing factor 1 (DDEF1), mRNA.
AA149644	Hs.150718	JAM3	junctional adhesion molecule 3
AF325460	Hs.351812	CLECSF7	C-type (calcium dependent, carbohydrate-recognition
			domain) lectin, superfamily member 7
AW665656	Hs.633892	GLUL	glutamate-ammonia ligase (glutamine synthase)
AA417099	Hs.465709		Transcribed sequences
NM_003897	Hs.591785	IER3	immediate early response 3
AF275260	Hs.592117	CXCL16	chemokine (C-X-C motif) ligand 16
AF001540		MALAT-1	PRO1073 protein
AI640434	Hs.601545	FLJ10357	hypothetical protein FLJ10357
AW043859	Hs.235795		Clone IMAGE: 5263020, mRNA
H68759	Hs.122514		Transcribed sequences
NM_004536	Hs.191356	BIRC1	baculoviral IAP repeat-containing 1
AF086010	Hs.335205		Full length insert cDNA clone YW04H08
NM_003189	Hs.73828	TAL1	T-cell acute lymphocytic leukemia 1
AW138767	Hs.274256	ELOVL7	hypothetical protein FLJ23563
NM_003693	Hs.534497	SCARF1	scavenger receptor class F, member 1
BG177759	Hs.497873	WDR26	WD repeat domain 26
AW264036	Hs.478588	BCL6	B-cell CLL/lymphoma 6 (zinc finger protein 51)
AL119957	Hs.59214	DNAJC3	DnaJ (Hsp40) homolog, subfamily C, member 3
NM_018388	Hs.105134	MBNL3	muscleblind-like 3 (Drosophila)
AI640434	Hs.601545	FLJ10357	hypothetical protein FLJ10357
AI332764	Hs.516646		Transcribed sequences
AI719730	Hs.24258	GUCY1A3	guanylate cyclase 1, soluble, alpha 3
NM_130441	Hs.351812	CLECSF7	C-type (calcium dependent, carbohydrate-recognition
			domain) lectin, superfamily member 7
AW796364	Hs.371594	MKNK1	Transcribed sequence with weak similarity
			to protein ref: NP_060265.1 (H. sapiens)
			hypothetical protein FLJ20378 [Homo sapiens]
BC043380	Hs.468274		CDNA clone IMAGE: 5223469, partial cds
NM_017698		FLJ22679
AW069181	Hs.603149	ZAK	cr43e01.x1 Human bone marrow stromal cells Homo sapiens
			cDNA clone HBMSC_cr43e01 3′, mRNA sequence.
AF350881	Hs.272225	TRPM6	transient receptor potential cation channel,
			subfamily M, member 6
AA082707	Hs.592262	MLL5	myeloid/lymphoid or mixed-lineage leukemia 5
			(trithorax homolog, Drosophila)
AL035700		SH3BGRL2	continued from bA177G23.1 in Em: AL451064 match:
			proteins: Tr: O75368 Sw: P55822 Tr: Q9BPY5
			Tr: Q9BRB8 Sw: Q9WUZ7; Human DNA sequence from
			clone RP1-75K24 on chromosome 6q13-15 Contains
			the the 3′ end of the SH3BGRL2 gene for SH3 domain
			binding glutamic acid-rich protein-like 2, complete
			sequence.
N66571	Hs.501898	MRVI1	murine retrovirus integration site 1 homolog
AA482548	Hs.497873	WDR26	zt34b03.s1 Soares ovary tumor NbHOT Homo sapiens cDNA
			clone IMAGE: 724205 3′, mRNA sequence.
AI052659	Hs.334019		Transcribed sequences
AF074331		PAPSS2	Homo sapiens PAPS synthetase-2 (PAPSS2)
			mRNA, complete cds.
AI682905	Hs.280342	PRKAR1A	protein kinase, cAMP-dependent, regulatory, type I, alpha
			(tissue specific extinguisher 1)
AI022066	Hs.480763		Transcribed sequences
AI953847	Hs.148741	IBRDC2	IBR domain containing 2
NM_000361	Hs.2030	THBD	thrombomodulin
AY151286	Hs.196384	PTGS2	prostaglandin-endoperoxide synthase 2 (prostaglandin
			G/H synthase and cyclooxygenase)
AL713724	Hs.487994		MRNA; cDNA DKFZp667O0416
			(from clone DKFZp667O0416)
AI831952	Hs.567518	NDE1	nudE nuclear distribution gene E homolog 1 (A. nidulans)
N45231	Hs.513053	DNAJA4	DnaJ (Hsp40) homolog, subfamily A, member 4
AA044825	Hs.520757	TBXAS1	thromboxane A synthase 1 (platelet, cytochrome
			P450, family 5, subfamily A)
AI476341	Hs.93825		CDNA FLJ39784 fis, clone SPLEN2002314
BF195718	Hs.221889	CSDA	cold shock domain protein A
AL833423	Hs.379548		MRNA; cDNA DKFZp313H2139
			(from clone DKFZp313H2139)
NM_009590	Hs.143102	AOC2	amine oxidase, copper containing 2 (retina-specific)
AA770170	Hs.499489	MIR	c-mir, cellular modulator of immune recognition
BE965029	Hs.501928	MICAL2	601658812R1 NIH_MGC_69 Homo sapiens cDNA clone
			IMAGE: 3886131 3′, mRNA sequence.
BC018042	Hs.279815	CSAD	cysteine sulfinic acid decarboxylase
AA218974		LOC158563	zr02g12.s1 Stmtagene NT2 neuronal precursor
			937230 Homo sapiens cDNA clone
			IMAGE: 650374 3′, mRNA sequence.
AF188298	Hs.481980	DAB2	disabled homolog 2, mitogen-responsive
			phosphoprotein (Drosophila)
NM_005906	Hs.446125	MAK	male germ cell-associated kinase
BC002716	Hs.496572	FLJ22679	hypothetical protein FLJ22679
AK023512	Hs.463439	SPAG9	sperm associated antigen 9
AA010315	Hs.60371		Transcribed sequences
AF051151	Hs.135853	TLR5	toll-like receptor 5
BU929456		OSTF1	AGENCOURT_10424238 NIH_MGC_79 Homo sapiens
			cDNA clone IMAGE: 6663343 5′, mRNA sequence.
NM_002607	Hs.535898	PDGFA	platelet-derived growth factor alpha polypeptide
AK024748	Hs.297343	CAMKK2	calcium/calmodulin-dependent protein kinase kinase 2, beta
U76248	Hs.477959	SIAH2	seven in absentia homolog 2 (Drosophila)
AI819198	Hs.208229	GPR54	G protein-coupled receptor 54
AI452469	Hs.605187		Transcribed sequence with weak similarity to protein
			ref: NP_009032.1 (H. sapiens) sarcosine dehydrogenase;
			dimethylglycine dehydrogenase-like 1 [Homo sapiens]
AA037483	Hs.458395	HIST1H2BC	zk34a02.s1 Soares_pregnant_uterus_NbHPU Homo sapiens
			cDNA clone IMAGE: 484682 3′, mRNA sequence.
U56237	Hs.631534	FCAR	Fc fragment of IgA, receptor for
N66045	Hs.29189		Transcribed sequences
AW299958	Hs.524491	PAPSS2	3′-phosphoadenosine 5′-phosphosulfate synthase 2
AK021983	Hs.106015		CDNA FLJ11921 fis, clone HEMBB1000318
NM_002398	Hs.526754	MEIS1	Meis1, myeloid ecotropic viral integration
			site
1 homolog (mouse)
AV725666	Hs.220950	FOXO3A	CDNA clone IMAGE: 4814010, partial cds
AK026714	Hs.7886	PELI1	pellino homolog 1 (Drosophila)
NM_005373	Hs.82906	MPL	CDC20 cell division cycle 20 homolog (S. cerevisiae)
AK024382			unnamed protein product; Homo sapiens cDNA
			FLJ14320 fis, clone PLACE3000455.
AA702409	Hs.592017		Transcribed sequences
AI074467	Hs.593643		Transcribed sequences
AI368358	Hs.496969	NPL	N-acetylneuraminate pyruvate lyase
			(dihydrodipicolinate synthase)
H28667	Hs.444451	ZAK	sterile alpha motif and leucine zipper containing kinase AZK
AL544951	Hs.280604	PPP3R1	AL544951 Homo sapiens PLACENTA
			COT 25-NORMALIZED Homo sapiens
			cDNA clone CSODI012VC11 5-PRIME, mRNA sequence.
AL050388	Hs.487046	SOD2	superoxide dismutase	2, mitochondrial
AI829674	Hs.584845		Transcribed sequences
NM_018324	Hs.24309	THEDC1	hypothetical protein FLJ11106
AA362254	Hs.529633		Transcribed sequences
AW130600	Hs.99472		MRNA; cDNA DKFZp564O0862
			(from clone DKFZp564O0862)
N25732	Hs.591328	FOXO3A	yx83c03.s1 Soares melanocyte 2NbHM Homo sapiens cDNA
			clone IMAGE: 268324 3′, mRNA sequence.
NM_017815	Hs.442782	C14orf94	chromosome 14 open reading frame 94
AK055448		ZNF587	Homo sapiens cDNA FLJ30886 fis, clone FEBRA2005014,
			weakly similar to ZINC FINGER PROTEIN 84.
S69189	Hs.464137	ACOX1	acyl-Coenzyme A oxidase 1, palmitoyl
AU146027	Hs.592326		AU146027 HEMBA1 Homo sapiens cDNA clone
			HEMBA1006595 3′, mRNA sequence.
BE439987	Hs.462214	GAS7	growth arrest-specific 7
AI363213	Hs.381058	KIAA0146	KIAA0146 protein
BF508786	Hs.613959		MRNA; cDNA DKFZp686J24234
			(from clone DKFZp686J24234)
BF680284	Hs.34558		CDNA: FLJ21199 fis, clone COL00235
H93077	Hs.519694	C5orf4	chromosome 5 open reading frame 4
AI798924	Hs.191850		Transcribed sequences
W19983	Hs.370725	OSBPL1A	oxysterol binding protein-like 1A
AA057437	Hs.458747		Transcribed sequences
NM_024565	Hs.14070	FLJ14166	hypothetical protein FLJ14166
AI356228	Hs.515351	KIAA1533	KIAA1533
AI937121	Hs.29282		Transcribed sequences
AI806045	Hs.61438		Transcribed sequences
N24643	Hs.446017	WSB1	WD repeat and SOCS box-containing 1
AU122258			AU122258 MAMMAL Homo sapiens cDNA clone
			MAMMA1002009 5′, mRNA sequence.
AI278204	Hs.99472		MRNA; cDNA DKFZp564O0862
			(from clone DKFZp564O0862)
AW450374	Hs.593734		Clone IMAGE: 4824518, mRNA
BE888885	Hs.220950	FOXO3A	CDNA clone IMAGE: 4814010, partial cds
AK023845		USP34	ubiquitin specific protease 34
BF511336	Hs.591641		Transcribed sequences
NM_007199	Hs.369265	IRAK3	interleukin-1 receptor-associated kinase 3
AI056872	Hs.591328		Transcribed sequences
BG251467	Hs.122514	MSCP	mitochondrial solute carrier protein
NM_022083		C1orf24	chromosome	1 open reading frame 24
AW057518	Hs.608694	ELL2	elongation factor, RNA polymerase II, 2
AI650285	Hs.287299		Transcribed sequence with weak similarity
			to protein ref: NP_060312.1 (H. sapiens)
			hypothetical protein FLJ20489 [Homo sapiens]
AU147506	Hs.7886	PELI1	pellino homolog 1 (Drosophila)
BF435852	Hs.464137	ACOX1	acyl-Coenzyme A oxidase 1, palmitoyl
W03103	Hs.106015	DDEF1	za04b05.r1 Soares melanocyte 2NbHM Homo sapiens
			cDNA clone IMAGE: 291537 5′, mRNA sequence.
AI458949	Hs.5204141	INGR1	interferon gamma receptor 1
AB030034	Hs.444451	ZAK	sterile alpha motif and leucine zipper containing kinase AZK
BC011877	Hs.195403	DOCK5	Hypothetical protein LOC286061 (LOC286061), mRNA
AL137028
NM_007219	Hs.589884	RNF24	ring finger protein 24
AA868809	Hs.25447		CDNA FLJ43180 fis, clone FCBBF3013846
NM_012329	Hs.463483	MMD	monocyte to macrophage differentiation-associated
AA778783	Hs.420024		Transcribed sequence with weak similarity
			to protein ref: NP_055301.1 (H. sapiens)
			neuronal thread protein [Homo sapiens]
NM_030918	Hs.192326	SNX27	sorting nexin family member 27
T79640	Hs.174312		Transcribed sequences
R91734			yp98f04.r1 Soares fetal liver spleen 1NFLS Homo sapiens
			cDNA clone IMAGE: 195487 5′, mRNA sequence.
U44403	Hs.75367	SLA	Src-like-adaptor
BF591270	Hs.595473	KLHL8	7h44e04.x1 NCI_CGAP_Co16 Homo sapiens cDNA
			clone IMAGE: 3318846 3′, mRNA sequence.
BC042590	Hs.434241	LOC404636	Homo sapiens cDNA clone IMAGE: 4821044, partial cds.
NM_018586		MSCP
BE221883	Hs.11184	UBE2R2	ubiquitin-conjugating enzyme E2R 2
BG337478	Hs.128037		CDNA FLJ38117 fis, clone D3OST2003797
AV723666		EFCBP2	AV723666 HTB Homo sapiens cDNA clone
			HTBABA11 5′, mRNA sequence.
AK025898	Hs.525232	LRP10	low density lipoprotein receptor-related protein 10
AB062477			Homo sapiens OK/SW-c1.41 mRNA, complete cds.
AW467357	Hs.371720	SYK	spleen tyrosine kinase
AI808120	Hs.479766	RRM1	TPA regulated locus
BE966748		ERO1L	601661247R1 NIH_MGC_72 Homo sapiens cDNA
			clone IMAGE: 3916235 3′, mRNA sequence.
AK024677	Hs.632602	ASAHL	N-acylsphingosine amidohydrolase (acid ceramidase)-like
AL038191	Hs.474536		DKFZp566P1724_s1 566 (synonym: hfkd2) Homo sapiens
			cDNA clone DKFZp566P1724 3′, mRNA sequence.
BG432887	Hs.442789		Transcribed sequence with weak similarity to protein
			ref: NP_005210.1 (H. sapiens) diaphanous 1; Diaphanous,
			Drosophila, homolog of, 1; deafness, autosomal dominant
			1; diaphanous
BF516252	Hs.528703	ANKRD13	ankyrin repeat domain 13
AA576497	Hs.492740	ATF6	activating transcription factor 6
NM_017593	Hs.146551	BMP2K	BMP2 inducible kinase
NM_003105	Hs.368592	SORL1	sortilin-related receptor, L(DLR class) A repeats-containing
AA706922	Hs.517034		Transcribed sequences
AI963142	Hs.48353		CDNA FLJ32274 fis, clone PROST2000036
AI735391	Hs.146551	BMP2K	at10e09.x1 Barstead aorta HPLRB6 Homo sapiens cDNA
			clone IMAGE: 2354728 3′, mRNA sequence.
AI807658	Hs.192326		Transcribed sequences
BE693389			Transcribed sequences
N32832	Hs.159430	FAD104	FAD104
AF015452	Hs.390736	CFLAR	CASP8 and FADD-like apoptosis regulator
AL049273	Hs.429434		MRNA; cDNA DKFZp564H023 (from clone DKFZp564H023)
BC039388	Hs.237886		Clone IMAGE: 5298774, mRNA
AA382004	Hs.122514	MSCP	EST95296 Activated T-cells II Homo sapiens
			cDNA 5′ end, mRNA sequence.
BG334495	Hs.631749	LOC284021	hypothetical protein LOC284021
AW367571	Hs.438673	LOC338692	hypothetical protein LOC338692
AI084056	Hs.464217	PGS1	phosphatidylglycerophosphate synthase
AK054840	Hs.106015		CDNA FLJ30278 fis, clone BRACE2002755
AI051950	Hs.99472		MRNA; cDNA DKFZp564O0862
			(from clone DKFZp564O0862)
BF724303	Hs.412293		Transcribed sequences
AK000794	Hs.520757		CDNA FLJ20787 fis, clone COL02178
AF153820	Hs.1547	KCNJ2	potassium inwardly-rectifying channel, subfamily J, member 2
BE671084	Hs.293593	ARHGAP26	GTPase regulator associated with focal
			adhesion kinase pp125(FAK)
AU146685	Hs.126667		CDNA FLJ11971 fis, clone HEMBB1001208
AI962978	Hs.469244	WASF2	WAS protein family, member 2
AI634046	Hs.390736	CFLAR	CASP8 and FADD-like apoptosis regulator
AW297879	Hs.436271		Transcribed sequences
AK025534	Hs.588289		CDNA: FLJ21881 fis, clone HEP02746
N72610	Hs.484363		Transcribed sequence with strong similarity to protein
			pdb: 1BGM (E. coli) O Chain O, Beta-Galactosidase
BF056507	Hs.372000	NSMAF	neutral sphingomyelinase (N-SMase)
			activation associated factor
W87434	Hs.106015		Transcribed sequence with moderate similarity
			to protein sp: P39188 (H. sapiens) ALU1_HUMAN
			Alu subfamily J sequence contamination warning entry
AF085978	Hs.474596		Homo sapiens full length insert cDNA clone YT87E05.
N63821	Hs.175437	DKFZp434C184	za26c12.s1 Soares fetal liver spleen 1NFLS Homo sapiens
			cDNA clone IMAGE: 293686 3′, mRNA sequence.
AV700891	Hs.517296		v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)
AI692401	Hs.29282		Transcribed sequences
N52625	Hs.603141	ZRANB1	yv37f12.s1 Soares fetal liver spleen 1NFLS Homo sapiens
			cDNA clone IMAGE: 244943 3′ similar to contains element
			MER22 repetitive element;, mRNA sequence.
R45471	Hs.479396	RBPSUH	recombining binding protein suppressor of hairless (Drosophila)
H67156	Hs.122514		Transcribed sequences
BF724558	Hs.636976		Transcribed sequence with moderate similarity
			to protein pir: T02670 (H. sapiens)
			T02670 probable thromboxane A2 receptor isoform beta-human
BE551054	Hs.279583	DREV1	DORA reverse strand protein 1
NM_021213	Hs.285218	PCTP	phosphatidylcholine transfer protein
N93399	Hs.494406	LOC349236	CDNA FLJ46484 fis, clone THYMU3026350
BF668314	Hs.221497	PRO0149	PRO0149 protein
NM_002213	Hs.536663	ITGB5	integrin, beta 5
AW974609	Hs.136398	ZCCHC6	zinc finger, CCHC domain containing 6
AK001393	Hs.134857	MGC12458	hypothetical protein MGC12458
NM_000313	Hs.64016	PROS1	protein S (alpha)
AW027474	Hs.446678	NCOA2	nuclear receptor coactivator 2
AI422414	Hs.484551		Transcribed sequences
NM_004196	Hs.280881	CDKL1	cyclin-dependent kinase-like 1 (CDC2-related kinase)
AI374686	Hs.122523		Transcribed sequences
AW184034	Hs.600998	BRAF	v-raf murine sarcoma viral oncogene homolog B1
BC025707	Hs.484099	KCNMB1	potassium large conductance calcium-activated
			channel, subfamily M, beta member 1
AA815354	Hs.520684		Hypothetical LOC284527 (LOC284527), mRNA
AF306674	Hs.132050	MGC40368	hypothetical protein MGC40368
W93728	Hs.77890	GUCY1B3	guanylate cyclase 1, soluble, beta 3
NM_003326	Hs.181097	TNFSF4	tumor necrosis factor (ligand) superfamily, member 4
			(tax-transcriptionally activated glycoprotein 1, 34 kDa)
R62432	Hs.211252	SLC24A3	solute carrier family 24 (sodium/potassium/
			calcium exchanger), member 3
AI821895	Hs.433060		Transcribed sequences
AW051591	Hs.388364	LOC285533	hypothetical protein LOC285533
NM_000187	Hs.368254	HGD	homogentisate 1,2-dioxygenase (homogentisate oxidase)
AK023837	Hs.159799	THRAP2	thyroid hormone receptor associated protein 2
BF446281	Hs.433307	BCKDHA	branched chain keto acid dehydrogenase E1, alpha
			polypeptide (maple syrup urine disease)
BE046521	Hs.191482	CUTL1	cut-like 1, CCAAT displacement protein (Drosophila)
AW006409	Hs.532144		histone 1, H3d
AI476341	Hs.93825		CDNA FLJ39784 fis, clone SPLEN2002314
BF512068	Hs.575090		Transcribed sequences
AA488687	Hs.390594	SLC7A11	solute carrier family 7, (cationic amino acid transporter,
			y+ system) member 11
NM_002413	Hs.81874	MGST2	microsomal glutathione S-transferase 2
R64696		CD58	yi22f12.r1 Soares placenta Nb2HP Homo sapiens
			cDNA clone IMAGE: 140015 5′
			similar to contains Alu repetitive element;, mRNA sequence.
AV699911	Hs.310421		Transcribed sequence with weak similarity
			to protein sp: P23961 (H. sapiens)
			ALUC_HUMAN !!!! ALU CLASS C WARNING ENTRY !!!!
NM_002350	Hs.491767	LYN	v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
AI698731	Hs.202238		Transcribed sequences
AA215519			zr97a07.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone
			IMAGE: 683604 5′, mRNA sequence.
BC000195	Hs.279583	DREV1	DORA reverse strand protein 1
AW304786	Hs.507260	SLC15A4	solute carrier family 15, member 4
AA705029	Hs.529488		Transcribed sequence with strong similarity to protein
			pdb: 1BGM (E. coli) O Chain O, Beta-Galactosidase
BC020868	Hs.632256	STAT5B	signal transducer and activator of transcription 5B
BM849515	Hs.636486	LRRK1	leucine-rich repeat kinase 1
AW269743	Hs.254477		CDNA FLJ20182 fis, clone COLF0190
BC039825	Hs.446125	MAK	male germ cell-associated kinase
NM_014339	Hs.129751	IL17R	interleukin 17 receptor
AW196696	Hs.484363		Transcribed sequence with strong similarity to protein
			ref: NP_060904.1 (H. sapiens) goliath protein; likely ortholog
			of mouse g1-related zinc finger protein [Homo
			sapiens]
AI583964	Hs.544636		Transcribed sequences
BE552138	Hs.632488	CR1	complement component (3b/4b) receptor 1-like
AI738802	Hs.644106	CDK11	cyclin-dependent kinase (CDC2-like) 11
BC025708	Hs.592017	FLJ11175	hypothetical protein FLJ11175
BE327650	Hs.369978	FLJ11753	hypothetical protein FLJ11753
AI972498	Hs.97469	a1/3GTP	Clone IMAGE: 4812754, mRNA
AI668625	Hs.380094		Full length insert cDNA YO61D09
AI342132	Hs.485241		qt26c08.x1 Soares_pregnant_uterus_NbHPU Homo sapiens
			cDNA clone IMAGE: 1949102 3′, mRNA sequence.
AF350251	Hs.132868	USP32	ubiquitin specific protease 32
BC038707	Hs.420559		Homo sapiens, Similar to neuronal thread protein,
			clone IMAGE: 3932744, mRNA.
AK022004	Hs.106015		CDNA FLJ11942 fis, clone HEMBB1000652
BF512846	Hs.471461	ACSL3	acyl-CoA synthetase long-chain family member 3
NM_014450	Hs.88012	SIT	SHP2-interacting transmembrane adaptor protein
BF345244	Hs.378501	LOC283989	hypothetical protein LOC283989
AI057637	Hs.234898	LOC283445	acetyl-Coenzyme A carboxylase beta
BC002918	Hs.213088	CHST12	carbohydrate (chondroitin 4) sulfotransferase 12
X79782	Hs.449601	IGLJ3	H. sapiens (T1.1) mRNA for IG lambda light chain
NM_024310	Hs.466383	PLEKHF1	pleckstrin homology domain containing, family
			F (with FYVE domain) member 1
BF116060	Hs.519783	FLJ44216	FLJ44216 protein
Y11339	Hs.105352	SIAT7A	sialyltransferase 7 ((alpha-N-acetylneuraminyl-
			2,3-beta-galactosyl-1,3)-N-acetyl
			galactosaminide alpha-2,6-sialyltransferase) A
BC003379	Hs.632714	L0057228	hypothetical protein from clone 643
NM_024947	Hs.529592	PHC3	polyhomeotic like 3 (Drosophila)
NM_000878	Hs.474787	IL2RB	interleukin	2 receptor, beta
AF031138	Hs.509513	NCR3	natural cytotoxicity triggering receptor 3
NM_014914	Hs.435039	CENTG2	centaurin, gamma 2
NM_030978	Hs.132499	ARPC5L	actin related protein ⅔ complex, subunit 5-like
NM_004758	Hs.112499	BZRAP1	benzodiazapine receptor (peripheral) associated protein 1
AW338214	Hs.437696		Clone IMAGE: 5275753, mRNA
AJ238374		TH1L	Homo sapiens mRNA for putative protein
			TH1, partial, clone IMAGE ID 785447.
AF288573	Hs.2007	TNFSF6	tumor necrosis factor (ligand) superfamily, member 6
NM_031213	Hs.465542	C19orf27	hypothetical protein MGC5244
AF044954	Hs.513266	NDUFB10	NADH dehydrogenase (ubiquinone) 1 beta
			subcomplex, 10, 22 kDa
BE671663	Hs.592102	EVER2	epidermodysplasia verruciformis 2
NM_007237	Hs.632549	SP140	SP140 nuclear body protein
AI003777	Hs.632176	1-Sep	septin	1
AI421559	Hs.106185	RALGDS	ral guanine nucleotide dissociation stimulator
NM_020886	Hs.503891	USP28	ubiquitin specific protease 28
AI042377	Hs.470457		Transcribed sequences
AA742584	Hs.125914	C8orf5	chromosome 8 open reading frame 5
BG231773	Hs.371680		CDNA FLJ46579 fis, clone THYMU3042758
BE788984		GALM	601481076F1 NIH_MGC_68 Homo sapiens cDNA clone
			IMAGE: 3883818 5′, mRNA sequence.
AA135722	Hs.597962		Transcribed sequences
NM_014349	Hs.474737	APOL3	apolipoprotein L, 3
AW268594	Hs.374421	C9orf81	chromosome 9 open reading frame 81
NM_018641	Hs.213088	CHST12	carbohydrate (chondroitin 4) sulfotransferase 12
BF678830		LOC152485	hypothetical protein LOC152485
NM_006117	Hs.15250	PECI	peroxisomal D3,D2-enoyl-CoA isomerase
AW977516	Hs.592755		Transcribed sequences
BF984830	Hs.190284	RAI1	retinoic acid induced 1
NM_005263	Hs.73172	GFI1	growth factor independent 1
AI347139	Hs.8162	MGC39372	hypothetical protein MGC39372
NM_002832	Hs.402773	PTPN7	protein tyrosine phosphatase, non-receptor type 7
NM_003362	Hs.191334	UNG	uracil-DNA glycosylase
AA679705	Hs.535464	EIF3S8	eukaryotic translation initiation factor 3, subunit 8, 110 kDa
AY007128	Hs.469728		CDNA FLJ26765 fis, clone PRS02774
AK074465	Hs.462833	FLJ31952	hypothetical protein FLJ31952
NM_001504	Hs.198252	CXCR3	chemokine (C-X-C motif) receptor 3
NM_005715	Hs.557541	UST	uronyl-2-sulfotransferase
AA683481	Hs.22546	MGC20446	hypothetical protein MGC20446
AI829961	Hs.36972	CD7	CD7 antigen (p41)
AI609285	Hs.503891	USP28	tw83h09.x1 NCI_CGAP_HN5 Homo sapiens
			cDNA clone IMAGE: 2266337 3′
			similar to contains Alu repetitive element; contains
			element MER29 repetitive element;, mRNA sequence.
AL582804	Hs.403857	LY9	lymphocyte antigen 9
NM_000107	Hs.643521	DDB2	damage-specific DNA binding protein 2, 48 kDa
AL833685	Hs.440508		MRNA; cDNA DKFZp667O0522
			(from clone DKFZp667O0522)
BE568184		15E1.2	cytochrome c oxidase subunit VIa polypeptide 1
BG250907	Hs.591503		Clone IMAGE: 5178133, mRNA
NM_018281	Hs.476319	FLJ10948	hypothetical protein FLJ10948
BG542955	Hs.133916	LOC152485	hypothetical protein LOC152485
AK024386	Hs.155742	GRHPR	glyoxylate reductase/hydroxypyruvate reductase
NM_024070	Hs.521075	STAG3	stromal antigen 3
AB014719	Hs.618112	APBA2	amyloid beta (A4) precursor protein-binding,
			family A, member 2 (X11-like)
D42043	Hs.98910	RAFTLIN	raft-linking protein
AY043466	Hs.292449	FCRH3	Fc receptor-like protein 3
AI017564	Hs.492716	MGC21654	unknown MGC21654 product
NM_005317	Hs.465511	GZMM	granzyme M (lymphocyte met-ase 1)
AL527430	Hs.2006	GSTM3	glutathione S-transferase M3 (brain)
NM_014767	Hs.523009	SPOCK2	synonym: testican-2; go_component: extracellular
			matrix [goid 0005578] [evidence NAS] [pmid 10386950];
			go_function: calcium ion binding [goid 0005509] [evidence
			IDA] [pmid 10386950]; go_process: synaptogenesis
			[goid 0007416] [evidence NAS] [pmid 10386950]; go_process:
			extracellular matrix organization and biogenesis [goid
			0030198] [evidence NAS] [pmid 10386950];
			go_process: regulation of cell differentiation [goid 0045595]
			[evidence NAS] [pmid 10386950]; Homo sapiens
			sparc/osteonectin, cwcv and kazal-like domains
			proteoglycan (testican) 2 (SPOCK2), mRNA.
BC040914	Hs.322462		Clone IMAGE: 5745627, mRNA
AK001164	Hs.599785		CDNA FLJ10302 fis, clone NT2RM2000042
AK097515	Hs.120250	FLJ40597	hypothetical protein FLJ40597
NM_005608	Hs.155975	PTPRCAP	protein tyrosine phosphatase, receptor type,
			C-associated protein
AI457120	Hs.331420	PPAT	phosphoribosyl pyrophosphate amidotransferase
AA541630	Hs.170019	RUNX3	runt-related transcription factor 3
NM_024709	Hs.519839	FLJ14146	hypothetical protein FLJ14146
NM_013330	Hs.642710	NME7	non-metastatic cells 7, protein expressed in
			(nucleoside-diphosphate kinase)
AL520200	Hs.420796	MGC15429	hypothetical protein MGC15429
NM_003752	Hs.567374	EIF3S8	eukaryotic translation initiation factor 3, subunit 8, 110 kDa
BE259729	Hs.438429	RPS19	ribosomal protein S19
AW043830	Hs.471441		Transcribed sequences
R12665	Hs.11594		CDNA FLJ27273 fis, clone TMS00761
BC006428	Hs.189119	CXXC5	CXXC finger 5
AI354636	Hs.586401		qu95c03.x1 NCI_CGAP_Gas4 Homo sapiens cDNA
			clone IMAGE: 1979812 3′, mRNA sequence.
AK025248	Hs.546419	FLJ13220	hypothetical protein FLJ13220
BE675549	Hs.79170	TTC9	tetratricopeptide repeat domain 9
NM_000579	Hs.450802	CCR5	chemokine (C-C motif) receptor 5
AB020630	Hs.45719	PPP1R16B	protein phosphatase 1, regulatory (inhibitor) subunit 16B
NM_002985	Hs.514821	CCL5	chemokine (C-C motif) ligand 5
NM_014392	Hs.518595	D4S234E	DNA segment on chromosome 4 (unique)
			234 expressed sequence
AI821566	Hs.642748	TTC16	torsin family 2, member A
AA771779	Hs.461074	ZFP90	zinc finger protein 90 homolog (mouse)
AI084226	Hs.58831	TOSO	regulator of Fas-induced apoptosis
AF057557	Hs.58831	TOSO	regulator of Fas-induced apoptosis
NM_005356	Hs.470627	LCK	lymphocyte-specific protein tyrosine kinase
BC041468	Hs.434746	LOC339988	Hypothetical protein LOC339988 (LOC339988), mRNA
BC002556		RAB3IP
NM_002002	Hs.465778	FCER2	Fc fragment of IgE, low affinity II, receptor for (CD23A)
NM_018556	Hs.590883	SIRPB2	signal-regulatory protein beta 2
AB020630	Hs.45719	PPP1R16B	protein phosphatase 1, regulatory (inhibitor) subunit 16B
AF298547	Hs.369279	NALP2	NACHT, leucine rich repeat and PYD containing 2
AW157571	Hs.479066	MARLIN1	multiple coiled-coil GABABR1-binding protein
AA767131	Hs.121432	KIAA0073	KIAA0073 protein
M21121	Hs.514821	CCL5	chemokine (C-C motif) ligand 5
NM_004356	Hs.54457	CD81	CD81 antigen (target of antiproliferative antibody 1)
BF432238	Hs.585799	ZNF286	CDNA FLJ31089 fis, clone IMR321000092
NM_004310	Hs.160673	RHOH	ras homolog gene family, member H
BC000533	Hs.567374	EIF3S8	eukaryotic translation initiation factor 3, subunit 8, 110 kDa
U07236	Hs.470627	LCK	lymphocyte-specific protein tyrosine kinase
AI702465	Hs.23606		Transcribed sequences
AU155091	Hs.633678		Clone IMAGE: 4814008, mRNA
U90339	Hs.584739	ADK	adenosine kinase
AW575245	Hs.266331	FREB	Fc receptor homolog expressed in B cells
NM_030915	Hs.567598	LBH	likely ortholog of mouse limb-bud and heart gene
AI524095	Hs.403857	LY9	lymphocyte antigen 9
AW204712	Hs.385493	C10orf128	hypothetical protein LOC170371
U49396	Hs.408615	P2RX5	purinergic receptor P2X, ligand-gated ion channel, 5
AA781795	Hs.546467	EPSTI1	epithelial stromal interaction 1 (breast)
BF433219			Transcribed sequences
BC003574	Hs.2484	TCL1A	T-cell leukemia/lymphoma 1A
AB051458	Hs.419171	KIAA1671	KIAA1671 protein
NM_004114	Hs.6540	FGF13	fibroblast growth factor 13
BF446578	Hs.125293	RASGEF1A	RasGEF domain family, member 1A
AA931562	Hs.444049		Transcribed sequence with weak similarity
			to protein ref: NP_060312.1 (H. sapiens)
			hypothetical protein FLJ20489 [Homo sapiens]
BF514552	Hs.292449	FCRH3	Fc receptor-like protein 3
X82240	Hs.2484	TCL1A	T-cell leukemia/lymphoma 1A
AW296309	Hs.405667	CD8B1	CD8 antigen, beta polypeptide 1 (p37)
M85256	Hs.554197	IGKC	Isolate donor Z clone Z55K immunoglobulin kappa light chain
			variable region mRNA, partial cds
AF439512	Hs.387787	KLRK1	killer cell lectin-like receptor subfamily K, member 1
NM_005442	Hs.591663	EOMES	eomesodermin homolog (Xenopus laevis)
AI424825	Hs.435052	ATP8A1	ATPase, aminophospholipid transporter (APLT),
			Class I, type 8A, member 1
NM_006159	Hs.505326	NELL2	NEL-like 2 (chicken)
BI547087			603190322F1 NIH_MGC_95 Homo sapiens cDNA clone
			IMAGE: 5261717 5′, mRNA sequence.
BC001872	Hs.510635	IGHM	synonym: MU; Homo sapiens immunoglobulin
			heavy constant mu, mRNA (cDNA
			clone MGC: 1228 IMAGE: 3544448), complete cds.
AW006735	Hs.85258	CD8A	CD8 antigen, alpha polypeptide (p32)
NM_007360	Hs.387787	KLRK1	killer cell lectin-like receptor subfamily K, member 1
NM_002261	Hs.74082	KLRC3	synonyms: NKG2E, NKG2-E; isoform NKG2-E is
			encoded by transcript variant NKG2-E; go_component:
			integral to membrane [goid 0016021] [evidence IEA];
			go_function: transmembrane receptor activity
			[goid 0004888] [evidence TAS] [pmid 9683661]; go_function:
			lectin [goid 0005530] [evidence IEA]; go_function: sugar
			binding [goid 0005529] [evidence IEA]; go_process:
			cellular defense response [goid 0006968] [evidence TAS]
			[pmid 9683661]; go_process: heterophilic cell adhesion
			[goid 0007157] [evidence IEA]; Homo sapiens
			killer cell lectin-like receptor subfamily C, member 3
			(KLRC3), transcript variant NKG2-E, mRNA.
M13231	Hs.534032	TRGV9	T cell receptor gamma locus
AI753792	Hs.502004	RRAS2	related RAS viral (r-ras) oncogene homolog 2
M16768	Hs.534032	TRGV9	T-cell receptor (V-J-C) precursor; Human T-cell receptor
			gamma chain VJCI-CII-CIII region mRNA, complete cds.
NM_003175	Hs.458346	XCL1	chemokine (C motif) ligand 2
U96394	Hs.449601	IGL1	Clone P2-147 anti-oxidized LDL immunoglobulin
			light chain Fab mRNA, partial cds
M27331	Hs.534032	TRGV9	T cell receptor gamma locus
U23772	Hs.546295	XCL1	chemokine (C motif) ligand 1
NM_004931	Hs.405667	CD8B1	CD8 antigen, beta polypeptide 1 (p37)
NM_006275	Hs.6891	SFRS6	splicing factor, arginine/serine-rich 6
BC020552	Hs.379186	PDCD6	programmed cell death 6
NM_001548	Hs.20315	IFIT1	interferon-induced protein with tetratricopeptide repeats 1
BC005248	Hs.461178	EIF1AY	eukaryotic translation initiation factor 1A, Y-linked
NM_004660	Hs.99120	DDX3Y	DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked
NM_001008	Hs.282376	RPS4Y1	ribosomal protein S4, Y-linked

TABLE 7

GenBank	Unigene
ID	ID	Gene Description

AA167449	Hs.529901	MRNA; cDNA DKFZp686K10163 (from clone DKFZp686K10163)
AV646597	Hs.529901	MRNA; cDNA DKFZp686K10163 (from clone DKFZp686K10163)
NM_000607	Hs.567311	orosomucoid 1
BE644917	Hs.529901	MRNA; cDNA DKFZp686K10163 (from clone DKFZp686K10163)
AA628440	Hs.529901	MRNA; cDNA DKFZp686K10163 (from clone DKFZp686K10163)
AI733564	Hs.478588	Transcribed sequence with weak similarity to protein pir:A40138 (H. sapiens) A40138 glycogen
		phosphorylase
NM_000419	Hs.411312	“integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41B)”
BE867789	Hs.110675	poliovirus receptor-related 2 (herpesvirus entry mediator B)
AA521086	Hs.99691	lymphocyte alpha-kinase
AB023212	Hs.158722	pecanex homolog (Drosophila)
AL109714	Hs.459049	hypothetical protein LOC283687
L10343		“elafin has been sequenced at the protein level; pre-elafin has not; its existence is assumed from its
		molecular weight (PAGE analysis); putative; Homo sapiens elafin precursor, gene, complete cds.”
AW167424	Hs.585653	numb homolog (Drosophila)
M35999	Hs.218040	“integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)”
NM_002638	Hs.112341	“protease inhibitor 3, skin-derived (SKALP)”
AI929792	Hs.21374	Transcribed sequences
NM_000607	Hs.567311	orosomucoid 1
R64130	Hs.2164	pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
NM_003118	Hs.111779	“secreted protein, acidic, cysteine-rich (osteonectin)”
NM_002736	Hs.433068	“protein kinase, cAMP-dependent, regulatory, type II, beta”
AA703239	Hs.159430	Transcribed sequence with weak similarity to protein prf:1303335A (H. sapiens) 1303335A decay
		accelerating factor long [Homo sapiens]
NM_004666	Hs.12114	vanin 1
NM_016348	Hs.519694	chromosome 5 open reading frame 4
BI868572		“603392679F1 NIH_MGC_90 Homo sapiens cDNA clone IMAGE:5402706 5′, mRNA sequence.”
AW205418	Hs.495097	KIAA2025 protein
NM_001999	Hs.519294	fibrillin 2 (congenital contractural arachnodactyly)
AI520949	Hs.110675	poliovirus receptor-related 2 (herpesvirus entry mediator B)
M25915	Hs.436657	“clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate
		message
2, apolipoprotein J)”
BF055462	Hs.164226	thrombospondin 1
AI679555	Hs.527653	Transcribed sequence with weak similarity to protein ref:NP_060312.1 (H. sapiens) hypothetical protein
		FLJ20489 [Homo sapiens]
AW051321	Hs.464137	“CDNA FLJ30303 fis, clone BRACE2003269”
NM_000129	Hs.335513	“coagulation factor XIII, A1 polypeptide”
BE896490	Hs.595327	“synaptosomal-associated protein, 29 kDa”
NM_000697	Hs.422967	arachidonate 12-lipoxygenase
AA181060	Hs.349283	“Clone IMAGE:5288883, mRNA”
NM_002619	Hs.81564	platelet factor 4 (chemokine (C-X-C motif) ligand 4)
AU157823		“AU157823 PLACE1 Homo sapiens cDNA clone PLACE1009595 3′, mRNA sequence.”
BE867789	Hs.110675	poliovirus receptor-related 2 (herpesvirus entry mediator B)
AA526844	Hs.556600	“MSTP083 mRNA, complete cds”
BF435438	Hs.80720	Full length insert cDNA YH93B03
NM_005231	Hs.632133	ems1 sequence (mammary tumor and squamous cell carcinoma-associated (p80/85 src substrate)
NM_007150	Hs.16622	zinc finger protein 185 (LIM domain)
NM_001928	Hs.155597	D component of complement (adipsin)
NM_003831	Hs.445511	RIO kinase 3 (yeast)
NM_022763	Hs.159430	FAD 104
NM_001343	Hs.481980	“disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)”
NM_020152	Hs.222802	chromosome 21 open reading frame 7
BC029493	Hs.369265	interleukin-1 receptor-associated kinase 3
BF976693	Hs.376675	“CDNA FLJ34100 fis, clone FCBBF3007597”
NM_000945	Hs.280604	“protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform (calcineurin B, type I)”
AI215106	Hs.591381	insulin receptor
AI817801	Hs.191356	Transcribed sequence with strong similarity to protein sp:Q13075 (H. sapiens) BIR1_HUMAN Baculoviral
		IAP repeat-containing protein 1
AW270105	Hs.643902	ring finger protein 3
BG913589	Hs.59214	“DnaJ (Hsp40) homolog, subfamily C, member 3”
W73230	Hs.200100	“zd56c09.s1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:344656 3′ similar to
		contains element MER10 repetitive element;, mRNA sequence.”
BF691447	Hs.644051	“UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5”
NM_005502	Hs.429294	“ATP-binding cassette, sub-family A (ABC1), member 1”
NM_000361	Hs.2030	thrombomodulin
AK024569	Hs.195403	dedicator of cytokinesis 5
AB051833	Hs.123239	acrosin binding protein
NM_004126	Hs.83381	“guanine nucleotide binding protein (G protein), gamma 11”
Y07846	Hs.322852	growth arrest-specific 2 like 1
BE327727	Hs.443301	Transcribed sequences
M36532	Hs.155097	carbonic anhydrase II
NM_017526	Hs.23581	leptin receptor
AW205122	Hs.496572	hypothetical protein FLJ22679
AI141116	Hs.123239	acrosin binding protein
AW293296	Hs.163893	Transcribed sequences
N63244	Hs.592143	“tubulin, beta 1“
BG120535		“602346858F1 NIH_MGC_90 Homo sapiens cDNA clone IMAGE:4441695 5′, mRNA sequence.”
AU152763	Hs.586165	“CDNA FLJ10742 fis, clone NT2RP3001629”
BC003064	Hs.481980	“disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)”
N63920	Hs.596025	“CDNA clone IMAGE:5294823, partial cds”
BG251467	Hs.122514	mitochondrial solute carrier protein
AF237762	Hs.306199	G protein-coupled receptor 84
AW206560	Hs.609146	Transcribed sequences
AI971212	Hs.434494	synaptojanin 2
AL136805	Hs.278436	zinc finger protein 537
BC026299	Hs.518727	“Clone IMAGE:4275461, mRNA”
BE675324	Hs.200770	Transcribed sequences
NM_021647	Hs.178121
NM_018482	Hs.106015	“synonyms: PAP, PAG2, ASAP1, ZG14P, KIAA1249; Homo sapiens development and differentiation
		enhancing factor 1 (DDEF1), mRNA.”
AA149644	Hs.150718	junctional adhesion molecule 3
AF325460	Hs.351812	“C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 7”
AW665656	Hs.633892	glutamate-ammonia ligase (glutamine synthase)
AA417099	Hs.465709	Transcribed sequences
NM_003897	Hs.591785	immediate early response 3
AF275260	Hs.592117	chemokine (C-X-C motif) ligand 16
AF001540		PRO1073 protein
AI640434	Hs.601545	hypothetical protein FLJ10357
AW043859	Hs.235795	“Clone IMAGE:5263020, mRNA”
H68759	Hs.122514	Transcribed sequences
NM_004536	Hs.191356	baculoviral IAP repeat-containing 1
AF086010	Hs.335205	Full length insert cDNA clone YW04H08
NM_003189	Hs.73828	T-cell acute lymphocytic leukemia 1
AW138767	Hs.274256	hypothetical protein FLJ23563
NM_003693	Hs.534497	“scavenger receptor class F, member 1”
BG177759	Hs.497873	WD repeat domain 26
AW264036	Hs.478588	B-cell CLL/lymphoma 6 (zinc finger protein 51)
AL119957	Hs.59214	“DnaJ (Hsp40) homolog, subfamily C, member 3”
NM_018388	Hs.105134	muscleblind-like 3 (Drosophila)
AI640434	Hs.601545	hypothetical protein FLJ10357
AI332764	Hs.516646	Transcribed sequences
AI719730	Hs.24258	“guanylate cyclase 1, soluble, alpha 3”
NM_130441	Hs.351812	“C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 7”
AW796364	Hs.371594	Transcribed sequence with weak similarity to protein ref:NP_060265.1 (H. sapiens) hypothetical protein
		FLJ20378 [Homo sapiens]
BC043380	Hs.468274	“CDNA clone IMAGE:5223469, partial cds”
NM_017698
AW069181	Hs.603149	“cr43e01.x1 Human bone marrow stromal cells Homo sapiens cDNA clone HBMSC_cr43e01 3′, mRNA
		sequence.”
AF350881	Hs.272225	“transient receptor potential cation channel, subfamily M, member 6”
AA082707	Hs.592262	“myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax homolog, Drosophila)”
AL035700		“continued from bA177G23.1 in Em:AL451064 match: proteins: Tr:O75368 Sw:P55822 Tr:Q9BPY5
		Tr:Q9BRB8 Sw:Q9WUZ7; Human DNA sequence from clone RP1-75K24 on chromosome 6q13-15
		Contains the the 3′ end of the SH3BGRL2 gene for SH3 domain binding glutamic acid-rich protein-like 2,
		complete sequence.”
N66571	Hs.501898	murine retrovirus integration site 1 homolog
AA482548	Hs.497873	“zt34b03.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:724205 3′, mRNA
		sequence.”
AI052659	Hs.334019	Transcribed sequences
AF074331		“Homo sapiens PAPS synthetase-2 (PAPSS2) mRNA, complete cds.”
AI682905	Hs.280342	“protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1)”
AI022066	Hs.480763	Transcribed sequences
AI953847	Hs.148741	IBR domain containing 2
NM_000361	Hs.2030	thrombomodulin
AY151286	Hs.196384	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)
AL713724	Hs.487994	MRNA; cDNA DKFZp667O0416 (from clone DKFZp667O0416)
AI831952	Hs.567518	nudE nuclear distribution gene E homolog 1 (A. nidulans)
N45231	Hs.513053	“DnaJ (Hsp40) homolog, subfamily A, member 4”
AA044825	Hs.520757	“thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A)”
AI476341	Hs.93825	“CDNA FLJ39784 fis, clone SPLEN2002314”
BF195718	Hs.221889	cold shock domain protein A
AL833423	Hs.379548	MRNA; cDNA DKFZp313H2139 (from clone DKFZp313H2139)
NM_009590	Hs.143102	“amine oxidase, copper containing 2 (retina-specific)”
AA770170	Hs.499489	“c-mir, cellular modulator of immune recognition”
BE965029	Hs.501928	“601658812R1 NrH_MGC_69 Homo sapiens cDNA clone IMAGE:3886131 3′, mRNA sequence.”
BC018042	Hs.279815	cysteine sulfinic acid decarboxylase
AA218974		“zr02g12.s1 Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone IMAGE:650374 3′,
		mRNA sequence.”
AF188298	Hs.481980	“disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)”
NM_005906	Hs.446125	male germ cell-associated kinase
BC002716	Hs.496572	hypothetical protein FLJ22679
AK023512	Hs.463439	sperm associated antigen 9
AA010315	Hs.60371	Transcribed sequences
AF051151	Hs.135853	toll-like receptor 5
BU929456		“AGENCOURT_10424238 NrH_MGC_79 Homo sapiens cDNA clone IMAGE:6663343 5′, mRNA
		sequence.”
NM_002607	Hs.535898	platelet-derived growth factor alpha polypeptide
AK024748	Hs.297343	“calcium/calmodulin-dependent protein kinase kinase 2, beta”
U76248	Hs.477959	seven in absentia homolog 2 (Drosophila)
AI819198	Hs.208229	G protein-coupled receptor 54
AI452469	Hs.605187	Transcribed sequence with weak similarity to protein ref:NP_009032.1 (H. sapiens) sarcosine
		dehydrogenase; dimethylglycine dehydrogenase-like 1 [Homo sapiens]
AA037483	Hs.458395	“zk34a02.s1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:484682 3′, mRNA
		sequence.”
U56237	Hs.631534	“Fc fragment of IgA, receptor for”
N66045	Hs.29189	Transcribed sequences
AW299958	Hs.524491	3′-phosphoadenosine 5′-phosphosulfate synthase 2
AK021983	Hs.106015	“CDNA FLJ11921 fis, clone HEMBB1000318”
NM_002398	Hs.526754	“Meis1, myeloid ecotropic viral integration site 1 homolog (mouse)”
AV725666	Hs.220950	“CDNA clone IMAGE:4814010, partial cds”
AK026714	Hs.7886	pellino homolog 1 (Drosophila)
NM_005373	Hs.82906	CDC20 cell division cycle 20 homolog (S. cerevisiae)
AK024382		“unnamed protein product; Homo sapiens cDNA FLJ14320 fis, clone PLACE3000455.”
AA702409	Hs.592017	Transcribed sequences
AI074467	Hs.593643	Transcribed sequences
AI368358	Hs.496969	N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase)
H28667	Hs.444451	sterile alpha motif and leucine zipper containing kinase AZK
AL544951	Hs.280604	“AL544951 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA clone
		CS0DI012YC11 5-PRIME, mRNA sequence.”
AL050388	Hs.487046	“superoxide dismutase 2, mitochondrial”
AI829674	Hs.584845	Transcribed sequences
NM_018324	Hs.24309	hypothetical protein FLJ11106
AA362254	Hs.529633	Transcribed sequences
AW130600	Hs.99472	MRNA; cDNA DKFZp564O0862 (from clone DKFZp564O0862)
N25732	Hs.591328	“yx83c03.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:268324 3′, mRNA
		sequence.”
NM_017815	Hs.442782	chromosome 14 open reading frame 94
AK055448		“Homo sapiens cDNA FLJ30886 fis, clone FEBRA2005014, weakly similar to ZINC FINGER PROTEIN
		84.”
S69189	Hs.464137	“acyl-Coenzyme A oxidase 1, palmitoyl”
AU146027	Hs.592326	“AU146027 HEMBA1 Homo sapiens cDNA clone HEMBA1006595 3′, mRNA sequence.”
BE439987	Hs.462214	growth arrest-specific 7
AI363213	Hs.381058	KIAA0146 protein
BF508786	Hs.613959	MRNA; cDNA DKFZp686J24234 (from clone DKFZp686J24234)
BF680284	Hs.34558	“CDNA: FLJ21199 fis, clone COL00235”
H93077	Hs.519694	chromosome 5 open reading frame 4
AI798924	Hs.191850	Transcribed sequences
W19983	Hs.370725	oxysterol binding protein-like 1A
AA057437	Hs.458747	Transcribed sequences
NM_024565	Hs.14070	hypothetical protein FLJ14166
AI356228	Hs.515351	KIAA1533
AI937121	Hs.29282	Transcribed sequences
AI806045	Hs.61438	Transcribed sequences
N24643	Hs.446017	WD repeat and SOCS box-containing 1
AU122258		“AU122258 MAMMA1 Homo sapiens cDNA clone MAMMA1002009 5′, mRNA sequence.”
AI278204	Hs.99472	MRNA; cDNA DKFZp564O0862 (from clone DKFZp564O0862)
AW450374	Hs.593734	“Clone IMAGE:4824518, mRNA”
BE888885	Hs.220950	“CDNA clone IMAGE:4814010, partial cds”
AK023845		ubiquitin specific protease 34
BF511336	Hs.591641	Transcribed sequences
NM_007199	Hs.369265	interleukin-1 receptor-associated kinase 3
AI056872	Hs.591328	Transcribed sequences
BG251467	Hs.122514	mitochondrial solute carrier protein
NM_022083		chromosome
1 open reading frame 24
AW057518	Hs.608694	“elongation factor. RNA polymerase II, 2”
AI650285	Hs.287299	Transcribed sequence with weak similarity to protein ref:NP_060312.1 (H. sapiens) hypothetical protein
		FLJ20489 [Homo sapiens]
AU147506	Hs.7886	pellino homolog 1 (Drosophila)
BF435852	Hs.464137	“acyl-Coenzyme A oxidase 1, palmitoyl”
W03103	Hs.106015	“za04b05.r1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:291537 5′, mRNA
		sequence.”
AI458949	Hs.520414	interferon gamma receptor 1
AB030034	Hs.444451	sterile alpha motif and leucine zipper containing kinase AZK
BC011877	Hs.195403	“Hypothetical protein LOC286061 (LOC286061), mRNA”
AL137028
NM_007219	Hs.589884	ring finger protein 24
AA868809	Hs.25447	“CDNA FLJ43180 fis, clone FCBBF3013846”
NM_012329	Hs.463483	monocyte to macrophage differentiation-associated
AA778783	Hs.420024	Transcribed sequence with weak similarity to protein ref:NP_055301.1 (H. sapiens) neuronal thread
		protein [Homo sapiens]
NM_030918	Hs.192326	sorting nexin family member 27
T79640	Hs.174312	Transcribed sequences
R91734		“yp98f04.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:195487 5′, mRNA
		sequence.”
U44403	Hs.75367	Src-like-adaptor
BF591270	Hs.595473	“7h44e04.x1 NCI_CGAP_Co16 Homo sapiens cDNA clone IMAGE:3318846 3′, mRNA sequence.”
BC042590	Hs.434241	“Homo sapiens cDNA clone IMAGE:4821044, partial cds.”
NM_018586
BE221883	Hs.11184	ubiquitin-conjugating enzyme E2R 2
BG337478	Hs.128037	“CDNA FLJ38117 fis, clone D3OST2003797”
AV723666		“AV723666 HTB Homo sapiens cDNA clone HTBABA11 5′, mRNA sequence.”
AK025898	Hs.525232	low density lipoprotein receptor-related protein 10
AB062477		“Homo sapiens OK/SW-cl.41 mRNA, complete cds.”
AW467357	Hs.371720	spleen tyrosine kinase
AI808120	Hs.479766	TPA regulated locus
BE966748		“601661247R1 NIH_MGC_72 Homo sapiens cDNA clone IMAGE:3916235 3′, mRNA sequence.”
AK024677	Hs.632602	N-acylsphingosine amidohydrolase (acid ceramidase)-like
AL038191	Hs.474536	“DKFZp566P1724_s1 566 (synonym: hfkd2) Homo sapiens cDNA clone DKFZp566P1724 3′, mRNA
		sequence.”
BG432887	Hs.442789	“Transcribed sequence with weak similarity to protein ref:NP_005210.1 (H. sapiens) diaphanous 1;
		Diaphanous, Drosophila, homolog of, 1; deafness, autosomal dominant 1; diaphanous”
BF516252	Hs.528703	ankyrin repeat domain 13
AA576497	Hs.492740	activating transcription factor 6
NM_017593	Hs.146551	BMP2 inducible kinase
NM_003105	Hs.368592	“sortilin-related receptor, L(DLR class) A repeats-containing”
AA706922	Hs.517034	Transcribed sequences
AI963142	Hs.48353	“CDNA FLJ32274 fis, clone PROST2000036”
AI735391	Hs.146551	“at10e09.x1 Barstead aorta HPLRB6 Homo sapiens cDNA clone IMAGE:2354728 3′, mRNA sequence.”
AI807658	Hs.192326	Transcribed sequences
BE693389		Transcribed sequences
N32832	Hs.159430	FAD 104
AF015452	Hs.390736	CASP8 and FADD-like apoptosis regulator
AL049273	Hs.429434	MRNA; cDNA DKFZp564H023 (from clone DKFZp564H023)
BC039388	Hs.237886	“Clone IMAGE:5298774, mRNA“
AA382004	Hs.122514	“EST95296 Activated T-cells II Homo sapiens cDNA 5′ end, mRNA sequence.”
BG334495	Hs.631749	hypothetical protein LOC284021
AW367571	Hs.438673	hypothetical protein LOC338692
AI084056	Hs.464217	phosphatidylglycerophosphate synthase
AK054840	Hs.106015	“CDNA FLJ30278 fis, clone BRACE2002755”
AI051950	Hs.99472	MRNA; cDNA DKFZp564O0862 (from clone DKFZp564O0862)
BF724303	Hs.412293	Transcribed sequences
AK000794	Hs.520757	“CDNA FLJ20787 fis, clone COL02178”
AF153820	Hs.1547	“potassium inwardly-rectifying channel, subfamily J, member 2”
BE671084	Hs.293593	GTPase regulator associated with focal adhesion kinase pp125(FAK)
AU146685	Hs.126667	“CDNA FLJ11971 fis, clone HEMBB1001208“
AI962978	Hs.469244	“WAS protein family, member 2”
AI634046	Hs.390736	CASP8 and FADD-like apoptosis regulator
AW297879	Hs.436271	Transcribed sequences
AK025534	Hs.588289	“CDNA: FLJ21881 fis, clone HEP02746”
N72610	Hs.484363	“Transcribed sequence with strong similarity to protein pdb:1BGM (E. coli) O Chain O, Beta-
		Galactosidase”
BF056507	Hs.372000	neutral sphingomyelinase (N-SMase) activation associated factor
W87434	Hs.106015	Transcribed sequence with moderate similarity to protein sp:P39188 (H. sapiens) ALU1_HUMAN Alu
		subfamily J sequence contamination warning entry
AF085978	Hs.474596	Homo sapiens full length insert cDNA clone YT87E05.
N63821	Hs.175437	“za26c12.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:293686 3′, mRNA
		sequence.”
AV700891	Hs.517296	v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)
AI692401	Hs.29282	Transcribed sequences
N52625	Hs.603141	“yv37f12.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:244943 3′ similar to
		contains element MER22 repetitive element;, mRNA sequence.”
R45471	Hs.479396	recombining binding protein suppressor of hairless (Drosophila)
H67156	Hs.122514	Transcribed sequences
BF724558	Hs.636976	Transcribed sequence with moderate similarity to protein pir:T02670 (H. sapiens) T02670 probable
		thromboxane A2 receptor isoform beta - human
BE551054	Hs.279583	DORA reverse strand protein 1
NM_021213	Hs.285218	phosphatidylcholine transfer protein
N93399	Hs.494406	“CDNA FLJ46484 fis, clone THYMU3026350”
BF668314	Hs.221497	PRO0149 protein
NM_002213	Hs.536663	“integrin, beta 5”
AW974609	Hs.136398	“zinc finger, CCHC domain containing 6”
AK001393	Hs.134857	hypothetical protein MGC12458
NM_000313	Hs.64016	protein S (alpha)
AW027474	Hs.446678	nuclear receptor coactivator 2
AI422414	Hs.484551	Transcribed sequences
NM_004196	Hs.280881	cyclin-dependent kinase-like 1 (CDC2-related kinase)
AI374686	Hs.122523	Transcribed sequences
AW184034	Hs.600998	v-raf murine sarcoma viral oncogene homolog B1
BC025707	Hs.484099	“potassium large conductance calcium-activated channel, subfamily M, beta member 1”
AA815354	Hs.520684	“Hypothetical LOC284527 (LOC284527), mRNA”
AF306674	Hs.132050	hypothetical protein MGC40368
W93728	Hs.77890	“guanylate cyclase 1, soluble, beta 3”
NM_003326	Hs.181097	“tumor necrosis factor (ligand) superfamily, member 4 (tax-transcriptionally activated glycoprotein 1,
		34 kDa)”
R62432	Hs.211252	“solute carrier family 24 (sodium/potassium/calcium exchanger), member 3”
AI821895	Hs.433060	Transcribed sequences
AW051591	Hs.388364	hypothetical protein LOC285533
NM_000187	Hs.368254	“homogentisate 1,2-dioxygenase (homogentisate oxidase)”
AK023837	Hs.159799	thyroid hormone receptor associated protein 2
BF446281	Hs.433307	“branched chain keto acid dehydrogenase E1, alpha polypeptide (maple syrup urine disease)”
BE046521	Hs.191482	“cut-like 1, CCAAT displacement protein (Drosophila)”
AW006409	Hs.532144	“histone 1, H3d”
AI476341	Hs.93825	“CDNA FLJ39784 fis, clone SPLEN2002314”
BF512068	Hs.575090	Transcribed sequences
AA488687	Hs.390594	“solute carrier family 7, (cationic amino acid transporter, y+ system) member 11”
NM_002413	Hs.81874	microsomal glutathione S-transferase 2
R64696		“yi22f12.r1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:140015 5′ similar to contains Alu
		repetitive element;, mRNA sequence.”
AV699911	Hs.310421	Transcribed sequence with weak similarity to protein sp:P23961 (H. sapiens) ALUC_HUMAN!!!! ALU
		CLASS C WARNING ENTRY!!!!
NM_002350	Hs.491767	v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
AI698731	Hs.202238	Transcribed sequences
AA215519		“zr97a07.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:683604 5′, mRNA sequence.”
BC000195	Hs.279583	DORA reverse strand protein 1
AW304786	Hs.507260	“solute carrier family 15, member 4”
AA705029	Hs.529488	“Transcribed sequence with strong similarity to protein pdb:1BGM (E. coli) O Chain O, Beta-
		Galactosidase”
BC020868	Hs.632256	signal transducer and activator of transcription 5B
BM849515	Hs.636486	leucine-rich repeat kinase 1
AW269743	Hs.254477	“CDNA FLJ20182 fis, clone COLF0190”
BC039825	Hs.446125	male germ cell-associated kinase
NM_014339	Hs.129751	interleukin 17 receptor
AW196696	Hs.484363	Transcribed sequence with strong similarity to protein ref:NP_060904.1 (H. sapiens) goliath protein; likely
		ortholog of mouse g1-related zinc finger protein [Homo sapiens]
AI583964	Hs.544636	Transcribed sequences
BE552138	Hs.632488	complement component (3b/4b) receptor 1-like
AI738802	Hs.644106	cyclin-dependent kinase (CDC2-like) 11
BC025708	Hs.592017	hypothetical protein FLJ11175
BE327650	Hs.369978	hypothetical protein FLJ11753
AI972498	Hs.97469	“Clone IMAGE:4812754, mRNA”
AI668625	Hs.380094	Full length insert cDNA YO61D09
AI342132	Hs.485241	“qt26c08.x1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:1949102 3′, mRNA
		sequence.”
AF350251	Hs. 132868	ubiquitin specific protease 32
BC038707	Hs.420559	“Homo sapiens, Similar to neuronal thread protein, clone IMAGE:3932744, mRNA.”
AK022004	Hs.106015	“CDNA FLJ11942 fis, clone HEMBB1000652”
BF512846	Hs.471461	acyl-CoA synthetase long-chain family member 3
AW450403	Hs.97270	“family with sequence similarity 13, member A1”
AW268357	Hs. 132868	ubiquitin specific protease 32
AF207547	Hs.78960	“LATS, large tumor suppressor, homolog 2 (Drosophila)”
AK025759	Hs.592692	Clone 23872 mRNA sequence
AW002073	Hs.606630	Transcribed sequences
AW974815	Hs.444451	Transcribed sequences
AW294022	Hs.308710	KIAA1718 protein
AI740571	Hs.159130	Transcribed sequence with weak similarity to protein sp:P39188 (H. sapiens) ALU1_HUMAN Alu
		subfamily J sequence contamination warning entry
AI290654	Hs.26403	hypothetical protein LOC283578
AW119113	Hs.2030	thrombomodulin
R71245		“yi54e05.s1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:143072 3′ similar to gb:M21121
		T-CELL SPECIFIC RANTES PROTEIN PRECURSOR (HUMAN);, mRNA sequence.”
BF357738	Hs.584811	Transcribed sequences
AW020871	Hs.499209	“CDNA FLJ90139 fis, clone HEMBB1001026, weakly similar to ENDOSOMAL P24A PROTEIN
		PRECURSOR.”
BE962615	Hs.643691	sorting nexin 3
NM_144665	Hs.191599	sestrin 3
AA252762	Hs.505516	KIAA1463 protein
AI023699	Hs.371594	MAP kinase-interacting serine/threonine kinase 1
AW502463	Hs.504096	Cas-Br-M (murine) ecotropic retroviral transforming sequence
AK096134	Hs.378150	“Chromosome 4 unknown transcript 1 variant 2 mRNA, partial sequence, alternatively spliced”
AW291297	Hs.420272	“H2A histone family, member Y”
AA524299	Hs.525232	Transcribed sequence with moderate similarity to protein sp:P39192 (H. sapiens) ALU5_HUMAN Alu
		subfamily SC sequence contamination warning entry
BE503981	Hs.420272	“H2A histone family, member Y”
BE894882	Hs.130853	“601434066F1 NIH_MGC_72 Homo sapiens cDNA clone IMAGE:3919073 5′, mRNA sequence.”
AV700946	Hs.432337	Transcribed sequence with weak similarity to protein pir:I49130 (M. musculus) I49130 reverse
		transcriptase - mouse
BF002625	Hs.612374	Transcribed sequences
AW295340	Hs.99691	Transcribed sequence with weak similarity to protein sp:P39192 (H. sapiens) ALU5_HUMAN Alu
		subfamily SC sequence contamination warning entry
BF062244	Hs.144333	lin-7 homolog A (C. elegans)
AF050145	Hs.460960	iduronate 2-sulfatase (Hunter syndrome)
AK091836	Hs.484678	MRNA; cDNA DKFZp686I05132 (from clone DKFZp686I05132)
AI939422	Hs.461253	Transcribed sequences
D29805	Hs.272011	“UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1”
NM_025158	Hs.306769	RUN and FYVE domain containing 1
AA195936	Hs.82719	hypothetical protein MGC21416
AI079521	Hs.594059	fring
AF130091	Hs.72071	potassium channel tetramerisation domain containing 9
BC020843	Hs.616365	hepatitis A virus cellular receptor 2
AW301766	Hs.527653	“decay accelerating factor for complement (CD55, Cromer blood group system)”
BC035084	Hs.536364	Full length insert cDNA clone ZD78D03
BC008306	Hs.287471	NICE-3 protein
M24779	Hs.81170	pim-1 oncogene
BM014995		“603640947F1 NIH_MGC_87 Homo sapiens cDNA clone IMAGE:5417266 5′, mRNA sequence.”
BC020868	Hs.632256	signal transducer and activator of transcription 5B
T83380		“ye03h05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:116697 3′, mRNA
		sequence.”
N39126	Hs.191346	Transcribed sequences
AB053312	Hs.390736	“ALS2CR10 mRNA,.”
BF223935	Hs.268774	Transcribed sequences
X62009	Hs.519294	fibrillin 2 (congenital contractural arachnodactyly)
BF508977	Hs.463059	signal transducer and activator of transcription 3 (acute-phase response factor)
BF510533	Hs.642655	Transcribed sequences
AK024177	Hs.529860	“Homo sapiens CDNA FLJ14115 fis, clone MAMMA1001760.”
AI754064	Hs.532315	“solute carrier family 31 (copper transporters), member 1”
BC016012	Hs.471492	“eukaryotic translation initiation factor 2C, 4”
BE083088	Hs.591602	“RC2-BT0642-030400-021-C05 BT0642 Homo sapiens cDNA, mRNA sequence.”
BC040178		“Homo sapiens GTP binding protein 5 (putative), mRNA (cDNA clone IMAGE:4797390), with apparent
		retained intron.”
AL039447	Hs.642739	chromosome 9 open reading frame 48
AL832141	Hs.369592	thyroid adenoma associated
AL555336	Hs.380635	Transcribed sequence with moderate similarity to protein pir:B28096 (H. sapiens) B28096 line-1 protein
		ORF2 - human
AF315688	Hs.591083	“interferon, kappa”
AI749193	Hs.374067	ubiquitin protein ligase E3B
AI201594	Hs.568928	MRNA; cDNA DKFZp762M127 (from clone DKFZp762M127)
NM_004488		glycoprotein V (platelet)
BC013319	Hs.506381	“FYVE, RhoGEF and PH domain containing 6”
NM_002359	Hs.252229	v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian)
AI357616	Hs.127934	hypothetical protein LOC90133
AU146585	Hs.386168	“CDNA FLJ10258 fis, clone HEMBB1000908”
M62762		“Human vacuolar H+ ATPase proton channel subunit mRNA, complete cds.”
BG109846	Hs.616796	protein x 013
NM_005890		“synonyms: MGC1348, KIAA0394; isoform b is encoded by transcript variant b; go_component: kinesin
		complex [goid 0005871] [evidence IEA]; go_function: transcription factor activity [goid 0003700]
		[evidence TAS] [pmid 9736752]; go_process: cell cycle arrest [goid 0007050] [evidence TAS] [pmid
		9736752]; go_process: cell growth and/or maintenance [goid 0008151] [evidence IEA]; go_process:
		development [goid 0007275] [evidence IEA]; go_process: neurogenesis [goid 0007399] [evidence IEA];
		Homo sapiens growth arrest-specific 7 (GAS7), transcript variant b, mRNA.”
AB040966	Hs.515351	KIAA1533
AI652645	Hs.475506	KIAA0763 gene product
AK022387	Hs.491682	“protein kinase, DNA-activated, catalytic polypeptide”
AK023308		“unnamed protein product; Homo sapiens CDNA FLJ13246 fis, clone OVARC1000682, highly similar to
		PROCESSING ALPHA-1,2-MANNOSIDASE (EC 3.2.1.—).”
BE855963	Hs.508725	hypothetical protein FLJ12118
NM_005955	Hs.591505	metal-regulatory transcription factor 1
AF132033		“intelligence reducing insertion protein INGRIN; Homo sapiens OPA-containing protein (HOPA) gene,
		complete cds.”
NM_024822		“synonyms: FLJ22601, dJ1158H2.1; Homo sapiens hypothetical protein FLJ22843 (FLJ22843), mRNA.”
BE856376	Hs.250616	lipidosin
AI684710	Hs.514920	nuclear domain 10 protein
NM_018407	Hs.492314	lysosomal associated protein transmembrane 4 beta
AF086079	Hs.231895	Full length insert cDNA clone YZ82H07
BC026969	Hs.492716	“Homo sapiens unknown MGC21654 product, mRNA (cDNA clone IMAGE:5116073), partial cds.”
AK000834	Hs.449434	“Homo sapiens CDNA FLJ20827 fis, clone ADKA03543.”
AF086444	Hs.390420	Full length insert cDNA clone ZD81E01
NM_015322	Hs.362733	fem-1 homolog b (C. elegans)
NM_016172	Hs.9194	ubiquitin associated domain containing 1
AL713719	Hs.29189	MRNA; cDNA DKFZp667K1916 (from clone DKFZp667K1916)
AA897191	Hs.279245	“transforming, acidic coiled-coil containing protein 1”
R91245		“yp94d10.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:195091 3′, mRNA
		sequence.”
AI867175	Hs.504907	chromosome 20 open reading frame 106
BG149547	Hs.408458	Transcribed sequences
NM_012204	Hs.22302	“general transcription factor IIIC, polypeptide 4, 90 kDa”
NM_025244	Hs.120267	“testis specific, 10”
BF433757	Hs.528993	ralA binding protein 1
BC026007	Hs.41735	“Clone IMAGE:4704511, mRNA”
BC014891	Hs.620701	KIAA0701 protein
AW590925	Hs.419240	Transcribed sequences
AL080215	Hs.516578	MRNA; cDNA DKFZp586J0323 (from clone DKFZp586J0323)
X13230	Hs.387262	MCF.2 cell line derived transforming sequence
AI821782	Hs.97858	Transcribed sequences
BI869014	Hs.627200	“CDNA FLJ33783 fis, clone BRSSN2007504”
BF434655	Hs.6734	“7p02f01.x1 NCI_CGAP_Ov18 Homo sapiens cDNA clone IMAGE:3644688 3′, mRNA sequence.”
AK026026	Hs.474150	BH3 interacting domain death agonist
AI819386	Hs.634057	MRNA; cDNA DKFZp686B 14224 (from clone DKFZp686B14224)
BF969352	Hs.195080	“CDNA clone IMAGE:4152985, partial cds”
AU145749	Hs.20516	“CDNA FLJ11764 fis, clone HEMBA1005685”
NM_006547	Hs.432616	IGF-II mRNA-binding protein 3
L11702	Hs.591810	glycosylphosphatidylinositol specific phospholipase D1
BE326728	Hs.642633	hypothetical protein MGC11266
AW379790	Hs.200063	“RC3-HT0253-181099-011-c03 HT0253 Homo sapiens cDNA, mRNA sequence.”
NM_023034	Hs.608111	Wolf-Hirschhorn syndrome candidate 1-like 1
AI936976	Hs.509017	“glycine-, glutamate-, thienylcyclohexylpiperidine-binding protein”
BC033224	Hs.207457	DKFZP434L187 protein
BC015590	Hs.382046	“CDNA clone IMAGE:4643842, partial cds”
AU144449		Transcribed sequence with moderate similarity to protein ref:NP_071431.1 (H. sapiens) cytokine receptor-
		like factor 2; cytokine receptor CRL2 precusor [Homo sapiens]
AB029030	Hs.21554	KIAA1107 protein
AI935717	Hs.471637	hypothetical protein MGC42174
AL050042	Hs.538604	Homo sapiens mRNA; cDNA DKFZp566L0824 (from clone DKFZp566L0824).
NM_024743	Hs.122583	hypothetical protein FLJ21934
BC017894	Hs.420024	chromosome 10 open reading frame 46
NM_024516	Hs.632177	hypothetical protein MGC4606
AI214466	Hs.283011	“qg69b04.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1840399 3′ similar to
		TR:Q13443 Q13443 METALLOPROTEASE/DISINTEGRIN/CYSTEINE-RICH PROTEIN
		PRECURSOR.;, mRNA sequence.”
BC039406	Hs.623811	“Clone IMAGE:5300951, mRNA”
AI280108	Hs.487511	chromosome 7 open reading frame 26
AL031228
AL139228		“match: proteins: Sw:P51151 Sw:P24408; Human DNA sequence from clone RP4-540A13 on
		chromosome Xq22.1-22.3 Contains the gene for a novel protein similar to RAB9 (member RAS oncogene
		family), ESTs, STSS and GSSs, complete sequence.”
BC001793	Hs.412468	kelch domain containing 3
AV741657	Hs.633089	amine oxidase (flavin containing) domain 2
AF078842	Hs.323342	“hqp0207; similar to bovine and pig tubulin-tyrosine ligase (TTL): Swiss-Prot Accession Numbers P38584
		and P38160; Homo sapiens HOTTL protein mRNA, complete cds.”
NM_017686	Hs.632427	ganglioside induced differentiation associated protein 2
AL390171	Hs.480356	vacuolar protein sorting 52 (yeast)
AI796581	Hs.438550	KIAA0056 protein
BE781103	Hs.43619	lung cancer metastasis-related protein 1
NM_024531	Hs.6459	putative G-protein coupled receptor GPCR41
AW628835	Hs.444950	“TBC1 domain family, member 10”
NM_017876	Hs.69554	ring finger protein 126
AB011117	Hs.128627	signal-induced proliferation-associated 1 like 3
NM_016579	Hs.558499	8D6 antigen
NM_016292	Hs.30345	heat shock protein 75
AA534894	Hs.162659	chromosome 9 open reading frame 28
NM_006876	Hs.8526	“UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6”
R67325	Hs.588291	“Hypothetical protein LOC255512, mRNA (cDNA clone IMAGE:5274144), partial cds”
AL050022	Hs.438991	DKFZP564D116 protein
AF219116	Hs.415299	inosine triphosphatase (nucleoside triphosphate pyrophosphatase)
NM_020153	Hs.533738	hypothetical protein FLJ21827
NM_145315	Hs.259666	lactation elevated 1
BC005133	Hs.326586	tRNA splicing 2′ phosphotransferase 1
AA514326	Hs.334684	hypothetical protein MGC10485
M99436	Hs.332173	“transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila)”
NM_012236	Hs.571874	sex comb on midleg homolog 1 (Drosophila)
H07095		“yl81h11.s1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:44797 3′, mRNA sequence.”
AK000185	Hs.306389	“CDNA FLJ20178 fis, clone COL09990”
BE677453	Hs.91531	“myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 6”
AA425633		“zv47a01.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:756744 3′, mRNA
		sequence.”
W22625		“71E5 Human retina cDNA Tsp509I-cleaved sublibrary Homo sapiens cDNA not directional, mRNA
		sequence.”
N21279		“yx53c01.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:265440 3′, mRNA
		sequence.”
M77171		“Human zinc finger protein gene, partial cds.”
NM_014015	Hs.592051	dexamethasone-induced transcript
AW016250	Hs.604838	“UI-H-BI0p-abl-c-02-0-UI.s1 NCI_CGAP_Sub2 Homo sapiens cDNA clone IMAGE:2712171 3′, mRNA
		sequence.”
AB011173	Hs.591518	amine oxidase (flavin containing) domain 2
NM_001667	Hs.502836	sorting nexin 15
NM_017514	Hs.632839	likely ortholog of mouse plexin 3
AK026088	Hs.493739	ubiquitin associated protein 2
AA404269	Hs.524348	prickle-like 1 (Drosophila)
NM_017637	Hs.435309
BC001745		DNA segment on chromosome 4 (unique) 234 expressed sequence
D38122	Hs.2007	“tumor necrosis factor (ligand) superfamily, member 6”
AI096888	Hs.475334	KIAA0280 protein
AV702405	Hs.632801	emopamil binding protein (sterol isomerase)
NM_015540	Hs.371045	DKFZP727M111 protein
NM_012222	Hs.271353	mutY homolog (E. coli)
NM_000386	Hs.371914	bleomycin hydrolase
NM_014593	Hs.180933	CXXC finger 1 (PHD domain)
NM_024096	Hs.632191	XTP3-transactivated protein A
AI885290	Hs.445818	“spondin 1, extracellular matrix protein”
AK002076	Hs.517948	DEAH (Asp-Glu-Ala-His) box polypeptide 30
NM_018127	Hs.434232	elaC homolog 2 (E. coli)
AF190863	Hs.460336	“golgi associated, gamma adaptin ear containing, ARF binding protein 2”
BE646227	Hs.613098	“protein tyrosine phosphatase, non-receptor type 23”
AW572279	Hs.515840	DNA (cytosine-5-)-methyltransferase 3 alpha
N49268	Hs.373857	Kruppel-like factor 12
D26351	Hs.65758	“inositol 1,4,5-triphosphate receptor, type 3”
BG149482		“nad29d02.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clone IMAGE:3366939 3′ similar to contains L1.t1
		L1 L1 repetitive element;, mRNA sequence.”
NM_024102	Hs.204773	MEP50 protein
NM_001610	Hs.532492	“acid phosphatase 2, lysosomal”
NM_024765
BF110434	Hs.562802	hypothetical protein R29124_1
BC030552	Hs.302963	“Clone IMAGE:5223566, mRNA”
AW571582	Hs.618112	“amyloid beta (A4) precursor protein-binding, family A, member 2 (X11-like)”
BC000638	Hs.514151	gasdermin-like
M57707	Hs.1497	“retinoic acid receptor, gamma”
NM_024092	Hs.13662	hypothetical protein MGC5508
AB011087	Hs.495349	KIAA0515
AK094684	Hs.363407	“LOC401124 (LOC401124), mRNA”
BC003170	Hs.490551	NICE-4 protein
AB033832	Hs.352298	platelet derived growth factor D
AL359941	Hs.593311	programmed cell death 6
NM_015185	Hs.54697
BC019022	Hs.531856	hypothetical gene supported by BC007071
AU154785	Hs.31532	“AU154785 NT2RP4 Homo sapiens cDNA clone NT2RP4002888 3′, mRNA sequence.”
BF508604	Hs.632709	regulator of nonsense transcripts 1
AF308301	Hs.18946	mitochondrial ribosomal protein S26
AA634138	Hs.593575	chromosome 6 open reading frame 49
BF339831	Hs.239500	hypothetical protein MGC13114
AI952009	Hs.523009	“sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2”
N29877	Hs.596783	taxilin
AW190316	Hs.221447	NADH:ubiquinone oxidoreductase MLRQ subunit homolog
N62126	Hs.32374	deltex 3 homolog (Drosophila)
BF447901	Hs.97837	“Similar to Group X secretory phospholipase A2 precursor (Phosphatidylcholine 2-acylhydrolase GX)
		(GX sPLA2) (SPLA2-X) (LOC388229), mRNA”
NM_022743	Hs.567571	SET and MYND domain containing 3
AL133055	Hs.636446	hypothetical protein DKFZp434J1015
D49958	Hs.75819	glycoprotein M6A
U37012	Hs.493202	“cleavage and polyadenylation specific factor 1, 160 kDa”
AI692169	Hs.379186	“wd37e07.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:2330340 3′, mRNA
		sequence.”
AK024800	Hs.612887	“CDNA: FLJ21147 fis, clone CAS09371”
NM_002378	Hs.631845	megakaryocyte-associated tyrosine kinase
BF057784	Hs.187884	G protein-coupled receptor 114
BF038366	Hs.199695	hypothetical protein MAC30
U92706		“Human rearranged immunoglobulin heavy chain (A1VH3) gene, partial cds.”
AA833716	Hs.460336	KIAA1970 protein
M98528		“Homo sapiens neuron-specific protein gene, last exon, clone D4S234.”
NM_007181		mitogen-activated protein kinase kinase kinase kinase 1
AF054994	Hs.31290	Clone 23832 mRNA sequence
NM_006255	Hs.333907	“protein kinase C, eta”
AC006033		“Homo sapiens, Similar to steroidogenic acute regulatory protein related, clone MGC:3251
		IMAGE:3505985, mRNA, complete cds.; H_NH0121A08.9 This gene was based on gi(13111773
		13543614 14042926); Homo sapiens BAC clone RP11-121A8 from 7, complete sequence.”
AF016535	Hs.489033	“ATP-binding cassette, sub-family B (MDR/TAP), member 1”
AA744529	Hs.95424	mitogen-activated protein kinase kinase kinase kinase 1
AU145682	Hs.308048	early B-cell factor
U76542	Hs.500645	pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase)
AA723370	Hs.546387	CGI-105 protein
AL521959	Hs.487479	“pleckstrin homology, Sec7 and coiled-coil domains 3”
W67995	Hs.54943	fracture callus 1 homolog (rat)
NM_020187	Hs.458320	DC12 protein
NM_052931	Hs.492348	SLAM family member 6
AW083371	Hs.173878	nipsnap homolog 1 (C. elegans)
AL049942	Hs.213735	zinc finger protein 337
AV700174	Hs.292580	hypothetical protein LOC283551
NM_017773	Hs.272794	hypothetical protein FLJ20340
NM_001628	Hs.521212	“aldo-keto reductase family 1, member B1 (aldose reductase)”
AF225422		“Homo sapiens AD023 mRNA, complete cds.”
X02189		H. sapiens adenosine deaminase (ADA) gene 5′ flanking region and exon 1 (and joined CDS).
NM_014450	Hs.88012	SHP2-interacting transmembrane adaptor protein
BF345244	Hs.378501	hypothetical protein LOC283989
AI057637	Hs.234898	acetyl-Coenzyme A carboxylase beta
BC002918	Hs.213088	carbohydrate (chondroitin 4) sulfotransferase 12
X79782	Hs.449601	H. sapiens (T1.1) mRNA for IG lambda light chain
NM_024310	Hs.466383	“pleckstrin homology domain containing, family F (with FYVE domain) member 1”
BF116060	Hs.519783	FLJ44216 protein
Y11339	Hs.105352	“sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-
		2,6-sialyltransferase) A”
BC003379	Hs.632714	hypothetical protein from clone 643
NM_024947	Hs.529592	polyhomeotic like 3 (Drosophila)
NM_000878	Hs.474787	“interleukin 2 receptor, beta”
AF031138	Hs.509513	natural cytotoxicity triggering receptor 3
NM_014914	Hs.435039	“centaurin, gamma 2”
NM_030978	Hs.132499	“actin related protein 2/3 complex, subunit 5-like”
NM_004758	Hs.112499	benzodiazapine receptor (peripheral) associated protein 1
AW338214	Hs.437696	“Clone IMAGE:5275753, mRNA”
AJ238374		“Homo sapiens mRNA for putative protein TH1, partial, clone IMAGE ID 785447.”
AF288573	Hs.2007	“tumor necrosis factor (ligand) superfamily, member 6”
NM_031213	Hs.465542	hypothetical protein MGC5244
AF044954	Hs.513266	“NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22 kDa”
BE671663	Hs.592102	epidermodysplasia verruciformis 2
NM_007237	Hs.632549	SP140 nuclear body protein
AI003777	Hs.632176	septin 1
AI421559	Hs.106185	ral guanine nucleotide dissociation stimulator
NM_020886	Hs.503891	ubiquitin specific protease 28
AI042377	Hs.470457	Transcribed sequences
AA742584	Hs.125914	chromosome 8 open reading frame 5
BG231773	Hs.371680	“CDNA FLJ46579 fis, clone THYMU3042758”
BE788984		“601481076F1 NIH_MGC_68 Homo sapiens cDNA clone IMAGE:3883818 5′, mRNA sequence.”
AA135722	Hs.597962	Transcribed sequences
NM_014349	Hs.474737	“apolipoprotein L, 3”
AW268594	Hs.374421	chromosome 9 open reading frame 81
NM_018641	Hs.213088	carbohydrate (chondroitin 4) sulfotransferase 12
BF678830		hypothetical protein LOC152485
NM_006117	Hs.15250	“peroxisomal D3,D2-enoyl-CoA isomerase”
AW977516	Hs.592755	Transcribed sequences
BF984830	Hs.190284	retinoic acid induced 1
NM_005263	Hs.73172	growth factor independent 1
AI347139	Hs.8162	hypothetical protein MGC39372
NM_002832	Hs.402773	“protein tyrosine phosphatase, non-receptor type 7”
NM_003362	Hs.191334	uracil-DNA glycosylase
AA679705	Hs.535464	“eukaryotic translation initiation factor 3, subunit 8, 110 kDa”
AY007128	Hs.469728	“CDNA FLJ26765 fis, clone PRS02774”
AK074465	Hs.462833	hypothetical protein FLJ31952
NM_001504	Hs.198252	chemokine (C-X-C motif) receptor 3
NM_005715	Hs.557541	uronyl-2-sulfotransferase
AA683481	Hs.22546	hypothetical protein MGC20446
AI829961	Hs.36972	CD7 antigen (p41)
AI609285	Hs.503891	“tw83h09.x1 NCI_CGAP_HN5 Homo sapiens cDNA clone IMAGE:2266337 3′ similar to contains Alu
		repetitive element; contains element MER29 repetitive element;, mRNA sequence.”
AL582804	Hs.403857	lymphocyte antigen 9
NM_000107	Hs.643521	“damage-specific DNA binding protein 2, 48 kDa”
AL833685	Hs.440508	MRNA; cDNA DKFZp667O0522 (from clone DKFZp667O0522)
BE568184		cytochrome c oxidase subunit VIa polypeptide 1
BG250907	Hs.591503	“Clone IMAGE:5178133, mRNA”
NM_018281	Hs.476319	hypothetical protein FLJ10948
BG542955	Hs.133916	hypothetical protein LOC152485
AK024386	Hs.155742	glyoxylate reductase/hydroxypyruvate reductase
NM_024070	Hs.521075	stromal antigen 3
AB014719	Hs.618112	“amyloid beta (A4) precursor protein-binding, family A, member 2 (X11-like)”
D42043	Hs.98910	raft-linking protein
AY043466	Hs.292449	Fc receptor-like protein 3
AI017564	Hs.492716	unknown MGC21654 product
NM_005317	Hs.465511	granzyme M (lymphocyte met-ase 1)
AL527430	Hs.2006	glutathione S-transferase M3 (brain)
NM_014767	Hs.523009	“synonym: testican-2; go_component: extracellular matrix [goid 0005578] [evidence NAS] [pmid
		10386950]; go_function: calcium ion binding [goid 0005509] [evidence IDA] [pmid 10386950];
		go_process: synaptogenesis [goid 0007416] [evidence NAS] [pmid 10386950]; go_process: extracellular
		matrix organization and biogenesis [goid 0030198] [evidence NAS] [pmid 10386950]; go_process:
		regulation of cell differentiation [goid 0045595] [evidence NAS] [pmid 10386950]; Homo sapiens
		sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 (SPOCK2), mRNA.”
BC040914	Hs.322462	“Clone IMAGE:5745627, mRNA”
AK001164	Hs.599785	“CDNA FLJ10302 fis, clone NT2RM2000042”
AK097515	Hs.120250	hypothetical protein FLJ40597
NM_005608	Hs.155975	“protein tyrosine phosphatase, receptor type, C-associated protein”
AI457120	Hs.331420	phosphoribosyl pyrophosphate amidotransferase
AA541630	Hs.170019	runt-related transcription factor 3
NM_024709	Hs.519839	hypothetical protein FLJ14146
NM_013330	Hs.642710	“non-metastatic cells 7, protein expressed in (nucleoside-diphosphate kinase)”
AL520200	Hs.420796	hypothetical protein MGC15429
NM_003752	Hs.567374	“eukaryotic translation initiation factor 3, subunit 8, 110 kDa”
BE259729	Hs.438429	ribosomal protein S19
AW043830	Hs.471441	Transcribed sequences
R12665	Hs.11594	“CDNA FLJ27273 fis, clone TMS00761”
BC006428	Hs.189119	CXXC finger 5
AI354636	Hs.586401	“qu95c03.x1 NCI_CGAP_Gas4 Homo sapiens cDNA clone IMAGE:1979812 3′, mRNA sequence.”
AK025248	Hs.546419	hypothetical protein FLJ13220
BE675549	Hs.79170	tetratricopeptide repeat domain 9
NM_000579	Hs.450802	chemokine (C-C motif) receptor 5
AB020630	Hs.45719	“protein phosphatase 1, regulatory (inhibitor) subunit 16B”
NM_002985	Hs.514821	chemokine (C-C motif) ligand 5
NM_014392	Hs.518595	DNA segment on chromosome 4 (unique) 234 expressed sequence
AI821566	Hs.642748	“torsin family 2, member A”
AA771779	Hs.461074	zinc finger protein 90 homolog (mouse)
AI084226	Hs.58831	regulator of Fas-induced apoptosis
AF057557	Hs.58831	regulator of Fas-induced apoptosis
NM_005356	Hs.470627	lymphocyte-specific protein tyrosine kinase
BC041468	Hs.434746	“Hypothetical protein LOC339988 (LOC339988), mRNA”
BC002556
NM_002002	Hs.465778	“Fc fragment of IgE, low affinity II, receptor for (CD23A)”
NM_018556	Hs.590883	signal-regulatory protein beta 2
AB020630	Hs.45719	“protein phosphatase 1, regulatory (inhibitor) subunit 16B”
AF298547	Hs.369279	“NACHT, leucine rich repeat and PYD containing 2”
AW157571	Hs.479066	multiple coiled-coil GABABR1-binding protein
AA767131	Hs.121432	KIAA0073 protein
M21121	Hs.514821	chemokine (C-C motif) ligand 5
NM_004356	Hs.54457	CD81 antigen (target of antiproliferative antibody 1)
BF432238	Hs.585799	“CDNA FLJ31089 fis, clone IMR321000092”
NM_004310	Hs.160673	“ras homolog gene family, member H”
BC000533	Hs.567374	“eukaryotic translation initiation factor 3, subunit 8, 110 kDa”
U07236	Hs.470627	lymphocyte-specific protein tyrosine kinase
AI702465	Hs.23606	Transcribed sequences
AU155091	Hs.633678	“Clone IMAGE:4814008, mRNA“
U90339	Hs.584739	adenosine kinase
AW575245	Hs.266331	Fc receptor homolog expressed in B cells
NM_030915	Hs.567598	likely ortholog of mouse limb-bud and heart gene
AI524095	Hs.403857	lymphocyte antigen 9
AW204712	Hs.385493	hypothetical protein LOC170371
U49396	Hs.408615	“purinergic receptor P2X, ligand-gated ion channel, 5”
AA781795	Hs.546467	epithelial stromal interaction 1 (breast)
BF433219		Transcribed sequences
BC003574	Hs.2484	T-cell leukemia/lymphoma 1A
AB051458	Hs.419171	KIAA1671 protein
NM_004114	Hs.6540	fibroblast growth factor 13
BF446578	Hs.125293	“RasGEF domain family, member 1A”
AA931562	Hs.444049	Transcribed sequence with weak similarity to protein ref:NP_060312.1 (H. sapiens) hypothetical protein
		FLJ20489 [Homo sapiens]
BF514552	Hs.292449	Fc receptor-like protein 3
X82240	Hs.2484	T-cell leukemia/lymphoma 1A
AW296309	Hs.405667	“CD8 antigen, beta polypeptide 1 (p37)”
M85256	Hs.554197	“Isolate donor Z clone Z55K immunoglobulin kappa light chain variable region mRNA, partial cds”
AF439512	Hs.387787	“killer cell lectin-like receptor subfamily K, member 1”
NM_005442	Hs.591663	eomesodermin homolog (Xenopus laevis)
AI424825	Hs.435052	“ATPase, aminophospholipid transporter (APLT), Class I, type 8A, member 1”
NM_006159	Hs.505326	NEL-like 2 (chicken)
BI547087		“603190322F1 NIH_MGC_95 Homo sapiens cDNA clone IMAGE:5261717 5′, mRNA sequence.”
BC001872	Hs.510635	“synonym: MU; Homo sapiens immunoglobulin heavy constant mu, mRNA (cDNA clone MGC:1228
		IMAGE:3544448), complete cds.”
AW006735	Hs.85258	“CD8 antigen, alpha polypeptide (p32)”
NM_007360	Hs.387787	“killer cell lectin-like receptor subfamily K, member 1”
NM_002261	Hs.74082	“synonyms: NKG2E, NKG2-E; isoform NKG2-E is encoded by transcript variant NKG2-E;
		go_component: integral to membrane [goid 0016021] [evidence IEA]; go_function: transmembrane
		receptor activity [goid 0004888] [evidence TAS] [pmid 9683661]; go_function: lectin [goid 0005530]
		[evidence IEA]; go_function: sugar binding [goid 0005529] [evidence IEA]; go_process: cellular defense
		response [goid 0006968] [evidence TAS] [pmid 9683661]; go_process: heterophilic cell adhesion [goid
		0007157] [evidence IEA]; Homo sapiens killer cell lectin-like receptor subfamily C, member 3 (KLRC3),
		transcript variant NKG2-E, mRNA.”
M13231	Hs.534032	T cell receptor gamma locus
AI753792	Hs.502004	related RAS viral (r-ras) oncogene homolog 2
M16768	Hs.534032	“T-cell receptor (V-J-C) precursor; Human T-cell receptor gamma chain VJCI-CII-CIII region mRNA,
		complete cds.”
NM_003175	Hs.458346	chemokine (C motif) ligand 2
U96394	Hs.449601	“Clone P2-147 anti-oxidized LDL immunoglobulin light chain Fab mRNA, partial cds”
M27331	Hs.534032	T cell receptor gamma locus
U23772	Hs.546295	chemokine (C motif) ligand 1
NM_004931	Hs.405667	“CD8 antigen, beta polypeptide 1 (p37)”
NM_006275	Hs.6891	“splicing factor, arginine/serine-rich 6”
BC020552	Hs.379186	programmed cell death 6
NM_001548	Hs.20315	interferon-induced protein with tetratricopeptide repeats 1
BC005248	Hs.461178	“eukaryotic translation initiation factor 1A, Y-linked”
NM_004660	Hs.99120	“DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked”
NM_001008	Hs.282376	“ribosomal protein S4, Y-linked”

TABLE 8

	Atheroembolic/	Cardioembolic/	Cardioembolic/
Common Name	control	control	Atheroembolic

DAB2	−1.754	−1.21	1.449
DAB2	−1.751	−1.142	1.531
ZNF185	−1.416	1.09	1.544
ITGA2B	−2.32	−1.081	2.146
JAM3	−1.694	−1.19	1.424
PPBP	−1.886	−1.077	1.75
C21orf7	−2.293	−1.503	1.527
SLC25A37	−1.326	1.089	1.444
C7orf41	−1.324	1.125	1.489
SYNJ2	−1.331	1.083	1.443

TABLE 9

	Atheroembolic/	Cardioembolic/	Cardioembolic/
Common Name	control	control	Atheroembolic

LAK	1.42	−1.375	1.952
PVRL2	1.357	−1.15	1.561
PVRL2	1.432	−1.145	1.64
PCGF3	1.323	−1.129	1.495
PPP3R1	1.34	−1.122	1.503
LEPROT	1.314	−1.114	1.464
INSR	1.369	−1.096	1.501
PVRL2	1.859	−1.09	2.028
NUMB	1.821	−1.041	1.896
FBN2	1.622	−1.011	1.64
BIRC1	1.426	1.007	1.417
TSHZ3	1.457	1.013	1.439
DF	1.595	1.034	1.542
IER3	1.701	1.197	1.421
RRAS2	−1.449	1.198	−1.736
CD8B1	−1.259	1.213	−1.526
CD8B1	−1.447	1.234	−1.785

TABLE 10

	Fold	Fold	Fold
	(Cardio-	(Cardio-	(Athero-
	embolic/	embolic/	embolic/		Human
	Athero-	healthy	healthy	GenBank	UniGene
Gene Symbol	embolic)	control)	control)	ID	ID	Gene description

PVRL2	2.028	1.859	−1.09	BE867789	110675	poliovirus receptor-related 2 (herpesvirus entry mediator B)
NUMB	1.896	1.821	−1.041	AW167424	585653	Numb homolog (Drosophila)
IER3	1.421	1.701	1.197	NM_003897	591785	immediate early response 3
FBN2	1.64	1.622	−1.011	NM_001999	519294	fibrillin 2 (congenital contractural amchnodactyly)
CFD	1.542	1.595	1.034	NM_001928	155597	complement factor D (adipsin)
TSHZ3	1.439	1.457	1.013	AL136805	278436	teashirt family zinc finger 3
PVRL2	1.64	1.432	−1.145	AI520949	110675	poliovirus receptor-related 2 (herpesvirus entry mediator B)
NAIP ///	1.417	1.426	1.007	NM_004536	191356	“NLR family, apoptosis inhibitory protein /// similar to Baculoviral
LOC728519						IAP repeat-containing protein 1 (Neuronal apoptosis inhibitory
						protein)”
ALPK1	1.952	1.42	−1.375	AA521086	99691	alpha-kinase 1
INSR	1.501	1.369	−1.096	AI215106	591381	Insulin receptor
PVRL2	1.561	1.357	−1.15	BE867789	110675	poliovirus receptor-related 2 (herpesvirus entry mediator B)
PPP3R1	1.503	1.34	−1.122	NM_000945	280604	“protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa,
						alpha isoform (calcineurin B, type I)”
PCGF3	1.495	1.323	−1.129	AW270105	144309	Polycomb group ring finger 3
LEPROT	1.464	1.314	−1.114	NM_017526	23581	leptin receptor overlapping transcript
C7orf41	1.489	1.125	−1.324	W73230	200100	chromosome 7 open reading frame 41
ZNF185	1.544	1.09	−1.416	NM_007150	16622	zinc finger protein 185 (LIM domain)
SLC25A37	1.444	1.089	−1.326	BG251467	122514	“solute carrier family 25, member 37”
SYNJ2	1.443	1.083	−1.331	AI971212	434494	synaptojanin 2
PPBP	1.75	−1.077	−1.886	R64130	2164	pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
ITGA2B	2.146	−1.081	−2.32	NM_000419	411312	“integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex,
						antigen CD41)”
DAB2	1.531	−1.142	−1.751	NM_001343	481980	“disabled homolog 2, mitogen-responsive phosphoprotein
						(Drosophila)”
JAM3	1.424	−1.19	−1.694	AA149644	150718	junctional adhesion molecule 3
DAB2	1.449	−1.21	−1.754	BC003064	481980	“disabled homolog 2, mitogen-responsive phosphoprotein
						(Drosophila)”
CD8B	−1.526	−1.259	1.213	AW296309	405667	CD8b molecule
CD8B	−1.785	−1.447	1.234	NM_004931	405667	CD8b molecule
RRAS2	−1.736	−1.449	1.198	AI753792	502004	related RAS viral (r-ras) oncogene homolog 2
C21orf7	1.527	−1.503	−2.293	NM_020152	222802	chromosome 21 open reading frame 7

Claims

What is claimed is:

1. A method for diagnosing an ischemia or a predisposition for developing an ischemia, the method comprising: determining a level of expression of a plurality of ischemia-associated genes in a biological sample from a mammalian subject, wherein an increase or decrease of said level compared to a normal control level of said genes indicates that said subject suffers from or is at risk of developing ischemia, wherein said plurality of ischemia-associated genes is selected from the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7.

2. The method of claim 1, wherein said plurality of ischemia-associated genes is selected from the genes set forth in Table 1.

3. The method of claim 1, wherein said increase is at least about 1.3 fold higher than said normal control level and said decrease is at least about 1.3 fold lower than said normal control level.

4. The method of claim 3, wherein at least about a 1.3 fold increase in expression of the following genes: LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, and LAK when compared to the normal control level, and at least about a 1.3 fold decrease in expression of the following genes: CD8B1 and RRAS2 when compared to the normal control level indicates that the subject has experienced or is at risk for a cardioembolic stroke.

5. The method of claim 3, wherein at least about a 1.3 fold decrease in expression of the following genes: C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41, and LAK when compared to the normal control level indicates that the subject has experienced or is at risk for an atherothrombotic stroke.

6. The method of claim 1, wherein said ischemia is a member selected from the group consisting of: embolic stroke, thrombotic stroke, and transient ischemic attack.

7. The method of claim 1, wherein said ischemia is cardioembolic stroke.

8. The method of claim 1, wherein said ischemia is atherothrombotic stroke.

9. The method of claim 1, wherein said sample is blood.

10. The method of claim 1, wherein said level of expression is determined by detecting hybridization of an ischemia-associated gene probe to a gene transcript of said biological sample.

11. The method of claim 10, wherein said hybridization step is carried out on a nucleic acid array.

12. An ischemia reference expression profile, comprising a pattern of gene expression of a plurality of the genes set forth in Table 1, 2, 3, 4, 5, 6, or 7.

13. An ischemia reference expression profile, comprising a pattern of gene expression of a plurality of the genes set forth in Table 1.

14. The ischemia reference expression profile of claim 13, wherein at least about a 1.3 fold increase in expression of the following genes: LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, and LAK when compared to the normal control level, and at least about a 1.3 fold decrease in expression of the following genes: CD8B1 and RRAS2 when compared to the normal control level is a reference expression profile for cardioembolic stroke.

15. The ischemia reference expression profile of claim 13, wherein at least about a 1.3 fold decrease in expression of the following genes: C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41, and LAK when compared to the normal control level is a reference expression profile for atherothrombotic stroke.

16. A method of screening for a compound for treating or preventing ischemia, said method comprising the steps of:

a) contacting a candidate compound with a cell expressing one or more genes set forth in Table 1, 2, 3, 4, 5, 6, or 7; and

b) selecting a compound that modulates the expression level of one or more genes set forth in Table 1, 2, 3, 4, 5, 6, or 7.

17. The method of claim 16, wherein a compound that decreases the expression of at least one gene selected from the group consisting of: LEPROT, PCGF3, PPP3R1, PVRL2, INSR, BIRC1, TSHZ3, DF, FBN2, IER3, NUMB, and LAK when compared to the normal control level, or increases the expression of at least one gene selected from the group consisting of: CD8B1 and RRAS2 relative to a control level is identified as a compound useful for treating or preventing ischemia.

18. The method of claim 17, wherein the ischemia is cardioembolic stroke.

19. The method of claim 16, wherein a compound that increases the expression of at least one gene selected from the group consisting of: C21orf7, DAB2, JAM3, ITGA2B, PPBP, SYNJ2, SLC25A37, ZNF185, C7orf41, and LAK is identified as a compound useful for treating or preventing ischemia.

20. The method of claim 19 wherein the ischemia is atherothrombotic stroke.

21. An array comprising a nucleic acid which binds to a plurality of nucleic acid sequences set forth in Table 1, 2, 3, 4, 5, 6, or 7.